var title_f30_30_31200="Mature cataract";
var content_f30_30_31200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mature cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of the red reflex signifies the presence of a mature cataract.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah S Jacobs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31200=[""].join("\n");
var outline_f30_30_31200=null;
var title_f30_30_31201="Shoulder and upper arm stretch";
var content_f30_30_31201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexibility exercise: Shoulder and upper arm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise to increase flexibility in your shoulders and upper arms will help make it easier to reach for your seatbelt. If you have shoulder problems, talk with your doctor before trying this stretch.",
"    <ol>",
"     <li>",
"      Stand with feet shoulder-width apart.",
"     </li>",
"     <li>",
"      Hold one end of a towel in your right hand.",
"     </li>",
"     <li>",
"      Raise and bend your right arm to drape the towel down your back. Keep your right arm in this position and continue holding on to the towel.",
"     </li>",
"     <li>",
"      Reach behind your lower back and grasp the towel with your left hand.",
"     </li>",
"     <li>",
"      To stretch your right shoulder, pull the towel down with your left hand. Stop when you feel a stretch or slight discomfort in your right shoulder.",
"     </li>",
"     <li>",
"      Repeat at least three to five times.",
"     </li>",
"     <li>",
"      Reverse positions, and repeat at least three to five times.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31201=[""].join("\n");
var outline_f30_30_31201=null;
var title_f30_30_31202="Macular degeneration view PI";
var content_f30_30_31202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    How age-related macular degeneration affects vision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Age-related macular degeneration can make certain spots look blurry, especially in the center of where you are looking.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the National Eye Institute. Available at:",
"     <a href=\"file://www.nei.nih.gov/health/examples/\" target=\"_blank\">",
"      file://www.nei.nih.gov/health/examples/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31202=[""].join("\n");
var outline_f30_30_31202=null;
var title_f30_30_31203="Econazole: Patient drug information";
var content_f30_30_31203=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Econazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/56/4995?source=see_link\">",
"     see \"Econazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/18/22818?source=see_link\">",
"     see \"Econazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to econazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12408 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31203=[""].join("\n");
var outline_f30_30_31203=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013645\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013644\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013649\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013650\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013652\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013647\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013648\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013653\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013654\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/56/4995?source=related_link\">",
"      Econazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/18/22818?source=related_link\">",
"      Econazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31204="Two handed tech";
var content_f30_30_31204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Two-hand bag mask ventilation techniques",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are two ways to perform the two hand technique. In the traditional method (picture A), both thumbs and index fingers hold pressure along the inferior and superior ridges of the mask. The other three fingers on each hand hold the mandible, in a fashion similar to the one-handed mask hold, and perform a simultaneous chin-lift and jaw-thrust maneuver. This position may not be comfortable to maintain for long periods of time. We recommend another method that uses the stronger thenar eminences to hold the mask in place (picture B). The thenar eminences are positioned parallel to each other along the long axis of each side of the mask, allowing the four remaining fingers to provide chin-lift and jaw-thrust maneuvers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31204=[""].join("\n");
var outline_f30_30_31204=null;
var title_f30_30_31205="Classification and diagnosis of gastritis and gastropathy";
var content_f30_30_31205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and diagnosis of gastritis and gastropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     Beverly A Dickson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31205/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/30/31205/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric inflammatory disease can be broadly categorized into gastritides and gastropathies. Gastritis is predominantly an inflammatory process while gastropathy demonstrates minimal to no inflammation. The term gastritis is used to denote inflammation associated mucosal injury. However, epithelial cell injury and regeneration are not always accompanied by mucosal inflammation. This distinction has caused considerable confusion since the term \"gastritis\" is often used to describe endoscopic or radiologic characteristics of the gastric mucosa rather than specific histologic findings. Epithelial cell damage and regeneration with minimal or no associated inflammation is properly referred to as \"gastropathy.\"",
"   </p>",
"   <p>",
"    The causes, natural history, and therapeutic implications of gastropathy differ from gastritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastritis is commonly secondary to infectious or autoimmune etiologies, although it can also result from drugs, hypersensitivity reactions, or extreme stress reactions.",
"     </li>",
"     <li>",
"      Gastropathy is commonly secondary to endogenous or exogenous irritants, such as bile reflux, alcohol, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and nonsteroidal antiinflammatory drugs. However, gastropathy can also be secondary to ischemia, stress, or chronic congestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    \"Gastritis\" is a term often used by endoscopists to describe the gastric mucosa rather than representing a particular endoscopic entity. A gastric mucosal biopsy is necessary to establish a definitive diagnosis of gastritis versus gastropathy.",
"   </p>",
"   <p>",
"    This topic review will discuss the classification and diagnosis of gastritis and gastropathy. The causes of acute and chronic gastritis are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The existence of gastric inflammation was debated during the 19",
"    <sup>",
"     th",
"    </sup>",
"    and early part of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century. It was recognized that postmortem digestion markedly altered gastric mucosa; as a result the significance of gastric mucosal inflammation was uncertain. This was clarified by the histologic demonstration of inflammation on gastric specimens prepared shortly after death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/1\">",
"     1",
"    </a>",
"    ] and by the use of gastroscopy beginning in the 1920s and gastric biopsy in the 1940s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF GASTRITIS AND GASTROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally accepted classification of",
"    <span class=\"nowrap\">",
"     gastritis/gastropathy,",
"    </span>",
"    although several classifications of gastritis and gastropathy (such as the Sydney system and the Olga staging system) have been proposed (",
"    <a class=\"graphic graphic_table graphicRef58995 \" href=\"mobipreview.htm?30/51/31549\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Gastritis has been classified by histologic features, time course (acute versus chronic), etiology, and proposed pathophysiology.",
"   </p>",
"   <p>",
"    However, classification remains controversial because of gaps in knowledge of etiology and pathogenesis, variation in nomenclature, and the coexistence of more than one type of gastritis or gastropathy in individual patients. Furthermore, the entities overlap morphologically, and so some conditions are classified by etiology and others by morphologic pattern. Thus, comparisons across studies using different nomenclature can be difficult.",
"   </p>",
"   <p>",
"    Most classification systems distinguish acute, short-term disease from chronic, long-term disease. The terms acute and chronic are also used to describe the type of inflammatory cell infiltrate. Acute inflammation is represented by neutrophilic infiltration, while chronic inflammation is characterized by a mixture of mononuclear cells, chiefly lymphocytes, plasma cells, and macrophages.",
"   </p>",
"   <p>",
"    A clinicopathologic framework for the classification of gastritis and gastropathy based upon these factors has been proposed (",
"    <a class=\"graphic graphic_table graphicRef73286 \" href=\"mobipreview.htm?38/54/39788\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/9\">",
"     9",
"    </a>",
"    ]. However, there are a number of cases with a diagnosis of chronic gastritis (generally mild) for which a specific etiology cannot be determined by histopathologic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mucosal biopsy is required to distinguish between acute, chronic active, and chronic gastritis and gastropathy, since the endoscopic and radiologic features may be similar and clinical features are often inaccurate for predicting histologic findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/11-18\">",
"     11-18",
"    </a>",
"    ]. Histologic findings can vary over a wide spectrum ranging from epithelial hyperplasia to extensive epithelial cell damage with infiltration by inflammatory cells.",
"   </p>",
"   <p>",
"    An illustrative study included 488 adults who were randomly selected from the general population and were screened by gastroscopy and biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/17\">",
"     17",
"    </a>",
"    ]. The authors determined the sensitivity and specificity of macroscopic features (including erythema, erosions, the absence or rugal folds and the presence of visible vessels) compared to histologic findings. None of these findings had sensitivity greater than 57 percent for determining the presence of gastritis or H. pylori infection. Similar conclusions have been reached in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. Another problem with relying on endoscopy alone is the interobserver variability for some features of gastritis such as erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of laboratory tests have proven to be useful for predicting gastric mucosal findings: noninvasive testing for H. pylori infection and serum pepsinogen isoenzyme measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Helicobacter pylori testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive testing for Helicobacter pylori has high sensitivity and specificity for gastritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Serum pepsinogen isoenzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pepsinogens are secreted by chief cells in the fundus and body, and by mucous cells in the cardia, fundus, body, antrum, and pylorus. Pepsinogen I is mostly secreted by chief cells in the gastric fundus, whereas pepsinogen II is also secreted in the antrum. Thus, in conditions associated with gastritis of the fundus (as in pernicious anemia), serum pepsinogen I concentrations are decreased relative to pepsinogen II.",
"   </p>",
"   <p>",
"    Low serum pepsinogen I levels are strongly associated with extensive intestinal metaplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/19\">",
"     19",
"    </a>",
"    ]. Intestinal metaplasia was found in 58 (88 percent) of 66 patients with a serum pepsinogen I value of less than 25 ng per milliliter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/20\">",
"     20",
"    </a>",
"    ]. The ratio of pepsinogen isozymes I and II in serum has good correlation with presence of metaplastic atrophic gastritis (principally autoimmune metaplastic atrophic gastritis and pernicious anemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ratio of serum pepsinogen I to pepsinogen II in the serum of people with normal gastric mucosa is approximately 6.2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/22\">",
"     22",
"    </a>",
"    ]. In one series, the presence of fundic gastritis was accurately predicted by the concentration of pepsinogen I and the ratio of pepsinogen isoenzymes in approximately 70 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/22\">",
"     22",
"    </a>",
"    ]. The ratio may also be useful for screening family members of patients with pernicious anemia and for identifying patients at high risk for gastric cancer in endemic countries or other populations at increased risk for gastric atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. On the other hand, measurement of serum pepsinogens and their ratio do not accurately discriminate nonatrophic versus",
"    <span class=\"nowrap\">",
"     antrum-restricted/predominant",
"    </span>",
"    atrophic gastritis in an asymptomatic population or first-degree relatives of patients with gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6983?source=see_link\">",
"     \"Screening and prevention of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate histologic assessment of gastritis and gastropathy depends upon optimizing the site and number of biopsy specimens. Magnification endoscopy may help in the identification of areas to biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy site preferences and number vary in clinical practice. However, there is general consensus among experts on the following biopsy approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All gross abnormalities should be biopsied and submitted in separate containers.",
"     </li>",
"     <li>",
"      Normal appearing mucosa adjacent to the lesional tissue should also be biopsied.",
"     </li>",
"     <li>",
"      Multiple biopsies (two to five) of both the corpus and the antrum should be obtained when attempting to establish the diagnosis of Helicobacter pylori or autoimmune gastritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biopsy of the incisura is also useful since it approximates the transition zone between the antrum and body, where intestinal metaplasia and atrophy are most frequently found in environmental metaplastic atrophic gastritis.",
"   </p>",
"   <p>",
"    Biopsies of the duodenum may also be helpful for diagnosing some forms of chronic gastritis. As examples, duodenal biopsies may show evidence of Crohn's disease in patients with granulomatous gastritis and celiac disease in patients with lymphocytic gastritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Communication with the pathologist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good communication between the endoscopist and pathologist cannot be overemphasized, and will optimize the interpretation of the biopsy specimens. This has become greatly facilitated by the availability of digital endoscopic pictures and readily available endoscopic procedural dictation in the electronic medical record.",
"   </p>",
"   <p>",
"    The pathologist should include a morphologic classification of the gastritis or gastropathy in the biopsy report (",
"    <a class=\"graphic graphic_table graphicRef80329 \" href=\"mobipreview.htm?7/39/7803\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31205/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastric inflammatory disease can be broadly categorized into gastritides and gastropathies. Gastritis is predominantly an inflammatory process while gastropathy demonstrates minimal to no inflammation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no universally accepted classification of",
"      <span class=\"nowrap\">",
"       gastritis/gastropathy,",
"      </span>",
"      although several classifications of gastritis and gastropathy (such as the Sydney system) have been proposed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification of gastritis and gastropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A mucosal biopsy is required to distinguish between acute, chronic active, and chronic gastritis and gastropathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is general consensus among experts on a biopsy approach. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good communication between the endoscopist and pathologist cannot be overemphasized, and will optimize the interpretation of the biopsy specimens. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Communication with the pathologist'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Faber K. Gastritis and its consequences, Oxford University Press, New York 1935.",
"    </li>",
"    <li>",
"     Wood IJ, Taft LI. Diffuse lesions of the stomach: An account with special reference to the value of gastric biopsy, Edward Arnold, London 1958.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/3\">",
"      Price AB. The Sydney System: histological division. J Gastroenterol Hepatol 1991; 6:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/4\">",
"      Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol 1988; 83:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/5\">",
"      Wyatt JI, Dixon MF. Chronic gastritis--a pathogenetic approach. J Pathol 1988; 154:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/6\">",
"      Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/7\">",
"      Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/8\">",
"      Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/9\">",
"      Dixon MF, Genta RM, Yardley JH, Correa P. Histological classification of gastritis and Helicobacter pylori infection: an agreement at last? The International Workshop on the Histopathology of Gastritis. Helicobacter 1997; 2 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/10\">",
"      Sepulveda AR, Patil M. Practical approach to the pathologic diagnosis of gastritis. Arch Pathol Lab Med 2008; 132:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/11\">",
"      Khakoo SI, Lobo AJ, Shepherd NA, Wilkinson SP. Histological assessment of the Sydney classification of endoscopic gastritis. Gut 1994; 35:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/12\">",
"      Cronstedt JL, Simson IW. Correlation between gastroscopic and direct vision biopsy findings. Gastrointest Endosc 1973; 19:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/13\">",
"      Elta GH, Appelman HD, Behler EM, et al. A study of the correlation between endoscopic and histological diagnoses in gastroduodenitis. Am J Gastroenterol 1987; 82:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/14\">",
"      J&ouml;nsson KA, Gotthard R, Bodemar G, Brodin U. The clinical relevance of endoscopic and histologic inflammation of gastroduodenal mucosa in dyspepsia of unknown origin. Scand J Gastroenterol 1989; 24:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/15\">",
"      Tytgat GN. The Sydney System: endoscopic division. Endoscopic appearances in gastritis/duodenitis. J Gastroenterol Hepatol 1991; 6:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/16\">",
"      Laine L, Cohen H, Sloane R, et al. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc 1995; 42:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/17\">",
"      Red&eacute;en S, Petersson F, J&ouml;nsson KA, Borch K. Relationship of gastroscopic features to histological findings in gastritis and Helicobacter pylori infection in a general population sample. Endoscopy 2003; 35:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/18\">",
"      Kaur G, Raj S. A study of the concordance between endoscopic gastritis and histological gastritis in an area with a low background prevalence of Helicobacter pylori infection. Singapore Med J 2002; 43:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/19\">",
"      Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007; 8:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/20\">",
"      Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci 2004; 49:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/21\">",
"      Samloff IM. Peptic ulcer: the many proteinases of aggression. Gastroenterology 1989; 96:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/22\">",
"      Samloff IM, Varis K, Ihamaki T, et al. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982; 83:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/23\">",
"      Yoshihara M, Sumii K, Haruma K, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. Am J Gastroenterol 1998; 93:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/24\">",
"      Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 2006; 4:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/25\">",
"      Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006; 163:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/26\">",
"      Ricci C, Vakil N, Rugge M, et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/27\">",
"      Haj-Sheykholeslami A, Rakhshani N, Amirzargar A, et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol 2008; 6:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31205/abstract/28\">",
"      Owen DA. Gastritis and carditis. Mod Pathol 2003; 16:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 29 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.179.173.170-A48E13D4B1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31205=[""].join("\n");
var outline_f30_30_31205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION OF GASTRITIS AND GASTROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Helicobacter pylori testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Serum pepsinogen isoenzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Communication with the pathologist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/29\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/29|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/51/31549\" title=\"table 1\">",
"      Updated Sydney system classification and grading of gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/54/39788\" title=\"table 2\">",
"      Classification of gastritis and gastropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/39/7803\" title=\"table 3\">",
"      Morphologic class gastritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/52/6983?source=related_link\">",
"      Screening and prevention of gastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31206="Approach to the patient with anisocoria";
var content_f30_30_31206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with anisocoria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Sachin Kedar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Val&eacute;rie Biousse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Nancy J Newman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31206/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/30/31206/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of anisocoria range in seriousness from a normal, physiologic condition to one that is immediately life threatening. When a patient presents with anisocoria, the fear of a serious condition, such as an intracranial aneurysm, often leads clinicians to obtain numerous tests, which are not always necessary. A logical clinical approach appreciating the mechanisms of anisocoria permits prompt recognition of true emergencies and often obviates the need for invasive and costly testing (",
"    <a class=\"graphic graphic_figure graphicRef71260 \" href=\"mobipreview.htm?38/18/39200\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupillary size is governed by the balance of actions of two opposing muscle groups of the iris: the dilator and sphincter pupillae. Regulation of the pupillary size is predominantly achieved by reflex mechanisms in response to the amount of ambient light. Other factors influencing pupillary size include patient age, emotional state (adrenergic tone), state of arousal, and intraocular pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Constriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupillary constriction to light and near stimuli is mediated via parasympathetic (cholinergic) nerve fibers that travel along the third cranial nerve. The pupillary light reflex pathway is a four neuron pathway (",
"    <a class=\"graphic graphic_figure graphicRef57842 \" href=\"mobipreview.htm?34/22/35173\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Light information from retinal ganglion cells travels though the optic nerves, optic chiasm (where the nasal fibers decussate), and the optic tracts, before synapsing in the pretectal nuclei of the dorsal midbrain. Both pretectal nuclei receive input from both eyes.",
"     </li>",
"     <li>",
"      Each pretectal nucleus sends axons to both Edinger-Westphal nuclei. This duality of pathways provides the anatomic basis for the consensual response to light (ie, the fact that both pupils constrict equally in response to a light stimulus in one eye).",
"     </li>",
"     <li>",
"      Parasympathetic fibers for pupillary constriction travel along the third cranial nerve to the ipsilateral ciliary ganglion within the orbit.",
"     </li>",
"     <li>",
"      The pupillary sphincter muscle (and ciliary muscle for lens accommodation) is innervated by the postganglionic parasympathetic fibers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The constriction of the pupil to near stimuli is also accomplished through the parasympathetic pathways. The near-reflex pathway descends from higher cortical centers directly to the Edinger-Westphal nuclei, bypassing the pretectal nuclei in the dorsal midbrain. This distinction between the light and near pathways forms the basis for some forms of pupillary light-near dissociation (ie, pupils that do not react to light but react to near stimuli), in which the dorsal midbrain and pretectal nuclei are damaged selectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupillary dilation is mediated through three-neuron sympathetic (adrenergic) pathways that originate in the hypothalamus (",
"    <a class=\"graphic graphic_figure graphicRef62879 \" href=\"mobipreview.htm?36/31/37367\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first-order neuron descends caudally from the hypothalamus to the first synapse, which is located in the cervical spinal cord (levels C8-T2, also called ciliospinal center of Budge).",
"     </li>",
"     <li>",
"      The second-order neuron travels from the sympathetic trunk, through the brachial plexus, over the lung apex. It then ascends to the superior cervical ganglion located near the angle of the mandible and the bifurcation of the common carotid artery.",
"     </li>",
"     <li>",
"      The third-order neuron then ascends within the adventitia of the internal carotid artery, through the cavernous sinus, where it is in close relation to the sixth cranial nerve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. The oculosympathetic pathway then joins the ophthalmic (V1) division of the fifth cranial nerve (trigeminal nerve). In the orbit and the eye, the oculosympathetic fibers innervate the iris dilator muscle as well as M&uuml;ller's muscle, a small smooth muscle in the eyelids responsible for a minor portion of the upper lid elevation and lower lid retraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXAMINATION OF THE PUPIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupillary examination is best conducted in dim light. It is essential to turn the lights off to evaluate the pupils. Horner's syndrome, in particular, is usually overlooked in an illuminated room. We often employ a storage room or closet if necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/4\">",
"     4",
"    </a>",
"    ]. A bright light (such as from a fully charged ophthalmoscope) and a pupillary size gauge (usually found on near acuity cards) are the only tools necessary for pupillary evaluation. The patient should be relaxed and fixing on a distant object, rather than focusing on the examiner's light, which may cause miosis from the pupillary near reaction.",
"   </p>",
"   <p>",
"    The size, shape, and position of each pupil should be noted in light and dark conditions. In a normal patient, the pupils are symmetric in size (difference less than 0.4 mm), shape, and position (",
"    <a class=\"graphic graphic_figure graphicRef61265 \" href=\"mobipreview.htm?27/61/28630\">",
"     figure 4",
"    </a>",
"    ). Pupillary reactivity is then assessed to light and near stimuli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Light reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pupillary reaction should be observed both when the light is shined into the eye (observe the pupillary constriction in both eyes) and later as the light is moved down and away from the eye. The magnitude, speed, and symmetry of the direct and consensual responses should be noted:",
"   </p>",
"   <p>",
"    Dilation lag is the asymmetry in pupillary redilation between the two eyes when the light source is moved away from the eye. It is usually indicative of a sympathetic innervation abnormality causing slower dilation of the affected pupil (Horner's syndrome), but is also a feature of the tonic (or Adie's) pupil (",
"    <a class=\"graphic graphic_picture graphicRef81184 \" href=\"mobipreview.htm?17/28/17857\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relative afferent pupillary defect is noted when one pupil's direct response to light is more sluggish than in the opposite eye. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link&amp;anchor=H35#H35\">",
"     \"The detailed neurologic examination in adults\", section on 'Afferent pupillary defect'",
"    </a>",
"    .) This is a sensitive test for an abnormality of the afferent visual pathways (eg, optic neuropathy). However, a relative afferent pupillary defect does not cause anisocoria even with severely decreased visual acuity in one eye. There is no anisocoria because of the intact consensual pupillary response to light.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Near reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The near target reaction is tested when the light response is abnormal. This is assessed with an accommodative target such as reading the near acuity card, viewed at about one foot from the eyes. In patients who are unable to converge or are blind, the near reaction can be elicited by having the patient look at their thumb when held at reading distance. The degree of pupillary constriction to near target is normally less than that seen with direct light stimulation.",
"   </p>",
"   <p>",
"    Light-near dissociation is said to exist when the light reaction is impaired with a normal near reaction. Causes of light-near dissociation are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef60550 \" href=\"mobipreview.htm?2/32/2571\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The figure shows a stepwise clinical approach to diagnosis in a patient with anisocoria (",
"    <a class=\"graphic graphic_figure graphicRef71260 \" href=\"mobipreview.htm?38/18/39200\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Identifying the abnormal side",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to determine whether the abnormal pupil is the large pupil or the small pupil by carefully evaluating the pupillary reactions in dark and light conditions (",
"    <a class=\"graphic graphic_figure graphicRef61265 \" href=\"mobipreview.htm?27/61/28630\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The small pupil is abnormal if anisocoria is greater in the dark than in light, indicating poor pupillary dilation on the abnormal side (",
"    <a class=\"graphic graphic_figure graphicRef61265 \" href=\"mobipreview.htm?27/61/28630\">",
"     figure 4",
"    </a>",
"    ). This indicates an abnormality of the sympathetic system.",
"   </p>",
"   <p>",
"    The larger pupil is abnormal if anisocoria is greater in the light than in dark, indicating poor pupillary constriction on the abnormal side (",
"    <a class=\"graphic graphic_figure graphicRef61265 \" href=\"mobipreview.htm?27/61/28630\">",
"     figure 4",
"    </a>",
"    ). This indicates an abnormality of the parasympathetic system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Associated clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anisocoria itself is not usually associated with clinical symptoms; however, patients with mydriasis can complain of photosensitivity and decreased near vision because of impaired accommodation.",
"   </p>",
"   <p>",
"    Other historical details or neurologic abnormalities on examination can be helpful in suggesting an etiology. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic anisocoria may go unnoticed by patients. Examination of old photographs and a driver's license can be helpful in establishing chronicity of the finding.",
"     </li>",
"     <li>",
"      Prior ocular disease (including eye surgeries) and head, ocular or orbital trauma can cause anisocoria.",
"     </li>",
"     <li>",
"      A detailed review of medications, in particular topical medications, and toxin exposure (including recent handling of plants) can reveal a potential pharmacologic etiology.",
"     </li>",
"     <li>",
"      Diplopia, ptosis, and impaired extraocular movements on the side of a large pupil point to a third nerve palsy, while a tonic pupil and pharmacologic mydriasis are usually isolated syndromes without ptosis or diplopia.",
"     </li>",
"     <li>",
"      Decreased palpebral fissure on the side of a small pupil suggests Horner's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physiologic anisocoria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic or simple anisocoria is seen in approximately 20 percent of the normal population at any given time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/7\">",
"     7",
"    </a>",
"    ]. The magnitude of anisocoria may be equal in light and dark, or slightly greater in the dark than in light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/8\">",
"     8",
"    </a>",
"    ]. The anisocoria is usually less than 0.4 mm difference between sides. There is no dilation lag.",
"   </p>",
"   <p>",
"    Reviewing the patient's old photographs or driver's license (with a magnifying glass) may help establish the diagnosis, as physiologic anisocoria is usually persistent. Depending on the degree of ambient lighting, the anisocoria may seem to come and go. Occasionally, the anisocoria may switch sides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Structural defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular causes responsible for structural defects of the iris can lead to anisocoria and abnormal pupillary shapes (",
"    <a class=\"graphic graphic_picture graphicRef81796 \" href=\"mobipreview.htm?30/58/31653\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Congenital defects such as aniridia, iris coloboma, congenital ectopic pupils, persistent pupillary membrane, polycoria, congenital heterochromia, Rieger's syndrome, and other developmental anomalies of the anterior segment can produce anisocoria, which is usually present in childhood.",
"   </p>",
"   <p>",
"    Numerous acquired ocular conditions, such as intraocular inflammation",
"    <span class=\"nowrap\">",
"     (iritis/iridocyclitis),",
"    </span>",
"    anterior segment ischemia, trauma, iris sphincter atrophy related to surgical or traumatic injury, mechanical distortion by an intraocular tumor, and angle-closure glaucoma, also produce anisocoria. Associated visual loss, ocular redness, or ocular pain is usually present with acute glaucoma. In the absence of a clear history of one of these disorders, an ophthalmologic evaluation with slit lamp examination will usually reveal the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     The small pupil is abnormal",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the small pupil does not dilate as well as the large pupil in dim light, then the small pupil is abnormal (",
"    <a class=\"graphic graphic_figure graphicRef61265 \" href=\"mobipreview.htm?27/61/28630\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This can occur due to ocular conditions that keep the small pupil from dilating (such as iridocyclitis, previous ocular surgery, or pseudoexfoliation syndrome) or to pharmacologic constriction of the pupil (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"     pilocarpine",
"    </a>",
"    eye drops). In the absence of these, asymmetric pupillary miosis usually results from dysfunction of the ipsilateral sympathetic pathway, ie, oculosympathetic paresis or Horner's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Horner's syndrome is caused by a lesion anywhere along the sympathetic pathway that supplies the head, eye, and neck (",
"    <a class=\"graphic graphic_figure graphicRef62879 \" href=\"mobipreview.htm?36/31/37367\">",
"     figure 3",
"    </a>",
"    ). The amount of anisocoria is worse in the dark than in the light, and it is associated with dilation lag of 15 to 20 seconds. Topical administration of one to two drops of 4 to 10 percent cocaine may be required to distinguish a Horner's syndrome from physiologic anisocoria. A normal pupil dilates more than the Horner's pupil, increasing the degree of anisocoria, a response not seen in physiologic anisocoria.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/28/36291?source=see_link\">",
"     Apraclonidine",
"    </a>",
"    drops (used for glaucoma) are now more often used than cocaine to confirm a Horner syndrome, and are widely available, while cocaine eye drops may not be. Apraclonidine has no effect on the size of a normal pupil, but moderately dilates a Horner pupil and increases the palpebral fissure on the side of the Horner syndrome; in effect, apraclonidine reverses the Horner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=see_link&amp;anchor=H10#H10\">",
"     \"Horner's syndrome\", section on 'Pharmacologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classic signs of Horner's syndrome also include ptosis and anhydrosis (",
"    <a class=\"graphic graphic_picture graphicRef54798 \" href=\"mobipreview.htm?16/1/16400\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67538 \" href=\"mobipreview.htm?15/62/16354\">",
"     picture 4",
"    </a>",
"    ). The ptosis is minor (2 mm or less) and may be missed. Ptosis involves both upper and lower lids. Unilateral anhidrosis is present in preganglionic lesions. Horner's syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=see_link\">",
"     \"Horner's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     The large pupil is abnormal",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the larger pupil does not constrict as well as the small pupil in response to a light stimulus, then the large pupil is abnormal (",
"    <a class=\"graphic graphic_figure graphicRef61265 \" href=\"mobipreview.htm?27/61/28630\">",
"     figure 4",
"    </a>",
"    ). This results from dysfunction of the ipsilateral parasympathetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef57842 \" href=\"mobipreview.htm?34/22/35173\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Causes include ocular conditions that keep the large pupil from constricting (such as posterior synechia, previous ocular surgery, ocular trauma, pseudoexfoliation syndrome, or chronic miotic medication use), pharmacologic agents (cycloplegics like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/43/35508?source=see_link\">",
"     homatropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/58/8100?source=see_link\">",
"     tropicamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/34/24100?source=see_link\">",
"     cyclopentolate",
"    </a>",
"    ), tonic pupil (Adie's pupil), or third nerve palsy.",
"   </p>",
"   <p>",
"    The clinical history, associated symptoms, or signs such as visual loss, diplopia, or ptosis help localize the lesion (",
"    <a class=\"graphic graphic_figure graphicRef71260 \" href=\"mobipreview.htm?38/18/39200\">",
"     figure 1",
"    </a>",
"    ). Appropriate investigations should be obtained once the mechanism of mydriasis is understood. Indeed, the non-contrast head computed tomography (CT) routinely ordered in the emergency department for a patient with mydriasis is not helpful and can be falsely reassuring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Traumatic mydriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pupillary dilation following ocular trauma often results from injury to the pupillary sphincter muscle. The pupil in such cases may be irregular in shape. Its ability to react to light and accommodation varies, depending on the extent of the damage. Anisocoria is more evident in bright light, as the pupil fails to constrict due to injury to the sphincter muscle. The pupillary abnormality is isolated without ptosis or diplopia (",
"    <a class=\"graphic graphic_picture graphicRef81796 \" href=\"mobipreview.htm?30/58/31653\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tonic pupil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tonic pupil (also called Adie's pupil) results from damage to the ciliary ganglion or short ciliary nerves followed by aberrant reinnervation. In the acute phase, findings may be isolated to unilateral mydriasis with poor light reactivity. Over days and weeks other characteristic signs develop:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Light near dissociation. The pupil constricts poorly to light but reacts better to accommodation (near response) (",
"      <a class=\"graphic graphic_picture graphicRef81184 \" href=\"mobipreview.htm?17/28/17857\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tonic response. When going from light to dark conditions, or after near fixation, the initially larger Adie's pupil becomes smaller than its normal fellow and remains tonically constricted, redilating very slowly.",
"     </li>",
"     <li>",
"      Denervation supersensitivity. Within 30 minutes of administration of two drops of dilute",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      (0.1 percent) in both eyes, the initially larger Adie's pupil becomes smaller than the normal pupil, which does not usually change in size (",
"      <a class=\"graphic graphic_picture graphicRef81184 \" href=\"mobipreview.htm?17/28/17857\">",
"       picture 1",
"      </a>",
"      ). Denervation supersensitivity is not present in the acute phase, and may take several weeks to develop.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tonic pupil is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44117?source=see_link\">",
"     \"Tonic pupil\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pharmacologic mydriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs can produce mydriasis either by stimulation of the sympathetic innervation of the dilator pupillae or inhibition of the parasympathetic innervation to the sphincter pupillae (",
"    <a class=\"graphic graphic_picture graphicRef62605 \" href=\"mobipreview.htm?25/49/26384\">",
"     picture 5",
"    </a>",
"    ). Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical medications used to treat ocular conditions include the parasympatholytic cycloplegic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/43/35508?source=see_link\">",
"       homatropine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/34/24100?source=see_link\">",
"       cyclopentolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/58/8100?source=see_link\">",
"       tropicamide",
"      </a>",
"      ; sympathomimetics such as adrenaline,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      (also used in topical allergy medications),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/28/36291?source=see_link\">",
"       apraclonidine",
"      </a>",
"      , and rarely",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/32/15877?source=see_link\">",
"       brimonidine",
"      </a>",
"      (used as antiglaucoma medication).",
"     </li>",
"     <li>",
"      Other autonomic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      patch (used for motion sickness) can also produce pharmacologic mydriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aerosolized anticholinergic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      ) administered through ventilator masks have also been known to produce unilateral mydriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain plants (eg, jimsonweed) contain substances with anticholinergic properties and have been known to produce isolated mydriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/14-16\">",
"       14-16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the agent is anticholinergic, the pupil is often largely dilated (8 mm or more) and does not constrict to light. In contrast, sympathomimetic drugs rarely dilate the pupil by more than 1 or 2 mm. Pharmacologic mydriasis is not associated with pain, ptosis, or diplopia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Third nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mydriasis from isolated third nerve palsies is almost always associated with an extraocular movement deficit",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ptosis (",
"    <a class=\"graphic graphic_picture graphicRef77466 \" href=\"mobipreview.htm?37/3/37936\">",
"     picture 6",
"    </a>",
"    ). A completely isolated mydriasis is extremely unlikely to be related to a third nerve palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31206/abstract/17\">",
"     17",
"    </a>",
"    ]. Tonic pupil and pharmacologic mydriasis should be specifically excluded by careful neuroophthalmologic evaluation and pharmacologic testing in this setting.",
"   </p>",
"   <p>",
"    The evaluation of the patient with a third nerve palsy depends on associated symptoms and signs, the pattern of oculomotor nerve involvement, and the age of the patient. Brain imaging studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lumbar puncture are often required. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36856?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of anisocoria range from a benign, physiologic condition to serious, life-threatening conditions. An approach to anisocoria is summarized in the Figure (",
"    <a class=\"graphic graphic_figure graphicRef71260 \" href=\"mobipreview.htm?38/18/39200\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anisocoria represents either impaired dilation or constriction of one pupil. These are mediated by sympathetic and parasympathetic pathways, respectively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neuroanatomy and physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic examination of the pupils notes their size, shape, and symmetry in light and dark conditions as well as the responses to light and near stimuli. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Examination of the pupil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The abnormal pupil can be identified by examination in light and dark conditions. Anisocoria that is greater in the dark identifies the small pupil as abnormal and implies a lesion in the sympathetic pathways. Anisocoria that is more pronounced in light conditions identifies the large pupil as abnormal and implies a lesion in the parasympathetic pathways. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Identifying the abnormal side'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anisocoria due to sympathetic lesions is usually a feature of Horner's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=see_link\">",
"       \"Horner's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parasympathetic causes of anisocoria include trauma, topical drugs, tonic pupil, and third nerve palsy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'The large pupil is abnormal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Biousse, V, Newman, NJ. Neuro-Ophthalmology Illustrated, Thieme Verlag, Germany 2009.",
"    </li>",
"    <li>",
"     Kardon, R. Anatomy and physiology of the autonomic nervous system. In: Walsh and Hoyt Clinical Neuro-ophthalmology, 6th ed, Miller, NR, Newman, NJ, Biousse, V, Kerrison, JB (Eds), Williams &amp; Wilkins, Baltimore 2005. p.649.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/3\">",
"      Johnston JA, Parkinson D. Intracranial sympathetic pathways associated with the sixth cranial nerve. J Neurosurg 1974; 40:236.",
"     </a>",
"    </li>",
"    <li>",
"     Digre, KB. Principles and techniques of examination of the pupils, accommodation and lacrimation. In: Walsh and Hoyt Clinical Neuro-ophthalmology, 6th ed, Miller, NR, Newman, NJ, Biousse, V, Kerrison, JB (Eds), Williams &amp; Wilkins, Baltimore 2005. p.715.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/5\">",
"      Pilley SF, Thompson HS. Pupillary \"dilatation lag\" in Horner's syndrome. Br J Ophthalmol 1975; 59:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/6\">",
"      Ettinger ER, Wyatt HJ, London R. Anisocoria. Variation and clinical observation with different conditions of illumination and accommodation. Invest Ophthalmol Vis Sci 1991; 32:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/7\">",
"      Lam BL, Thompson HS, Corbett JJ. The prevalence of simple anisocoria. Am J Ophthalmol 1987; 104:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/8\">",
"      Lam BL, Thompson HS, Walls RC. Effect of light on the prevalence of simple anisocoria. Ophthalmology 1996; 103:790.",
"     </a>",
"    </li>",
"    <li>",
"     Kawasaki, A. Disorders of pupillary function, accommodation and lacrimation. In: Walsh and Hoyt Clinical Neuro-ophthalmology, 6th ed, Miller, NR, Newman, NJ, Biousse, V, Kerrison, JB (Eds), Williams &amp; Wilkins, Baltimore 2005. p.739.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/10\">",
"      Lin YC. Anisocoria from transdermal scopolamine. Paediatr Anaesth 2001; 11:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/11\">",
"      Iosson N. Images in clinical medicine. Nebulizer-associated anisocoria. N Engl J Med 2006; 354:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/12\">",
"      Lust K, Livingstone I. Nebulizer-induced anisocoria. Ann Intern Med 1998; 128:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/13\">",
"      Openshaw H. Unilateral mydriasis from ipratropium in transplant patients. Neurology 2006; 67:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/14\">",
"      Savitt DL, Roberts JR, Siegel EG. Anisocoria from jimsonweed. JAMA 1986; 255:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/15\">",
"      Meng K, Graetz DK. Moonflower-induced anisocoria. Ann Emerg Med 2004; 44:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/16\">",
"      Havelius U, Asman P. Accidental mydriasis from exposure to Angel's trumpet (Datura suaveolens). Acta Ophthalmol Scand 2002; 80:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31206/abstract/17\">",
"      Biousse V, Newman NJ. Third nerve palsies. Semin Neurol 2000; 20:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5240 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31206=[""].join("\n");
var outline_f30_30_31206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Constriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXAMINATION OF THE PUPIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Light reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Near reflex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Identifying the abnormal side",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Associated clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physiologic anisocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Structural defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      The small pupil is abnormal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      The large pupil is abnormal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Traumatic mydriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tonic pupil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pharmacologic mydriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Third nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5240\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5240|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/18/39200\" title=\"figure 1\">",
"      Approach to anisocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/22/35173\" title=\"figure 2\">",
"      pupillary reflex pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/31/37367\" title=\"figure 3\">",
"      Sympathetic input to pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/61/28630\" title=\"figure 4\">",
"      Identification of the abnormal pupil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5240|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/28/17857\" title=\"picture 1\">",
"      Adie's pupil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/58/31653\" title=\"picture 2\">",
"      Ocular causes of anisocoria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/1/16400\" title=\"picture 3\">",
"      Horners syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/62/16354\" title=\"picture 4\">",
"      Postganglionic Horners syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26384\" title=\"picture 5\">",
"      Pharmacologic mydriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/3/37936\" title=\"picture 6\">",
"      Nonpupil-sparing 3rd nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5240|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/32/2571\" title=\"table 1\">",
"      Causes of light near dissociation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36856?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44117?source=related_link\">",
"      Tonic pupil",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31207="Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients";
var content_f30_30_31207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31207/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31207/contributors\">",
"     Aruna Subramanian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31207/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31207/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31207/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/30/31207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) are ubiquitous in the environment, and more than 125 species have been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/1\">",
"     1",
"    </a>",
"    ]. Solid organ transplant recipients have an increased risk for infection with NTM due to depressed cell-mediated immunity. Although NTM infection rates are low compared with other types of infection, when NTM infections occur in transplant recipients they cause significant morbidity and mortality, due in part to difficulties in disease recognition, delayed diagnosis, and complex drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews NTM infections in solid organ transplant recipients. Tuberculosis and the evaluation, treatment, and prophylaxis of infection in solid organ transplant recipients, as well as bacterial, viral, and fungal infections in lung transplant recipients, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most nontuberculous mycobacterial (NTM) species have been found in soil or water and are not known to be transmitted from animal-to-human or human-to-human [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/5\">",
"     5",
"    </a>",
"    ]. In tuberculosis (TB) non-endemic countries, NTM are more common etiologic agents of disease in solid organ transplant recipients than TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Solid organ transplant recipients have an increased risk for infection with NTM due to depressed cell-mediated immunity, but NTM infections are nevertheless rare in this population.",
"   </p>",
"   <p>",
"    The slowly growing mycobacteria M. avium and M. intracellulare (together known as Mycobacterium avium complex, MAC) are the most common NTM species to cause infection in the United States, and are the most common species isolated after solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The other NTM species that are known to cause disease in solid organ transplant recipients include the slowly growing species M. kansasii, M. haemophilum, and M. marinum, along with the rapidly growing species, M. fortuitum, M. chelonae, and M. abscessus (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"mobipreview.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In solid organ transplant recipients, the median onset of NTM infection is usually a year or more after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. Heart and lung transplant recipients have the highest rates of infection, ranging from 0.2 to 2.8 percent and 0.5 to 8.0 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. By contrast, rates of NTM infection in renal transplant recipients range from 0.16 to 0.38 percent, and in one series of liver transplant recipients, the rate was 0.04 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A large retrospective study of all lung and heart-lung transplant recipients at a single center in Australia over a 12-year period was performed to better define the epidemiology of NTM infection in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/6\">",
"     6",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 261 transplants, 23 cases of mycobacterial disease were detected (9 percent), only two of which were caused by TB. One of the patients with TB was coinfected with MAC.",
"     </li>",
"     <li>",
"      The most common site of infection was the lungs (19 cases [83 percent]).",
"     </li>",
"     <li>",
"      Thirteen cases (57 percent) were caused by MAC. Other NTM species that caused disease were M. haemophilum (five cases), M. abscessus (three cases), M. kansasii (one case), and M. asiaticum (one case).",
"     </li>",
"     <li>",
"      The median time to diagnosis of NTM infection following transplantation was 450 days (range 50 to 3272 days); this is much later than the median time to onset of TB. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=see_link&amp;anchor=H5#H5\">",
"       \"Tuberculosis in solid organ transplant candidates and recipients\", section on 'Timing following transplantation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although no deaths were attributed to mycobacterial infection, many patients with MAC experienced a decline in pulmonary function that persisted despite treatment of the infection. Thus, infection with MAC should be considered in the differential diagnosis of chronic allograft dysfunction. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Outcomes'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of NTM disease depends upon the infecting species, the site(s) of involvement, and whether the infection is localized or disseminated.",
"   </p>",
"   <p>",
"    Pleuropulmonary disease is the most common manifestation of NTM infection after transplantation, and lung transplant recipients are most commonly affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with NTM involving the lungs usually present with respiratory signs and symptoms such as chronic cough, sputum production, and, occasionally, hemoptysis. Disease can be fibrocavitary,",
"    <span class=\"nowrap\">",
"     nodular/bronchiectatic,",
"    </span>",
"    or a combination of both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. Patients may present with radiographic abnormalities such as pulmonary nodules or tree-in-bud opacities on chest computed tomography. M. avium complex (MAC), M. kansasii, M. abscessus, and M. xenopi are the most common causes of pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. M. kansasii, in particular, can cause aggressive disease in lung transplant recipients and often mimics reactivated pulmonary TB, including cavitary infiltrates with an upper lobe predilection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous and disseminated infections are the next most common presentations. Disseminated infection caused by MAC and other NTM typically presents with constitutional symptoms (weight loss, fever, night sweats). Interestingly, MAC infection in organ transplant recipients can primarily involve the allograft. There are case reports of MAC causing acute interstitial nephritis in renal transplant recipients and hepatic infection in liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical spectrum of disease caused by the rapidly growing mycobacteria (M. fortuitum, M. chelonae, and M. abscessus) varies depending upon the species. M. fortuitum and M. marinum tend to cause localized skin infections, which disseminate infrequently. These may present as papules or nodules (frequently with purple discoloration). M. marinum infection is commonly known as fish tank granuloma, and usually occurs after exposure to aquariums or marine environments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/10\">",
"     10",
"    </a>",
"    ]. Skin infection with the rapidly growing mycobacteria may result in recurrent abscesses, or chronic draining sinuses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=see_link\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    M. abscessus tends to be particularly virulent and can cause pulmonary, cutaneous,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disseminated disease. Several cases of fatal post-transplant M. abscessus infection involving the lungs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural space have been reported in lung transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]; severe cases have also been reported in renal, heart, and multivisceral transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/17\">",
"     17",
"    </a>",
"    ]. A retrospective study of patients with cystic fibrosis found that colonization with M. abscessus prior to transplantation strongly predicted invasive disease as compared with isolation of other NTM species (odds ratio 7.45, 95% CI 2.9-16.9); this association was not observed for other NTM species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an international survey of lung transplant centers, M. abscessus infections were identified in 17 of 5200 patients (0.33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/14\">",
"     14",
"    </a>",
"    ]. Eleven of 16 patients (73 percent) who were treated had a radiographic or microbiologic response to therapy, and two died from the infection. Two patients had late recurrence of infection at a distant site following cessation of therapy.",
"   </p>",
"   <p>",
"    In addition to M. abscessus, other NTM species that have rarely caused disseminated infections in solid organ transplant recipients are M. chelonae and M. haemophilum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NTM should be considered in solid organ transplant recipients with pulmonary complaints, especially lung transplant recipients. Staining and culture for acid fast bacilli (AFB) should be performed on all bronchoscopy specimens. In addition, mycobacterial infections should be considered in transplant recipients with atypical skin lesions or soft tissue infections. Skin biopsy should be performed in all patients with suspicious lesions and should be sent for AFB staining and culture, as well as histopathology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=see_link\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because NTM can be found as environmental or laboratory contaminants and can transiently colonize the lungs, a positive culture from bronchoalveolar lavage (BAL) fluid does not necessarily indicate infection. The burden of organisms recovered, the specific NTM species involved, and clinical and radiographic signs and symptoms should be considered when defining the approach to treatment. For example, since M. abscessus is particularly virulent, the isolation of this species from a post-transplant sputum culture should warrant an aggressive evaluation and careful consideration of treatment.",
"   </p>",
"   <p>",
"    Specific criteria exist for establishing the diagnosis of NTM disease, as outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"mobipreview.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    ); these criteria are discussed in detail separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11045?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For solid organ transplant recipients with disease caused by NTM, recommendations for initial management are similar to those for the general population, and involve combination therapy with multiple antimycobacterial agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/5\">",
"     5",
"    </a>",
"    ]. There have been no randomized trials of treatment of NTM in solid organ transplant recipients, and data regarding response to therapy among lung transplant recipients are limited to case series and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/6-22\">",
"     6-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=see_link\">",
"     \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following issues regarding management in solid organ transplant recipients should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interactions between antimycobacterial agents and both calcineurin inhibitors and rapamycin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      ) exist and must be taken into account when choosing a regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The rifamycins, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (also known as rifampicin), reduce serum concentrations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , rapamycin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      ), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      via induction of cytochrome p450 isoenzyme CYP3A4, and their use has been associated with the development of rejection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=see_link&amp;anchor=H10#H10\">",
"       \"Tuberculosis in solid organ transplant candidates and recipients\", section on 'Management of active TB'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain macrolides, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , can lead to increased serum concentrations of the calcineurin inhibitors and rapamycin via cytochrome p450 inhibition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      is less likely to cause this effect, although calcineurin inhibitor and rapamycin levels should be monitored closely in all patients receiving any macrolide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there are no specific recommendations regarding the duration of antimycobacterial therapy in solid organ transplant recipients, such patients often require a longer course than immunocompetent hosts in order to prevent relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2\">",
"       2",
"      </a>",
"      ]. For example, in immunocompetent hosts with MAC pulmonary infection, 12 months of therapy following negative sputum cultures is recommended, but this should be the minimum treatment duration among solid organ transplant recipients. In patients in whom immunosuppression cannot be reduced or in whom there is a high burden of disease, prolonged or lifelong suppression may be necessary. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link\">",
"       \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The intensity of the immunosuppressive regimen should be reduced whenever possible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility testing of NTM can be particularly helpful in managing infections with NTM in solid organ transplant recipients, given the potential for drug interactions and toxicities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. Susceptibility testing should be performed routinely; the agents that should be included in susceptibility testing vary depending upon which species is isolated. In addition to determining the optimal initial regimens, such testing is important for tailoring therapy to an oral regimen once control of the infection has been achieved. It is important to have susceptibility testing done in a laboratory with expertise in evaluating NTM species. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link\">",
"       \"Microbiology of nontuberculous mycobacteria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\", section on 'Susceptibility testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=see_link&amp;anchor=H16#H16\">",
"       \"Rapidly growing mycobacterial infections in HIV-negative patients\", section on 'Susceptibility testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical resection of localized skin lesions can be used as an adjunct to medical therapy in the setting of abscess formation, to debulk areas with a large burden of disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in patients who have not responded to antimycobacterial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes of NTM infections among solid organ transplant recipients have not been well established given the low rates of infection.",
"   </p>",
"   <p>",
"    In a retrospective study that included 13 lung transplant recipients with M. avium complex (MAC) pulmonary infection, none died from MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/6\">",
"     6",
"    </a>",
"    ]. However, among eight patients who were treated with antimycobacterial therapy for more than two months, most had no improvement in graft function following therapy.",
"   </p>",
"   <p>",
"    A retrospective review of 201 lung transplant recipients found nine with post-transplant NTM disease and 27 with NTM colonization. NTM colonization was a risk factor for NTM disease (hazard ratio [HR] 8.39, 95% CI 2.08-33.85) and presence of either colonization or disease significantly increased the risk of death after lung transplant even when controlling for factors such as bronchiolitis obliterans syndrome (adjusted HR 2.18, 95% CI 1.26-3.76) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, M. abscessus can be particularly aggressive in lung transplant recipients, sometimes leading to relapse even after long courses of antimicrobial therapy or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible efficacy of prophylaxis in transplant candidates or recipients colonized with NTM species has not been established. There is wide variation in the management of solid organ transplant candidates known to be colonized with NTM species, ranging from no therapy to pre-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peri-transplant prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the risk of surgical site infections, the American Society of Transplantation recommends that lung transplant candidates with cystic fibrosis who are colonized with rapidly growing NTM species (M. abscessus, M. chelonae, and M. fortuitum) be considered for post-transplant prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3\">",
"     3",
"    </a>",
"    ]. Many transplant programs give azithromycin prophylaxis routinely to all lung transplant recipients as prophylaxis against bronchiolitis obliterans. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In lung transplant candidates who are colonized or infected with Mycobacterium avium complex (MAC), multidrug MAC therapy should be considered prior to lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3\">",
"     3",
"    </a>",
"    ]. Optimally, those with active infection should complete a minimum of six months of multidrug MAC therapy prior to transplantation and should continue to receive therapy following transplantation; however, the duration of therapy both prior to and following transplantation must be individualized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\", section on 'Mycobacterium avium complex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although successful treatment has been achieved in some lung transplant recipients with M. abscessus infection, lung transplantation in individuals known to be colonized, particularly those with cystic fibrosis, remains controversial. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycobacterium avium and M. intracellulare (together known as Mycobacterium avium complex, MAC), are the most common nontuberculous mycobacterial (NTM) species isolated after solid organ transplantation and typically involve the lungs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of NTM disease depends on the infecting species, the site(s) of involvement, and whether the infection is localized or disseminated. Pleuropulmonary disease is the most common manifestation of NTM infection among solid organ transplant recipients, occurring in over 50 percent of cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NTM should be considered in solid organ transplant recipients with pulmonary complaints. Staining and culture for acid fast bacilli should be performed on all bronchoscopy specimens. In addition, mycobacterial infections should be considered in solid organ transplant recipients with atypical skin lesions or soft tissue infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific criteria exist for establishing the diagnosis of NTM disease as outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"mobipreview.htm?10/48/11020\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11045?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For solid organ transplant recipients with disease caused by nontuberculous mycobacteria, we suggest similar initial antimycobacterial regimens to those used in immunocompetent hosts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following issues regarding management in solid organ transplant recipients should be noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Interactions between antimycobacterial agents and calcineurin inhibitors exist and must be taken into account when choosing a regimen. &nbsp;The most significant interaction is between the rifamycins and both the calcineurin inhibitors and rapamycin. Certain macrolides, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , also interact significantly with both the calcineurin inhibitors and rapamycin.",
"     </li>",
"     <li>",
"      Solid organ transplant recipients often require a longer course than immunocompetent hosts in order to prevent relapse.",
"     </li>",
"     <li>",
"      The intensity of the immunosuppressive regimen should be reduced whenever possible.",
"     </li>",
"     <li>",
"      Susceptibility testing can be particularly helpful in managing NTM infections in solid organ transplant recipients given the potential for drug interactions and toxicities. The agents that should be included in susceptibility testing vary depending upon which species is isolated.",
"     </li>",
"     <li>",
"      Surgical resection of localized skin lesions can be used as an adjunct to medical therapy in the setting of abscess formation, to debulk areas with a large burden of disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in patients who have not responded to antimycobacterial therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For lung transplant candidates with cystic fibrosis who are colonized with rapidly growing NTM species (M. abscessus, M. chelonae, and M. fortuitum), we suggest post-transplant prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For lung transplant candidates who are colonized or infected with Mycobacterium avium complex (MAC), we suggest multidrug MAC therapy prior to and following lung transplantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/1\">",
"      Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/2\">",
"      Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/3\">",
"      Dorman S, Subramanian A, AST Infectious Diseases Community of Practice. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/4\">",
"      Daley CL. Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/5\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/6\">",
"      Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/7\">",
"      Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/8\">",
"      Rawla MS, Kozak A, Hadley S, LeCates WW. Mycobacterium avium-intracellulare-associated acute interstitial nephritis: a rare cause of renal allograft dysfunction. Transpl Infect Dis 2009; 11:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/9\">",
"      Singhal A, Gates C, Malhotra N, et al. Successful management of primary nontuberculous mycobacterial infection of hepatic allograft following orthotopic liver transplantation for hepatitis C. Transpl Infect Dis 2011; 13:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/10\">",
"      Pandian TK, Deziel PJ, Otley CC, et al. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 2008; 10:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/11\">",
"      Sanguinetti M, Ardito F, Fiscarelli E, et al. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol 2001; 39:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/12\">",
"      Fairhurst RM, Kubak BM, Shpiner RB, et al. Mycobacterium abscessus empyema in a lung transplant recipient. J Heart Lung Transplant 2002; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/13\">",
"      Taylor JL, Palmer SM. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient. J Heart Lung Transplant 2006; 25:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/14\">",
"      Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/15\">",
"      Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/16\">",
"      Zaidi S, Elidemir O, Heinle JS, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/17\">",
"      Garrison AP, Morris MI, Doblecki Lewis S, et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/18\">",
"      Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/19\">",
"      Woo MS, Downey S, Inderlied CB, et al. Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient. Pediatr Transplant 1997; 1:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/20\">",
"      Swetter SM, Kindel SE, Smoller BR. Cutaneous nodules of Mycobacterium chelonae in an immunosuppressed patient with preexisting pulmonary colonization. J Am Acad Dermatol 1993; 28:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/21\">",
"      Baldi S, Rapellino M, Ruffini E, et al. Atypical mycobacteriosis in a lung transplant recipient. Eur Respir J 1997; 10:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/22\">",
"      Torres F, Hodges T, Zamora MR. Mycobacterium marinum infection in a lung transplant recipient. J Heart Lung Transplant 2001; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/23\">",
"      S&aacute;daba B, L&oacute;pez de Oc&aacute;riz A, Azanza JR, et al. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998; 42:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/24\">",
"      Capone D, Palmiero G, Gentile A, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr Drug Metab 2007; 8:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31207/abstract/25\">",
"      Huang HC, Weigt SS, Derhovanessian A, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30:790.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1413 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31207=[""].join("\n");
var outline_f30_30_31207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1413\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1413|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/48/11020\" title=\"table 2\">",
"      Criteria for NTM diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5530?source=related_link\">",
"      Rapidly growing mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31208="Vaginal cancer";
var content_f30_30_31208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vaginal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     John C Elkas, MD, JD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31208/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/30/31208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cancer of the vagina comprises approximately three percent of all malignant neoplasms of the female genital tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 2900 cases are diagnosed annually in the United States, with about 800 deaths.",
"   </p>",
"   <p>",
"    Most of these tumors are squamous cell carcinomas, but melanoma, sarcoma, adenocarcinoma, and other histologic types also occur (",
"    <a class=\"graphic graphic_table graphicRef72984 \" href=\"mobipreview.htm?33/42/34475\">",
"     table 1",
"    </a>",
"    ). Although primary vaginal cancer is rare, metastatic disease to the vagina is not uncommon. As a result, the majority of vaginal malignancies are metastatic, often arising from the endometrium, cervix, vulva, ovary, breast, rectum, and kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Vaginal metastases may occur by direct extension (eg, cervix, vulva, endometrium) or by lymphatic or hematogenous spread (eg, breast, ovary, kidney).",
"   </p>",
"   <p>",
"    The clinical manifestations, evaluation, and therapy of invasive vaginal cancer are reviewed here. Vaginal intraepithelial neoplasia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5560?source=see_link\">",
"     \"Vaginal intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of in situ or invasive squamous cell cancer of the vagina is 1 per 100,000 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/6\">",
"     6",
"    </a>",
"    ]. There is a paucity of information on the etiology of squamous cell vaginal cancer due to the rarity of the disease.",
"   </p>",
"   <p>",
"    In general, in situ and invasive vagina neoplasia are associated with the same risk factors as in cervical neoplasia: multiple lifetime sexual partners, early age at first intercourse, and being current smoker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Most cases of vaginal cancer are likely mediated by human papillomavirus (HPV) infection, as with cervical cancer. In a case-control study of 156 women with in situ or invasive vaginal cancer, over 50 percent were positive for antibodies to HPV subtypes 16 or 18 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that some high grade vulvar and vaginal intraepithelial neoplasia is a monoclonal lesion derived from high grade or malignant cervical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/8\">",
"     8",
"    </a>",
"    ]. This was supported by a retrospective cohort study of over 130,000 women in which women with cervical intraepithelial neoplasia 3 (CIN) had a significantly increased rate of developing vaginal cancer compared with all women within the same population and time period (standardized incidence ratio 6.8, 95% CI 5.6-8.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/9\">",
"     9",
"    </a>",
"    ]. A fourfold or greater increased risk was found until 25 years following CIN 3 diagnosis. Similarly, in a case series, 30 percent of all women with in situ or invasive vaginal disease had been treated for a prior anogenital tumor (primarily cervical) and 17 of 25 (70 percent) of invasive cancer biopsy specimens contained human papillomavirus",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    DNA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5560?source=see_link&amp;anchor=H3#H3\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5560?source=see_link&amp;anchor=H5#H5\">",
"     \"Vaginal intraepithelial neoplasia\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with vaginal carcinoma present with vaginal bleeding, either postmenopausal or postcoital. Other symptoms include a watery, blood-tinged, or malodorous vaginal discharge, vaginal mass, urinary symptoms (eg, frequency, dysuria, hematuria), or gastrointestinal complaints (eg, tenesmus, constipation, melena) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Pelvic pain from extension of disease beyond the vagina is present in 5 percent of patients. However, as many as 20 percent of women are asymptomatic at time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. These vaginal cancers may be detected as a result of cytological screening for cervical cancer.",
"   </p>",
"   <p>",
"    The posterior wall of the upper one-third of the vagina is the most common site of primary vaginal carcinoma. In one review, tumors occurred in the upper, middle, and lower third of the vagina in 50, 20, and 30 percent of cases, respectively, with more than one-half of the tumors arising from the posterior vaginal wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of vaginal carcinoma can be difficult. The lesion may be missed on initial examination if it is small and situated in the lower two-thirds of the vagina. During visual examination of the vagina, the anterior and posterior blades of the speculum obscure this area, so the tumor may be missed unless the vagina is inspected as the speculum is removed or the lesion is palpated on bimanual examination. Papanicolaou (Pap) smear may detect malignant cells; 20 percent of vaginal tumors are detected incidentally as a result of cytologic screening for cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive diagnosis is accomplished by biopsy of the suspected lesion, which may appear as a mass, a plaque, or an ulcer. If a lesion is not visualized in the presence of abnormal cytologic results, colposcopy of the cervix and vagina must be performed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    followed by Lugol's iodine stain. An office biopsy of abnormal areas of the vagina can be done with either a punch (Baker's or Keyes) or cervical (Tischler or Burke) biopsy forceps. Anesthesia may be necessary for examination and biopsy for women with significant vaginal stenosis that precludes an adequate office examination, in elderly women, or if cystoscopy and proctoscopy are necessary for clinical staging (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Staging'",
"    </a>",
"    below). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary vaginal tumors comprise a heterogeneous group of malignancies (",
"    <a class=\"graphic graphic_table graphicRef72984 \" href=\"mobipreview.htm?33/42/34475\">",
"     table 1",
"    </a>",
"    ) that tend to be multicentric, thus, the entire vaginal mucosa is at risk. Many women with vaginal cancer have a prior history of gynecologic malignancy. As an example, in a series of 153 women with vaginal cancer treated at the Princess Margaret Hospital, 51 patients had a prior gynecologic malignancy; of these, 34 had cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean age at diagnosis of squamous cell carcinomas is approximately 60 years, although the disease is seen occasionally in women in their 20s and 30s. Squamous carcinoma is more common as the age of the patient increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/17\">",
"     17",
"    </a>",
"    ]. Grossly, these tumors may be nodular, ulcerative, indurated, endophytic, or exophytic. Histologically, they are similar to squamous cell tumors from other sites. Vaginal cancer is also associated with the human papillomavirus. However, vaginal epithelium is more stable than cervical epithelium, which undergoes constant metaplasia, and is thus less susceptible to oncogenic viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Verrucous carcinoma is an uncommon variant of vaginal squamous cell carcinoma that is well-differentiated and has low malignant potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/19\">",
"     19",
"    </a>",
"    ]. It usually presents as a large, warty, fungating mass that is locally aggressive but rarely metastasizes. Histologically, it is composed of large papillary fronds covered by dense keratin. Its deep margin creates a pushing border of well-oriented rete ridges in contrast to the well demarcated margins of benign condyloma acuminata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinomas represent nearly all of the primary vaginal cancers in women less than 20 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/17\">",
"     17",
"    </a>",
"    ]. Adenocarcinomas may arise in areas of vaginal adenosis, Wolffian rest elements, periurethral glands, and foci of endometriosis. Clear-cell variants are the best known type of adenocarcinoma, primarily because of their occurrence in young women who have been exposed in utero to diethylstilbestrol (DES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/11,20\">",
"     11,20",
"    </a>",
"    ]. Grossly, clear cell carcinomas of the vagina usually present as polypoid masses, most often on the anterior wall of the vagina. Approximately 70 percent of patients are stage I at the time of diagnosis.",
"   </p>",
"   <p>",
"    DES exposure can result in both cervical and vaginal clear cell adenocarcinomas. As an example, in one report of genital clear cell carcinomas in the Netherlands, vaginal tumors were detected in 33 percent of cases and cervical tumors were detected in 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the incidence of invasive or in situ squamous cell cancer of the cervix is increased in women exposed to DES in utero. In one report from the Netherlands DES Information Center, the prevalence of cervical cancer was 5.4-fold higher than expected, based on age and period-specific prevalence rates from the Netherlands cancer registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In females exposed in utero to DES, the actual risk of developing clear cell adenocarcinoma through age 34 is only one in 1000, with the highest risk in those who were exposed before 12 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The median age at diagnosis of DES-related clear cell adenocarcinoma of the vagina is 19 years, with a range of 7 to 33 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/23\">",
"     23",
"    </a>",
"    ]. Nonmalignant abnormalities can also occur; areas of vaginal adenosis and structural abnormalities of the uterus, cervix, or vagina are present in 45 and 25 percent of these women, respectively. Thus, it is recommended that women exposed to DES in utero have their first gynecologic examination at menarche with a careful assessment of the cervix and vagina, in addition to cervical and vaginal cytological examination. An examination of DES-exposed women should consist of colposcopic inspection of the cervix and vagina, yearly cytologic examination of the cervix and vagina, and careful palpation of the cervix and entire vaginal wall. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=see_link\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most women with DES-associated clear cell vaginal cancer have good outcomes with primary radiation, surgery, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. On the other hand, adenocarcinomas that occur in non DES-exposed women tend to have a poorer outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyosarcomas, endometrial stromal sarcomas, malignant mixed m&uuml;llerian tumors, and rhabdomyosarcomas are the major types of primary vaginal sarcomas. The most common of these is the embryonal rhabdomyosarcoma (sarcoma botryoides), a highly malignant tumor that occurs in the vagina during infancy and early childhood (mean age three years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/28\">",
"     28",
"    </a>",
"    ]. This sarcoma generally presents as soft nodules that fill and sometimes protrude from the vagina, resembling a bunch of grapes (botryoides comes from the Greek word botrys which means \"grapes\") (",
"    <a class=\"graphic graphic_picture graphicRef56001 \" href=\"mobipreview.htm?41/52/42822\">",
"     picture 1",
"    </a>",
"    ). The prognosis for patients with this malignancy has improved with the use of multimodality therapy including surgery, chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and actinomycin D) and radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas arising on the vaginal mucosa are rare and are thought to originate from mucosal melanocytes in areas of melanosis or from atypical melanocytic hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/30\">",
"     30",
"    </a>",
"    ]. The majority all of the reported cases have been in Caucasian women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These malignancies occur at a mean age of approximately 60 years (range 22 to 84 years). The presenting symptom is most commonly vaginal bleeding. They appear as a blue-black or black-brown mass, plaque, or ulceration, most frequently on the distal one-third of the anterior vaginal wall. Importantly, they are often nonpigmented. Primary malignant melanomas of the urogenital mucous membranes may have aggressive biological behavior with a high rate of local failure and metastases. The five-year survival rate for vaginal melanomas is usually less than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/17,31-33\">",
"     17,31-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=see_link\">",
"     \"Role of radiation therapy in the management of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Federation of Gynecology and Obstetrics (FIGO) and TNM staging use a clinical staging system for vaginal cancer (",
"    <a class=\"graphic graphic_table graphicRef70622 \" href=\"mobipreview.htm?15/23/15741\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Clinical staging is based upon findings from physical and pelvic examination, cystoscopy, proctoscopy, and chest and skeletal radiography. The results of biopsy or fine-needle aspiration of the",
"    <span class=\"nowrap\">",
"     inguinal/femoral",
"    </span>",
"    or other nodes may be included in the clinical staging. In addition to data used for clinical staging, information available from examination of the resected specimen, including pelvic and peritoneal lymph nodes, is to be used, as noted using the TNM system.",
"   </p>",
"   <p>",
"    A review of five series, which included 1375 cases of vaginal cancer, reported the following distribution of patients by FIGO stage: stage I (26 percent), stage II (37 percent), stage III (24 percent), stage IV (13 percent) (",
"    <a class=\"graphic graphic_table graphicRef79926 \" href=\"mobipreview.htm?16/62/17387\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Routes of spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal tumors may invade locally and disseminate by several routes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct extension to pelvic soft tissue structures: parametria, bladder, urethra, and rectum. Eventually, the bony pelvis may become involved.",
"     </li>",
"     <li>",
"      Lymphatic spread to the pelvic and paraaortic lymph nodes. The lymphatic drainage of the upper vagina communicates with that of the cervix, draining initially into the pelvic nodes and then the paraaortic nodes. By comparison, the lymphatics of the distal one third of the vagina drain first into the inguinal and femoral nodes, and secondarily into the pelvic nodes.",
"     </li>",
"     <li>",
"      Hematogenous dissemination to other organs, including the lungs, liver, and bone, usually is a late manifestation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus as to the appropriate management of vaginal carcinoma. Treatment plans should be individualized depending upon the location, size, and clinical stage of the tumor. A single institution review suggested that tumor stage, site, and size are all important prognostic factors in patients with vaginal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/37\">",
"     37",
"    </a>",
"    ]. Several factors must be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proximity of the bladder, urethra, and rectum to the vagina, which precludes the administration of high dose rate radiation.",
"     </li>",
"     <li>",
"      Local anatomic constraints, which may not permit wide negative surgical margins without an exenterative procedure (eg, removal of the internal genitalia, supporting structures, rectosigmoid, lymphatic pathways, and bladder).",
"     </li>",
"     <li>",
"      Psychosexual issues, including the patient's desire to maintain a functional vagina.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I lesions in the upper vagina that are less than 2 cm in diameter may be treated with either surgery or intracavitary radiation therapy. Lesions in the mid-to lower vagina are typically treated with radiation therapy. The surgical approach requires a radical hysterectomy, upper vaginectomy, and bilateral pelvic lymphadenectomy. If a hysterectomy has been performed previously, then radical vaginectomy and bilateral lymphadenectomies should be done to complete the surgical therapy.",
"   </p>",
"   <p>",
"    For stage II disease, neoadjuvant chemotherapy followed by radical surgery may be a promising alternative to radiation therapy. In a small prospective study, of 11 patients treated with three 21-day cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    chemotherapy, 91 percent demonstrated a clinical response, all were able to undergo surgical resection, and 27 percent achieved a complete pathologic response. Postoperative complications were mild and long term survival was satisfactory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one literature review of surgical treatment with or without adjuvant radiotherapy, the mean five-year survival for stage I, II, III, and IV disease was 77, 52, 44, and 14 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/39\">",
"     39",
"    </a>",
"    ]. The authors concluded that initial surgical therapy followed by selective radiotherapy offered good survival and local tumor control in women with stage I and II squamous vaginal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more superficial lesions may be treated with brachytherapy alone, the treatment of stage I lesions that are greater than 2 cm in diameter and all patients with stage II to IV disease is external beam radiation with or without intracavitary or interstitial brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. Despite the general acceptance of radiation therapy as the main treatment modality, stage-related treatment protocols have not been unequivocally accepted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/41,46\">",
"     41,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22570?source=see_link\">",
"     \"Overview of radiation therapy for gynecologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A total external radiation dose of 40 to 50 Gy is usually necessary for adequate treatment of the primary tumor and the regional lymphatics. Whole pelvic radiation is usually administered to 20 to 40 Gy, followed by an additional parametrial treatment field with a midline block. Extended field radiation to include the paraaortic lymph nodes may be necessary if bulky pelvic or paraaortic disease is present on CT scan or demonstrated at the time of surgical exploration. In addition, inguinofemoral lymph node irradiation is indicated when the primary tumor involves the mid or distal third of the vagina.",
"   </p>",
"   <p>",
"    Pelvic external beam radiation may be followed by intracavitary or interstitial radiation to a total tumor dose of approximately 75 Gy. For primary treatment of tumors involving the upper third of the vagina, intracavitary tandem and ovoids may be used. However, a vaginal cylinder is required if a hysterectomy has been performed. Paravaginal or parametrial interstitial implants or both are used to increase the depth of radiation penetration for carcinomas with more than 0.5 cm of invasion, without delivering excessive doses to the vaginal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/46\">",
"     46",
"    </a>",
"    ]. Interstitial implants are also used if residual tumor is present after the planned external and intracavitary therapy has been completed.",
"   </p>",
"   <p>",
"    Outcomes with contemporary radiation therapy alone for vaginal cancer can be illustrated by the following results from a series of 78 women treated at Stanford University [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/45\">",
"     45",
"    </a>",
"    ]. Five year rates of pelvic control, distant metastasis-free survival and disease-specific survival were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; 83, 100, and 92 percent, respectively",
"     </li>",
"     <li>",
"      Stage II &mdash; 76, 95, and 68 percent, respectively",
"     </li>",
"     <li>",
"      Stage III &mdash; 62, 65, and 44 percent, respectively",
"     </li>",
"     <li>",
"      Stage IV &mdash; 30, 18, and 13 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the view that radiation alone is adequate treatment for stage I and II disease, but that more advanced stage disease requires a combined modality approach. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Locoregionally advanced disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten to 15 percent of patients treated for vaginal cancer will develop treatment related complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/47\">",
"     47",
"    </a>",
"    ]. These include rectovaginal or vesicovaginal fistulas, radiation cystitis or proctitis, rectal and vaginal strictures, and, rarely, vaginal necrosis. The close proximity of the urethra, bladder, and rectum predisposes these structures to injury from surgery or radiation. To decrease the degree of vaginal stenosis, women who are sexually active should be encouraged to remain so throughout radiation treatment. Those who are not sexually active or in whom intercourse is temporarily too painful should use a vaginal dilator with topical estrogen.",
"   </p>",
"   <p>",
"    In women under 40 years of age who receive radiation for vaginal cancer, the risk of radiation-induced premature menopause is substantial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .) Attempts to reduce the toxicity of radiation exposure by moving the ovaries either behind the uterus or to the lateral pelvic walls (oophoropexy) have been variably successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. We perform oophoropexy in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Locoregionally advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the poor prognosis with radiation alone (predominantly local failures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/45\">",
"     45",
"    </a>",
"    ], some investigators advocate the combined use of radiation and concurrent chemotherapy (as is used for cervical or vulvar cancer) in women with high-risk disease (eg, stage III or IV, or tumor size larger than 4 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/41,50,51\">",
"     41,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data on this approach are limited to small retrospective series which conclude that locoregional control rates are high after chemoradiotherapy, and radiation-related long-term side effects do not seem worse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/41,51-53\">",
"     41,51-53",
"    </a>",
"    ]. However, many of these trials enrolled women with stage I or II disease, and prospective randomized trials have not proven the superiority of this approach over radiation alone in women with locoregionally advanced vaginal cancer. Furthermore, at least some data suggests that despite high rate of clinical response, long-term results may be disappointing. This was shown in a series of 67 patients with locally advanced cancer of the lower female genital tract (cervix, vagina, or vulva) who were treated with concomitant radiation and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/52\">",
"     52",
"    </a>",
"    ]. Eighty-five percent had a complete clinical response; however, 35 of the 57 complete clinical responders (61 percent) recurred within a median of six months, and the actuarial five-year survival was only 22 percent.",
"   </p>",
"   <p>",
"    Nevertheless, in light of frequent problems with control of central tumor, the concurrent use of 5-fluorouracil (5-FU)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , as in cervical cancer, seems appropriate for most patients with locoregionally advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of locally advanced cervical cancer\", section on 'Primary chemoradiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/14/9449?source=see_link&amp;anchor=H618915858#H618915858\">",
"     \"Management of early stage cervical cancer\", section on 'Treatment of high-risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a central recurrence after previous radiation therapy may be candidates for pelvic exenteration with or without vaginal reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Exenteration may also be considered in patients with stage IVa disease, especially if a rectovaginal or vesicovaginal fistula is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chemotherapy in patients with recurrent or advanced vaginal cancer is unclear. The Gynecologic Oncology Group experience in 26 patients with advanced disease suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    has insignificant activity in these patients, although the dose was subtherapeutic by modern standards (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/57\">",
"     57",
"    </a>",
"    ]. Similarly, combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C, and cisplatin appears to be relatively inactive in patients with advanced or recurrent disease despite significant activity in earlier stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/58\">",
"     58",
"    </a>",
"    ]. Anecdotal reports suggest activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and combination",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , bleomycin, and cisplatin, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and cisplatin, in patients with early stage squamous vaginal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/17,59,60\">",
"     17,59,60",
"    </a>",
"    ]. However, there are no large series of these regimens to confirm activity in advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surveillance strategy has not been established and clinical practice is variable. Guidelines are available from the expert group the Society of Gynecologic Oncologists (SGO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of symptoms and physical examination:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For low-risk disease (early stage, treated with surgery alone, no adjuvant therapy) &ndash; for the first two years, every six months; and then annually.",
"     </li>",
"     <li>",
"      For high-risk disease (advanced stage, treated with primary",
"      <span class=\"nowrap\">",
"       chemotherapy/radiation",
"      </span>",
"      therapy or surgery plus adjuvant therapy) &ndash; for the first two years, every three months; for year 3 through 5, every six months, and then annually.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cytology (or vaginal cytology if the cervix has been removed) annually. However, the panel concluded that there was insufficient evidence for use of cytology for detection of cancer recurrence but it may have value in the detection of other lower genital tract neoplasia.",
"     </li>",
"     <li>",
"      Routine use of imaging studies was not recommended. Computed tomography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positron emission tomography should be performed",
"      <strong>",
"       ONLY",
"      </strong>",
"      if recurrence is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaginal colposcopy and biopsy are indicated if abnormalities are noted on physical examination.",
"   </p>",
"   <p>",
"    Given the potential for other human papillomavirus-related diseases, such as cervical, vulvar, and anal neoplasia, as well as multifocal vaginal disease, these patients should also be screened for these conditions.",
"   </p>",
"   <p>",
"    Sexual dysfunction and alterations in body image are common after treatment and should be addressed during follow-up visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important variable affecting prognosis is the stage at the time of presentation, reflecting the size and depth of tumor penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/16,40,44,64-67\">",
"     16,40,44,64-67",
"    </a>",
"    ]. As an example, data from a United States national cancer database showed an increased risk of mortality in women with vaginal cancer with stage II or greater disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tumor size &gt;4 cm (five-year survival 65 versus 84 percent in tumors &le;4 cm); mortality was 51 percent higher in women in melanoma compared with squamous vaginal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31208/abstract/67\">",
"     67",
"    </a>",
"    ]. Rates of survival according to disease stage as noted in the latest FIGO statistics are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef80495 \" href=\"mobipreview.htm?43/5/44123\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lower survival rates among women with vaginal cancer compared to those with cancer of the cervix or vulva may reflect the higher proportion of vaginal tumors initially diagnosed at an advanced stage and the potential for treatment complications that prevents aggressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/40/33411?source=see_link\">",
"       \"Patient information: Vaginal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary vaginal cancer is usually a squamous cell carcinoma, but melanoma, sarcoma, adenocarcinoma, and other histologic types also occur (",
"      <a class=\"graphic graphic_table graphicRef72984 \" href=\"mobipreview.htm?33/42/34475\">",
"       table 1",
"      </a>",
"      ). Metastatic disease to the vagina is not uncommon. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vagina neoplasia is associated with the same risk factors as in cervical neoplasia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients present with vaginal bleeding. The posterior wall of the upper one-third of the vagina is the most common site of the tumor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vagina should be inspected as the speculum is removed so as not to miss a lesion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis is accomplished by biopsy of the suspected lesion, which may appear as a mass, a plaque, or an ulcer. If a lesion is not visualized in the presence of abnormal cytologic results, colposcopy of the cervix and vagina should be performed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaginal tumors are staged clinically, based upon findings from physical and pelvic examination, cystoscopy, proctoscopy, and chest and skeletal radiography (",
"      <a class=\"graphic graphic_table graphicRef70622 \" href=\"mobipreview.htm?15/23/15741\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment planning should be individualized depending upon the location, size, and clinical stage of the tumor. Factors that must be considered include the proximity of the tumor to adjacent structures that preclude the administration of high dose rate radiation; local anatomic constraints, which may not permit wide negative surgical margins without an exenterative procedure; and psychosexual issues. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/2\">",
"      Dunn LJ, Napier JG. Primary carcinoma of the vagina. Am J Obstet Gynecol 1966; 96:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/3\">",
"      WAY S. Vaginal metastases of carcinoma of the body of the uterus. J Obstet Gynaecol Br Emp 1951; 58:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/4\">",
"      Bergman F. Carcinoma of the ovary. A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966; 45:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/5\">",
"      Nerdrum TA. Vaginal metastasis of hypernephroma. Report of three cases. Acta Obstet Gynecol Scand 1966; 45:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/6\">",
"      Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002; 84:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/7\">",
"      Madsen BS, Jensen HL, van den Brule AJ, et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. Int J Cancer 2008; 122:2827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/8\">",
"      Vinokurova S, Wentzensen N, Einenkel J, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 2005; 97:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/9\">",
"      Strander B, Andersson-Ellstr&ouml;m A, Milsom I, Spar&eacute;n P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007; 335:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/10\">",
"      Choo YC, Anderson DG. Neoplasms of the vagina following cervical carcinoma. Gynecol Oncol 1982; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/11\">",
"      Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284:878.",
"     </a>",
"    </li>",
"    <li>",
"     Livingston RC. Primary Carcinoma of the Vagina, Thomas CC (Ed), Springfield, IL 1950.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/13\">",
"      Underwood PB Jr, Smith RT. Carcinoma of the vagina. JAMA 1971; 217:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/14\">",
"      Pride GL, Schultz AE, Chuprevich TW, Buchler DA. Primary invasive squamous carcinoma of the vagina. Obstet Gynecol 1979; 53:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/15\">",
"      Gallup DG, Talledo OE, Shah KJ, Hayes C. Invasive squamous cell carcinoma of the vagina: a 14-year study. Obstet Gynecol 1987; 69:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/16\">",
"      Kirkbride P, Fyles A, Rawlings GA, et al. Carcinoma of the vagina--experience at the Princess Margaret Hospital (1974-1989). Gynecol Oncol 1995; 56:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/17\">",
"      Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. Cancer 1998; 83:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/18\">",
"      Ikenberg H, Runge M, G&ouml;ppinger A, Pfleiderer A. Human papillomavirus DNA in invasive carcinoma of the vagina. Obstet Gynecol 1990; 76:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/19\">",
"      Isaacs JH. Verrucous carcinoma of the female genital tract. Gynecol Oncol 1976; 4:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/20\">",
"      Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer 1970; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/21\">",
"      Hanselaar AG, Van Leusen ND, De Wilde PC, Vooijs GP. Clear cell adenocarcinoma of the vagina and cervix. A report of the Central Netherlands Registry with emphasis on early detection and prognosis. Cancer 1991; 67:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/22\">",
"      Verloop J, Rookus MA, van Leeuwen FE. Prevalence of gynecologic cancer in women exposed to diethylstilbestrol in utero. N Engl J Med 2000; 342:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/23\">",
"      Melnick S, Cole P, Anderson D, Herbst A. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 1987; 316:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/24\">",
"      Troisi R, Hatch EE, Titus-Ernstoff L, et al. Cancer risk in women prenatally exposed to diethylstilbestrol. Int J Cancer 2007; 121:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/25\">",
"      Senekjian EK, Frey KW, Anderson D, Herbst AL. Local therapy in stage I clear cell adenocarcinoma of the vagina. Cancer 1987; 60:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/26\">",
"      Senekjian EK, Frey KW, Stone C, Herbst AL. An evaluation of stage II vaginal clear cell adenocarcinoma according to substages. Gynecol Oncol 1988; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/27\">",
"      Frank SJ, Deavers MT, Jhingran A, et al. Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecol Oncol 2007; 105:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/28\">",
"      Hilgers RD, Malkasian GD Jr, Soule EH. Embryonal rhabdomyosarcoma (botryoid type) of the vagina. A clinicopathologic review. Am J Obstet Gynecol 1970; 107:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/29\">",
"      Andrassy RJ, Wiener ES, Raney RB, et al. Progress in the surgical management of vaginal rhabdomyosarcoma: a 25-year review from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Surg 1999; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/30\">",
"      DeMatos P, Tyler D, Seigler HF. Mucosal melanoma of the female genitalia: a clinicopathologic study of forty-three cases at Duke University Medical Center. Surgery 1998; 124:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/31\">",
"      Frumovitz M, Etchepareborda M, Sun CC, et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010; 116:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/32\">",
"      Pandey M, Mathew A, Abraham EK, et al. Primary malignant melanoma of the mucous membranes. Eur J Surg Oncol 1998; 24:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/33\">",
"      Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994; 171:1225.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. Vagina. In: AJCC Cancer Staging Manual, 7th, Springer, New York  p.387.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/35\">",
"      Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209.",
"     </a>",
"    </li>",
"    <li>",
"     Berek JS, Hacker NF. Berek &amp; Hacker's Gynecologic Oncology, 5th, Lippincott Williams &amp; Wilkins, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/37\">",
"      Lian J, Dundas G, Carlone M, et al. Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol 2008; 111:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/38\">",
"      Benedetti Panici P, Bellati F, Plotti F, et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecol Oncol 2008; 111:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/39\">",
"      Tjalma WA, Monaghan JM, de Barros Lopes A, et al. The role of surgery in invasive squamous carcinoma of the vagina. Gynecol Oncol 2001; 81:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/40\">",
"      Tewari KS, Cappuccini F, Puthawala AA, et al. Primary invasive carcinoma of the vagina: treatment with interstitial brachytherapy. Cancer 2001; 91:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/41\">",
"      Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005; 62:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/42\">",
"      Reddy S, Saxena VS, Reddy S, et al. Results of radiotherapeutic management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1991; 21:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/43\">",
"      Spirtos NM, Doshi BP, Kapp DS, Teng N. Radiation therapy for primary squamous cell carcinoma of the vagina: Stanford University experience. Gynecol Oncol 1989; 35:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/44\">",
"      Perez CA, Grigsby PW, Garipagaoglu M, et al. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1999; 44:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/45\">",
"      Tran PT, Su Z, Lee P, et al. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 2007; 105:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/46\">",
"      Stock RG, Mychalczak B, Armstrong JG, et al. The importance of brachytherapy technique in the management of primary carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1992; 24:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/47\">",
"      Rubin SC, Young J, Mikuta JJ. Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. Gynecol Oncol 1985; 20:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/48\">",
"      Chambers SK, Chambers JT, Kier R, Peschel RE. Sequelae of lateral ovarian transposition in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys 1991; 20:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/49\">",
"      Damewood MD, Hesla HS, Lowen M, Schultz MJ. Induction of ovulation and pregnancy following lateral oophoropexy for Hodgkin's disease. Int J Gynaecol Obstet 1990; 33:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/50\">",
"      Grigsby PW. Vaginal cancer. Curr Treat Options Oncol 2002; 3:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/51\">",
"      Dalrymple JL, Russell AH, Lee SW, et al. Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer 2004; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/52\">",
"      Roberts WS, Hoffman MS, Kavanagh JJ, et al. Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract. Gynecol Oncol 1991; 43:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/53\">",
"      Samant R, Lau B, E C, et al. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 2007; 69:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/54\">",
"      Al-Kurdi M, Monaghan JM. Thirty-two years experience in management of primary tumours of the vagina. Br J Obstet Gynaecol 1981; 88:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/55\">",
"      Berek JS, Hacker NF, Lagasse LD. Vaginal reconstruction performed simultaneously with pelvic exenteration. Obstet Gynecol 1984; 63:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/56\">",
"      Benson C, Soisson AP, Carlson J, et al. Neovaginal reconstruction with a rectus abdominis myocutaneous flap. Obstet Gynecol 1993; 81:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/57\">",
"      Thigpen JT, Blessing JA, Homesley HD, et al. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol 1986; 23:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/58\">",
"      Belinson JL, Stewart JA, Richards AL, McClure M. Bleomycin, vincristine, mitomycin-C, and cisplatin in the management of gynecological squamous cell carcinomas. Gynecol Oncol 1985; 20:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/59\">",
"      Umesaki N, Kawamura N, Tsujimura A, et al. Stage II vaginal cancer responding to chemotherapy with irinotecan and cisplatin: a case report. Oncol Rep 1999; 6:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/60\">",
"      Kim DS, Moon H, Hwang YY, Park MI. Histologic disappearance of locally advanced vaginal cancer after combination chemotherapy. Gynecol Oncol 1990; 38:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/61\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/62\">",
"      Andreasson B, Moth I, Jensen SB, Bock JE. Sexual function and somatopsychic reactions in vulvectomy-operated women and their partners. Acta Obstet Gynecol Scand 1986; 65:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/63\">",
"      Green MS, Naumann RW, Elliot M, et al. Sexual dysfunction following vulvectomy. Gynecol Oncol 2000; 77:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/64\">",
"      Nori D, Hilaris BS, Stanimir G, Lewis JL Jr. Radiation therapy of primary vaginal carcinoma. Int J Radiat Oncol Biol Phys 1983; 9:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/65\">",
"      Brady LW, Perez CA, Bedwinek JM. Failure patterns in gynecologic cancer. Int J Radiat Oncol Biol Phys 1986; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/66\">",
"      Hellman K, Lundell M, Silfversw&auml;rd C, et al. Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer 2006; 16:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31208/abstract/67\">",
"      Beller U, Sideri M, Maisonneuve P, et al. Carcinoma of the vagina. J Epidemiol Biostat 2001; 6:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3221 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-A006EFEBA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31208=[""].join("\n");
var outline_f30_30_31208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Routes of spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment-related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Locoregionally advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3221\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3221|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/52/42822\" title=\"picture 1\">",
"      Sarcoma botryoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3221|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/42/34475\" title=\"table 1\">",
"      Histology of vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/23/15741\" title=\"table 2\">",
"      Staging vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/62/17387\" title=\"table 3\">",
"      Vaginal CA stage distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/5/44123\" title=\"table 4\">",
"      Vaginal cancer survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/40/33411?source=related_link\">",
"      Patient information: Vaginal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8713?source=related_link\">",
"      Role of radiation therapy in the management of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/27/5560?source=related_link\">",
"      Vaginal intraepithelial neoplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31209="Treatment and prognosis of cutaneous squamous cell carcinoma";
var content_f30_30_31209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of cutaneous squamous cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Timothy K Chartier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31209/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/30/31209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous squamous cell carcinoma (SCC) is a common cancer arising from malignant proliferation of the keratinocytes of the epidermis. Treatment of cutaneous SCC is indicated since progression of the tumor may lead to local tissue destruction or metastasis resulting in significant morbidity or death. Early treatment provides the best opportunity to cure cutaneous SCC.",
"   </p>",
"   <p>",
"    In contrast to basal cell carcinoma (BCC), which rarely metastasizes, around 2 to 5 percent of cutaneous SCCs metastasize to regional lymph nodes or more distant sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The approach to treatment is dependent upon the presence or absence of tumor features and patient characteristics that portend an increased risk for aggressive tumor behavior. Cutaneous SCCs that do not have high-risk features have low frequencies of recurrence and metastasis.",
"   </p>",
"   <p>",
"    The treatment of cutaneous SCCs",
"    <strong>",
"     without",
"    </strong>",
"    features associated with aggressive behavior (low-risk cutaneous SCC) and the prognosis of cutaneous SCC will be reviewed here. The management of high-risk and metastatic cutaneous SCCs, the treatment of keratoacanthomas, and the risk factors, clinical features, and diagnosis of cutaneous SCC are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24632?source=see_link\">",
"     \"Keratoacanthoma: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of locoregional recurrence and regional or distant metastasis is the most important factor for determining the approach to the treatment for cutaneous SCC. Examples of characteristics that impact the risk for recurrence and metastasis include the site, size, and histological features of a tumor, as well as patient comorbidities (",
"    <a class=\"graphic graphic_table graphicRef83683 \" href=\"mobipreview.htm?21/43/22203\">",
"     table 1",
"    </a>",
"    ). &ldquo;High-risk&rdquo; SCCs are tumors that exhibit characteristics that are associated with elevated risk for aggressive tumor behavior. The features of high-risk cutaneous SCC are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major treatment options for low-risk cutaneous SCC include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical excision",
"     </li>",
"     <li>",
"      Cryotherapy",
"     </li>",
"     <li>",
"      Electrosurgery (ie, electrodesiccation and curettage)",
"     </li>",
"     <li>",
"      Topical treatment (5-fluorouracil or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Radiation therapy",
"     </li>",
"     <li>",
"      Photodynamic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mohs surgery, a specialized tissue-sparing procedure that involves histological assessment of 100 percent of the excised tumor margin, is primarily reserved for the treatment of tumors with high-risk features. However, Mohs surgery has also been used for the treatment of tumors without high-risk features, particularly for tumors in locations in which a tissue-sparing surgical modality is desired (eg, tumors in cosmetically sensitive areas) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H1262413#H1262413\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Mohs surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LOW-RISK LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision, cryotherapy, electrosurgery, radiation therapy, topical therapy, and photodynamic therapy can be effective treatments for cutaneous SCC in properly selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is appropriate for both low-risk and high-risk cutaneous SCCs, and is frequently used for treatment. Excision usually can be performed in an outpatient setting under local anesthesia.",
"   </p>",
"   <p>",
"    Surgical excision is well-tolerated and effective, and the completeness of the procedure can be evaluated through histological assessment of the specimen's margins. Five-year cure rates are reported to be 92 and 77 percent for primary and recurrent cutaneous SCCs, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for surgical margins vary depending upon the risk for local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/6\">",
"     6",
"    </a>",
"    ]. Well-defined, small (&lt;2 cm) cutaneous SCCs lacking any high-risk features require a 4 mm margin of normal tissue around the visible tumor to result in a 95 percent histologic cure rate (",
"    <a class=\"graphic graphic_table graphicRef83683 \" href=\"mobipreview.htm?21/43/22203\">",
"     table 1",
"    </a>",
"    ). Surgical excision for high-risk cutaneous SCC is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084851#H90084851\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryotherapy destroys malignant cells by freezing and thawing. It may be used for small, well-defined, low-risk invasive cutaneous SCCs and for Bowen&rsquo;s disease (cutaneous SCC in situ) (",
"    <a class=\"graphic graphic_picture graphicRef82358 \" href=\"mobipreview.htm?38/34/39464\">",
"     picture 1",
"    </a>",
"    ). Contraindications to cryotherapy are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef64333 \" href=\"mobipreview.htm?11/17/11547\">",
"     table 2",
"    </a>",
"    ). The procedure should only be performed by clinicians trained in the treatment of skin cancer with cryotherapy.",
"   </p>",
"   <p>",
"    In the most common cryosurgery technique, liquid nitrogen is applied to the tumor and a surrounding rim of normal-appearing skin (usually &ge;3 mm). The frozen area is then allowed to thaw in an unaided fashion. In most cases, the tumor is refrozen to complete two freeze-thaw cycles; for Bowen's disease, a single freeze-thaw cycle may be sufficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/7\">",
"     7",
"    </a>",
"    ]. Tumor cell death is due to the formation of intracellular and extracellular ice crystals, hypertonicity, disruption of the phospholipid membrane, and vascular stasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H19#H19\">",
"     \"Dermatologic procedures\", section on 'Cryosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cryosurgery does not permit histological confirmation of the adequacy of treatment margins; thus, a substantial amount of training and experience is required to achieve consistently high cure rates.",
"   </p>",
"   <p>",
"    Cryotherapy is fast, cost effective, and requires little if any anesthesia. Following treatment, there is usually moderate to severe swelling, pain, and oozing that resolve over days to weeks. The treated area subsequently sloughs, leaving behind an ulceration that heals over four to six weeks. This may result in residual hypopigmentation, permanent alopecia, or hypertrophic scarring that may be unacceptable to some patients. Treated areas on the lower extremities may take longer to heal.",
"   </p>",
"   <p>",
"    Hypopigmentation can persist for many years and may be a particular problem for darkly pigmented individuals or patients with SCCs in cosmetically sensitive areas. When performed by experienced clinicians, cosmetic results are generally excellent, and cure rates as high as 96 to 99 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryosurgery is not indicated for recurrent, large, deeply invasive, poorly-defined, and other high-risk cutaneous SCCs because of the increased risk of local recurrence and metastatic spread. However, it can be considered for patients with high-risk tumors who are unable to tolerate either Mohs or excisional surgery or the frequent visits necessary for radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084858#H90084858\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodesiccation and curettage (ED&amp;C) may be used for small, superficial, well-defined cutaneous SCCs and lesions of Bowen&rsquo;s disease (cutaneous SCC in situ) that are located in noncritical, low-risk sites. Electrosurgery is a relatively quick, well-tolerated office procedure that spares adjacent healthy tissue. It is associated with a low complication rate, is relatively inexpensive, and usually gives favorable cosmetic results.",
"   </p>",
"   <p>",
"    Cutaneous SCCs and BCCs have a distinctive \"feel\" that is distinctly different from normal healthy tissue. This \"feel\" guides the curettage of tumor tissue away from surrounding healthy tissue. By alternately curetting away tumor and then electrodesiccating the ulcer base plus a rim of surrounding normal skin, cure rates of 95 percent or better have been reported in carefully selected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/5,11-15\">",
"     5,11-15",
"    </a>",
"    ]. However, higher recurrence rates (10 to 20 percent) have been reported by others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatologic procedures\", section on 'Curettage and electrodesiccation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with cryosurgery, the main disadvantage of electrosurgery is the lack of histologic confirmation of the tumor margins, thereby limiting its use to small, well-defined primary (non-recurrent) low-risk tumors. In addition, the cosmetic outcome in areas such as the nose, face, lips, or ears can be inferior to that obtained with either surgical excision or Mohs surgery, particularly for younger patients in whom cosmesis is an important secondary objective.",
"   </p>",
"   <p>",
"    Electrosurgery is contraindicated for recurrent, large, poorly-defined, and other high-risk tumors. Furthermore, it is inappropriate for tumors that invade into or beyond the subcutaneous tissues where the expected discriminating \"feel\" between cancerous and healthy tissue is lost. In this situation, electrosurgery should be abandoned in favor of surgical excision or Mohs surgery.",
"   </p>",
"   <p>",
"    Electrosurgery should also be avoided on the mid-face (mid-nose, nasal alae and sulci, medial canthi, and nasolabial folds). The embryonic fusion planes in these areas are believed to offer little resistance to the early and deep invasion by cancer cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/16\">",
"     16",
"    </a>",
"    ]. If tumors in this area are partially treated, healing skin can bury residual tumor beneath scar tissue. By the time a recurrence is clinically evident, the tumor can be massive and curative treatment extremely difficult or impossible. Thus, cutaneous SCCs located in the mid-face are better treated by standard excision or Mohs surgery. Radiation therapy is an option for patients not able or willing to undergo surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is an option for the initial management of small, well-defined, primary cutaneous SCCs. However, due to the potential long-term adverse effects of radiation treatment, this modality is primarily reserved for older patients and patients who are not surgical candidates.",
"   </p>",
"   <p>",
"    Various techniques have been used, including superficial x-rays, electrons, and megavoltage photons; radiation therapy is usually administered in a fractionated schedule over several weeks, requiring as many as 30 treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/17\">",
"     17",
"    </a>",
"    ]. For low risk cutaneous SCCs, the five-year cure rate is approximately 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the major benefits of radiation therapy is its sparing of normal, healthy tissue, thereby permitting superior cosmetic results for tumors located on or around the lips, nose, and eyelids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/20\">",
"     20",
"    </a>",
"    ]. These cosmetic results may deteriorate with time and are less favorable for larger tumors because of the higher doses of radiation required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drawbacks associated with the use of radiation therapy include the lack of histologic control of tumor margins, high cost compared to other modalities, and the potential short-term and long-term side effects associated with radiation (",
"    <a class=\"graphic graphic_table graphicRef82148 \" href=\"mobipreview.htm?12/54/13163\">",
"     table 3",
"    </a>",
"    ). In addition, cutaneous SCCs that recur following radiation may behave more aggressively than those that recur after surgery, with higher rates of local recurrence and metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Situations in which radiation therapy generally should be avoided include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors located on the hands and feet. These areas are subjected to greater trauma and tension than skin on the head, neck, trunk, and proximal extremities, and may be more likely to break down and ulcerate as a result of the atrophy and poor vascularity of irradiated tissue.",
"     </li>",
"     <li>",
"      Patients younger than 40 to 50 years of age, because of the potential for late complications.",
"     </li>",
"     <li>",
"      Lesions over the nose or ears. Radiation of cartilaginous and bony structures may result in painful and disfiguring chondroradionecrosis and osteoradionecrosis, although this is uncommon with modern fractionated regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent SCCs that have been previously irradiated, because of the potential damage to normal tissues from high cumulative doses of radiation.",
"     </li>",
"     <li>",
"      Radiation therapy should never be used in patients with basal cell nevus syndrome since it may induce numerous skin cancers that are difficult to manage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=see_link&amp;anchor=H11#H11\">",
"       \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Basal cell nevus syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Verrucous carcinoma, since several reports have documented anaplastic transformation with subsequent widespread metastases following radiation therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiation therapy is generally not used as monotherapy for recurrent SCCs, large or poorly defined lesions, and cancers with other high-risk features, since cure rates are lower compared to Mohs surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/17-19,26\">",
"     17-19,26",
"    </a>",
"    ]. In one series, the long-term control rates with radiation therapy were 91, 76, and 56 percent for lesions less than 1 cm in diameter, between 1 and 5 cm, and larger than 5 cm, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/17\">",
"     17",
"    </a>",
"    ]. Recurrent SCCs were adequately controlled in only 65 percent of cases. In another report of 121 locally advanced cutaneous SCCs, the four-year disease-specific survival after radiation therapy alone was only 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084858#H90084858\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Topical 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical 5-fluorouracil (5-FU) is approved by the US Food and Drug Administration (FDA) for the treatment of actinic keratoses. Although topical 5-FU is not approved for the treatment of Bowen&rsquo;s disease (cutaneous SCC in situ), it is widely used for this indication when other treatment modalities are impractical and for patients who refuse surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. It is especially valuable for situations in which postoperative healing is compromised, such as lesions that involve the lower extremity in elderly patients or patients with venous stasis disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/30\">",
"     30",
"    </a>",
"    ]. Topical 5-FU is also useful to treat the widespread SCC in situ lesions that may occur in arsenical dermatitis or xeroderma pigmentosum (XP). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=see_link\">",
"     \"Arsenic exposure and poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical 5-FU is available in 5%, 1%, and 0.5% concentrations. The 1% and 0.5% concentrations are prescribed for the management of actinic keratoses, and are not recommended for the treatment of Bowen&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30968?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of actinic keratosis\", section on 'Topical 5-fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the treatment of Bowen&rsquo;s disease, 5-FU 5% cream is applied twice daily for four to eight weeks, depending upon the response. Treatment courses of four weeks (once daily for one week, then twice daily for three weeks) with this formulation have resulted in clinical cure rates of 48 and 56 percent in small, randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Longer treatment courses may result in higher clearance rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/33\">",
"     33",
"    </a>",
"    ]. In one small, uncontrolled study in which the 5% cream was administered twice daily for an average of eight weeks, clinical cure occurred in 85 percent of patients (average follow-up time = 4.6 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    length of treatment, insufficient drug concentration, application to an insufficiently wide area around clinically obvious tumor, and improper tumor selection all can contribute to treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/27,28,35\">",
"     27,28,35",
"    </a>",
"    ]. Local recurrences may also result from poor penetration of 5-FU into the epithelium of involved pilosebaceous units, the source of regenerative epithelium following destruction of the epidermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Courses can be repeated as necessary for residual or recurrent disease. Efficacy may be enhanced by using an occlusive dressing, or applying it in conjunction with a topical keratolytic agent (salicylic acid, lactic acid, ammonium lactate) or retinoic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An inflammatory reaction is expected with topical 5-FU, and its absence can be associated with a poor response to treatment. The inflammatory reaction to 5-FU is usually more intense in patients treated for Bowen's disease than for those with actinic keratoses or superficial BCCs.",
"   </p>",
"   <p>",
"    Following discontinuation of 5-FU, healing generally occurs over two or more weeks, leaving residual erythema and hyperpigmentation that fade with time. Favorable cosmetic results are one of the primary advantages of topical 5-FU over other treatment modalities for patients with Bowen's disease.",
"   </p>",
"   <p>",
"    Prior to treatment, patients should be thoroughly educated about the anticipated effects, including stinging, burning, pain, erythema, edema, erosions and ulceration with serous oozing, and possible secondary infections. It is not uncommon for patients to become social recluses during treatment because of the undesirable cosmetic effects.",
"   </p>",
"   <p>",
"    If the patient cannot tolerate the intense inflammatory reaction, options include reducing the concentration of drug, applying an emollient such as chilled vaseline or hydrated petrolatum or an intermediate potency topical steroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    ), or the temporary or even permanent discontinuation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special care should be taken when applying 5-FU to areas near the eyes, lips, and nose because of increased sensitivity in these areas. In addition, patients should avoid intense sun exposure during treatment.",
"   </p>",
"   <p>",
"    Unusual side effects include temporary reversible onycholysis and onychodystrophy, persistent telangiectasias, hypertrophic scarring in high-risk areas, and bullous pemphigoid.",
"   </p>",
"   <p>",
"    Toxicity due to systemic drug absorption is rare, but serious side effects (eg, cardiac ischemia, enterotoxicity) have been reported in patients with an inherited deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H5#H5\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on '5-Fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical 5-FU is contraindicated in the management of invasive lesions, except possibly for palliation of tumors not amenable to other more effective treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy can be used for the treatment of Bowen&rsquo;s disease (cutaneous SCC in situ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. PDT is not recommended for the treatment of invasive SCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Photodynamic therapy (PDT) is based upon the ability of porphyrins to produce cytotoxicity in the presence of oxygen after stimulation by light of an appropriate wavelength. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/7/35955?source=see_link\">",
"     methyl aminolevulinate",
"    </a>",
"    (MAL) is utilized as a photosensitizer. Application of the topical photosensitizer is followed by an incubation period after which the site of treatment is irradiated with a selected light.",
"   </p>",
"   <p>",
"    The efficacy of PDT for Bowen&rsquo;s disease was illustrated by a randomized trial in which 225 patients were randomly assigned to PDT with MAL (MAL-PDT), PDT using a placebo, or conventional treatment (either cryotherapy or topical 5-FU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/32\">",
"     32",
"    </a>",
"    ]. The lesion recurrence rates at 12 months were similar with MAL-PDT, cryotherapy, and topical 5-FU (15, 21, and 17 percent, respectively).",
"   </p>",
"   <p>",
"    Factors influencing study outcome include different methods of photosensitizer administration, variability in the types and methods of light exposure, the definition of recurrent disease (clinically detected versus histologically assessed), and the length of follow-up. Clinical disadvantages associated with PDT include the high number of treatments required and the associated discomfort. Rare cases of invasive SCC and melanoma have been reported following PDT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is a topical immune response modifier approved by the FDA for the treatment of anogenital warts, actinic keratoses, and superficial basal cell carcinomas. Its antitumor effects are thought to be mediated by the stimulation of local cytokine production, cell-mediated immunity, and possibly the promotion of apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=see_link&amp;anchor=H16#H16\">",
"     \"Condylomata acuminata (anogenital warts)\", section on 'Imiquimod'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    has been used to treat Bowen&rsquo;s disease (cutaneous SCC in situ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/30,42,47-49\">",
"     30,42,47-49",
"    </a>",
"    ]. Treatment regimens vary, with most requiring daily application for 6 to 16 weeks. The required course of treatment is significantly longer than with topical 5-FU, and the inflammatory response can be quite dramatic. These factors can create difficulty in patient compliance and result in lower cure rates. Although a small, randomized trial and several small, uncontrolled studies have demonstrated cure rates ranging from 73 to 88 percent, large, well-designed, prospective, double-blind studies with long-term follow-up and histologic confirmation of clinical response are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its use as a single agent, daily applications of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    have been successfully combined with topical 5-FU to treat patients who had failed to respond to monotherapy with one or the other of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the reports of the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , invasive SCC has developed following treatment in at least two cases, one of which had clinically responded to the initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is not approved by the FDA for patients with invasive SCC or Bowen&rsquo;s disease. Larger randomized trials are necessary to define the role of imiquimod compared to other treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HIGH-RISK LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive treatment is required for high-risk lesions to maximize the likelihood of cure with the initial treatment (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Approach to treatment'",
"    </a>",
"    above). Surgery, using either conventional excision or the Mohs technique, is the primary approach in this setting. The management of cutaneous SCC with high-risk features or locoregional or distant metastases is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15063?source=see_link\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LOCOREGIONAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the extent of disease is critical to maximize the likelihood of long-term control. The initial evaluation of all patients should include physical examination of locoregional lymph nodes. For most localized SCCs, this initial evaluation is sufficient and, if negative, no further work-up is required. Surgery plus adjuvant radiation therapy is often used for the management of nodal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15063?source=see_link&amp;anchor=H19785703#H19785703\">",
"     \"Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma\", section on 'Squamous cell carcinoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084865#H90084865\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Management of nodal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15392004\">",
"    <span class=\"h1\">",
"     SYSTEMIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy for the treatment of patients with distant metastases or locally advanced disease that cannot be managed with surgery or radiation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall prognosis for patients with a primary cutaneous SCC is excellent, with an overall five-year cure rate of greater than 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/5\">",
"     5",
"    </a>",
"    ]. In the United States, the estimated yearly disease-specific mortality rate is about 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], while in Australia and Denmark, which have more well-established registration systems for cancer incidence and mortality, an estimated overall mortality rate of 3 to 4 percent has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/1,54\">",
"     1,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the initial treatment is unsuccessful, disease is most likely to recur either locally or in regional lymph nodes, with approximately 75 percent of recurrences developing within the first two years and 95 percent within five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/5\">",
"     5",
"    </a>",
"    ]. Rates of metastasis from primary SCC are reported to be around 2 to 5 percent overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of regional lymph node metastases places the patient at increased risk for the subsequent development of distant metastases. About 85 percent of metastases occur in regional lymph nodes, with the remainder occurring in distant sites such as the lungs, liver, brain, skin, and bone. Distant metastases are generally limited to patients who recurred locally or in regional lymph nodes, or to those whose original tumor was neglected and left untreated for a prolonged period or was misdiagnosed.",
"   </p>",
"   <p>",
"    The risks for local recurrence and distant metastasis are impacted by tumor characteristics and patient characteristics (",
"    <a class=\"graphic graphic_table graphicRef83683 \" href=\"mobipreview.htm?21/43/22203\">",
"     table 1",
"    </a>",
"    ). The effect of tumor size was illustrated by a series of 615 assessable patients with SCC who were referred to a single center for primary surgical excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of 43 months, both the rates of local recurrence and distant metastasis were related to the thickness of the tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Among 207 patients with tumors &le;2 mm thick, one had a local recurrence (0.5 percent), and none developed metastases.",
"     </li>",
"     <li>",
"      Among 318 with tumors 2.1 to 6.0 mm thick, eight (2.5 percent) had a local recurrence and 12 (3.8 percent) had metastases.",
"     </li>",
"     <li>",
"      Among 90 patients with tumors &gt;6.0 mm thick, 11 (12.2 percent) developed a local recurrence and 14 (15.6 percent) developed metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, the diameter size of the tumor correlated with the likelihood of local recurrence and distant metastasis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Among the 425 patients with tumors &le;20 mm in diameter, seven had a local recurrence (1.6 percent) and eight (1.9 percent) developed metastases.",
"     </li>",
"     <li>",
"      Among 160 patients with tumors 21 to 50 mm, nine (2.1 percent) had a local recurrence and 12 (7.5 percent) had metastases.",
"     </li>",
"     <li>",
"      Among 30 patients with tumors &gt;6.0 mm, four (13.3 percent) developed a local recurrence and six (20 percent) developed metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The size and depth of tumors are included in the TNM staging system for cutaneous SCC (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"mobipreview.htm?5/0/5134\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084812#H90084812\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both regional lymph node and distant metastases are associated with a markedly increased risk of disease-related mortality. Overall survival rates for patients with regional lymph node metastases are about 25 to 35 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/1,5,55,56\">",
"     1,5,55,56",
"    </a>",
"    ] and less than 20 percent at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/57\">",
"     57",
"    </a>",
"    ]. In patients with distant metastases, the five-year survival rate is less than 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/5,57\">",
"     5,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with recessive dystrophic epidermolysis bullosa and SCC constitute an exception to the favorable prognosis associated with SCC. Although SCCs in these patients are well differentiated, they are biologically aggressive, with a high incidence of metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Epidermolysis bullosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Second skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of a nonmelanoma skin cancer have a much higher incidence of a second skin cancer (SCC, BCC, or melanoma) compared to the general population, presumably because all of these tumors share common risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. After a primary SCC, the estimated risk for any second nonmelanoma skin cancer is about 50 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/58,63\">",
"     58,63",
"    </a>",
"    ], and the risk of another SCC is estimated to be about 18 percent at three years and 30 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of a second skin cancer is greatest in the first year after primary diagnosis, because of increased surveillance after the initial diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/60,63\">",
"     60,63",
"    </a>",
"    ]. Patients at an especially high risk for a second skin cancer include those with more than one previous SCC, fair-skinned individuals, and those who are immunosuppressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other second cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data suggest that cutaneous SCC is associated with an increased incidence of cancers at other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/60,65-69\">",
"     60,65-69",
"    </a>",
"    ]. Increased mortality among patients with other types of cancer who have a history of cutaneous SCC has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased incidence for other cancers in individuals with cutaneous SCC was illustrated by a cohort study that followed a group of 19,174 persons over a 16-year follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31209/abstract/65\">",
"     65",
"    </a>",
"    ]. People with either confirmed cutaneous SCC or basal cell carcinoma had an overall twofold increase in second malignancies (including lung, colon, and breast), after adjusting for differences in sex, age, body mass index, smoking status, and educational level. The study was based upon nonmelanoma skin cancers ascertained through a cancer registry of pathologically confirmed tumors and may not be representative of all people with such skin cancers. As such, the reported risk is likely to be overestimated.",
"   </p>",
"   <p>",
"    Although these observations suggest a modest increase in the incidence of multiple other cancers, routine evaluation for systemic malignancy is not indicated in healthy individuals who are diagnosed with primary cutaneous SCC or basal cell carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30602820\">",
"    <span class=\"h1\">",
"     ORGAN TRANSPLANT RECIPIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cutaneous SCC in organ transplant recipients is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=see_link\">",
"     \"Management of skin cancer in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients treated for cutaneous SCC need surveillance for the early recognition and management of treatment-related complications, local or regional recurrences, and the development of new skin cancers. We recommend that patients be seen every three to six months for the first two years, then yearly thereafter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084886#H90084886\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The examination should include inspection of the treated area for visible signs of recurrence and palpation of the skin and adjacent structures (including lymph nodes) to evaluate for possible deeper recurrence or regional metastasis. Asking patients about any visible, textural, or sensory changes involving the treated area can often be a helpful clue of a subclinical or deeper recurrence. In addition, patients should be encouraged to perform interim skin self-examinations and to see their health care provider for any new skin growths or other suspicious lesions.",
"   </p>",
"   <p>",
"    Any suspicious areas should be biopsied. For suspected deep recurrences, deeper punch biopsies may be required. Early detection and treatment may prevent an incurable local recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/26/26018?source=see_link\">",
"       \"Patient information: Skin cancer (non-melanoma) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous squamous cell carcinomas (SCCs) are common lesions that are cured with local therapy in over 90 percent of cases. Cutaneous SCCs have a higher potential for local recurrence and regional or distant metastases than basal cell carcinomas. Delayed diagnosis or inadequate treatment can result in increased morbidity or death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of local regional recurrence and regional or distant metastasis is the most important factor in determining the approach to the treatment of cutaneous SCC. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Approach to treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=see_link&amp;anchor=H90084722#H90084722\">",
"     \"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma\", section on 'High-risk features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major treatment options for cutaneous SCC with features that suggest a low-risk for recurrence and metastasis are surgical excision, cryotherapy, electrosurgery, and radiation therapy. The specific choice of treatment modality depends upon the experience of the physician, the expected cure rate, cosmetic factors, and patient preference.",
"     </li>",
"     <li>",
"      Topical chemotherapy with 5-FU or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      and photodynamic therapy are additional treatment options for patients with Bowen&rsquo;s disease (cutaneous SCC in situ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgical excision'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Cryotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Electrosurgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation therapy is an additional option for the management of primary cutaneous SCCs in older patients and those who are not surgical candidates. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful follow-up is required to evaluate for evidence of local recurrence, regional or distant metastasis, and treatment-related complications. We generally reassess patients every three to six months for two years and then annually after the initial diagnosis and treatment of SCC. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/1\">",
"      Joseph MG, Zulueta WP, Kennedy PJ. Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. Aust N Z J Surg 1992; 62:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/2\">",
"      Brantsch KD, Meisner C, Sch&ouml;nfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/3\">",
"      Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012; 106:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/4\">",
"      Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012; 67:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/5\">",
"      Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/6\">",
"      Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 27:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/7\">",
"      Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/8\">",
"      Kuflik EG. Cryosurgery updated. J Am Acad Dermatol 1994; 31:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/9\">",
"      Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991; 24:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/10\">",
"      Zacarian SA. Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol 1983; 9:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/11\">",
"      KNOX JM, LYLES TW, SHAPIRO EM, MARTIN RD. Curettage and electrodesiccation in the treatment of skin cancer. Arch Dermatol 1960; 82:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/12\">",
"      Whelan CS, Deckers PJ. Electrocoagulation and curettage for carcinoma involving the skin of the face, nose, eyelids, and ears. Cancer 1973; 31:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/13\">",
"      Honeycutt WM, Jansen GT. Treatment of squamous cell carcinoma of the skin. Arch Dermatol 1973; 108:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/14\">",
"      Whelan CS, Deckers PJ. Electrocoagulation for skin cancer: an old oncologic tool revisited. Cancer 1981; 47:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/15\">",
"      Chren MM, Linos E, Torres JS, et al. Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma. J Invest Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/16\">",
"      Panje WR, Ceilley RI. The influence of embryology of the mid-face on the spread of epithelial malignancies. Laryngoscope 1979; 89:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/17\">",
"      Lovett RD, Perez CA, Shapiro SJ, Garcia DM. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990; 19:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/18\">",
"      Locke J, Karimpour S, Young G, et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001; 51:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/19\">",
"      Petrovich Z, Parker RG, Luxton G, et al. Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients. Radiother Oncol 1987; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/20\">",
"      Petsuksiri J, Frank SJ, Garden AS, et al. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 2008; 112:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/21\">",
"      Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/22\">",
"      Petrovich Z, Kuisk H, Langholz B, et al. Treatment of carcinoma of the skin with bone and/or cartilage involvement. Am J Clin Oncol 1988; 11:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/23\">",
"      Kraus FT, Perezmesa C. Verrucous carcinoma. Clinical and pathologic study of 105 cases involving oral cavity, larynx and genitalia. Cancer 1966; 19:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/24\">",
"      Perez CA, Kraus FT, Evans JC, Powers WE. Anaplastic transformation in verrucous carcinoma of the oral cavity after radiation therapy. Radiology 1966; 86:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/25\">",
"      Demian SD, Bushkin FL, Echevarria RA. Perineural invasion and anaplastic transformation of verrucous carcinoma. Cancer 1973; 32:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/26\">",
"      Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/27\">",
"      Sturm HM. Bowen's disease and 5-fluorouracil. J Am Acad Dermatol 1979; 1:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/28\">",
"      Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981; 4:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/29\">",
"      Klein E, Stoll HL Jr, Milgrom H, et al. Tumors of the skin. XII. Topical 5-Fluorouracil for epidermal neoplasms. J Surg Oncol 1971; 3:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/30\">",
"      Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/31\">",
"      Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/32\">",
"      Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 2006; 142:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/33\">",
"      Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/34\">",
"      Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg 2003; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/35\">",
"      Stone N, Burge S. Bowen's disease of the leg treated with weekly pulses of 5% fluorouracil cream. Br J Dermatol 1999; 140:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/36\">",
"      Hunter GA. Follicular Bowen's disease. Br J Dermatol 1977; 97:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/37\">",
"      Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995; 49:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/38\">",
"      Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/39\">",
"      Hamouda B, Jamila Z, Najet R, et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol 2001; 44:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/40\">",
"      Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/41\">",
"      Truchuelo M, Fern&aacute;ndez-Guarino M, Fleta B, et al. Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions. J Eur Acad Dermatol Venereol 2012; 26:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/42\">",
"      Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg 2011; 37:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/43\">",
"      Varma S, Holt PJ, Anstey AV. Erythroplasia of queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 2000; 142:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/44\">",
"      Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/45\">",
"      Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/46\">",
"      Sch&ouml;n M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/47\">",
"      Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001; 137:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/48\">",
"      Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/49\">",
"      Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007; 33:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/50\">",
"      Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol 2006; 55:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/51\">",
"      Goh MS. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 2006; 47:186.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer facts and figures 2003 www.cancer.org/docroot/STT/stt_0_2003.asp?sitearea=STT&amp;level=1 (Accessed on April 02, 2004).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/53\">",
"      Weinstock MA. Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back Study. J Invest Dermatol 1994; 102:6S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/54\">",
"      Osterlind A, Hjalgrim H, Kulinsky B, Frentz G. Skin cancer as a cause of death in Denmark. Br J Dermatol 1991; 125:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/55\">",
"      Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/56\">",
"      Kraus DH, Carew JF, Harrison LB. Regional lymph node metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/57\">",
"      Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/58\">",
"      Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/59\">",
"      Schinstine M, Goldman GD. Risk of synchronous and metachronous second nonmelanoma skin cancer when referred for Mohs micrographic surgery. J Am Acad Dermatol 2001; 44:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/60\">",
"      Wassberg C, Th&ouml;rn M, Yuen J, et al. Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. Int J Cancer 1999; 80:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/61\">",
"      Hemminki K, Dong C. Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin. Arch Dermatol 2000; 136:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/62\">",
"      Marghoob AA, Slade J, Salopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995; 75:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/63\">",
"      Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. J Am Acad Dermatol 1992; 26:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/64\">",
"      Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/65\">",
"      Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 2008; 100:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/66\">",
"      Karagas MR, Greenberg ER, Mott LA, et al. Occurrence of other cancers among patients with prior basal cell and squamous cell skin cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/67\">",
"      Levi F, Randimbison L, La Vecchia C, et al. Incidence of invasive cancers following squamous cell skin cancer. Am J Epidemiol 1997; 146:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/68\">",
"      Adami J, Frisch M, Yuen J, et al. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/69\">",
"      Cantwell MM, Murray LJ, Catney D, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer 2009; 100:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31209/abstract/70\">",
"      Johannesdottir SA, Lash TL, Jensen A&Oslash;, et al. Mortality in cancer patients with a history of cutaneous squamous cell carcinoma--a nationwide population-based cohort study. BMC Cancer 2012; 12:126.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5339 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31209=[""].join("\n");
var outline_f30_30_31209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LOW-RISK LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgical excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Topical 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HIGH-RISK LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LOCOREGIONAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15392004\">",
"      SYSTEMIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Second skin cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other second cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30602820\">",
"      ORGAN TRANSPLANT RECIPIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5339|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/34/39464\" title=\"picture 1\">",
"      Squamous cell carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/43/22203\" title=\"table 1\">",
"      NCCN risk factors for cutaneous SCC recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/17/11547\" title=\"table 2\">",
"      Contraindications cryo cut SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/54/13163\" title=\"table 3\">",
"      Side effects of radiation therapy for cutaneous SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 4\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/0/5134\" title=\"table 5\">",
"      TNM stage cutaneous SCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15063?source=related_link\">",
"      Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24632?source=related_link\">",
"      Keratoacanthoma: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/8/2186?source=related_link\">",
"      Management of skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21226?source=related_link\">",
"      Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30968?source=related_link\">",
"      Treatment of actinic keratosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31210="Treatment of intermediate, low, or very low risk myelodysplastic syndromes";
var content_f30_30_31210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Elihu H Estey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/30/31210/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/30/31210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by clonal hematopoiesis and variable cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with MDS, particularly those with lower risk MDS, die because of the consequences of bone marrow failure rather than transformation to AML. Thus, use of terms such as \"pre-leukemia\" or \"smoldering leukemia\" can be misleading if taken to imply that death or morbidity from MDS results only when AML develops. Indeed, the distinction between MDS and AML is itself arbitrary, as patients with 20 to 30 percent blasts are considered to have MDS by French-American-British (FAB) criteria, but AML by the World Health Organization (WHO) classification.",
"   </p>",
"   <p>",
"    For many years, transfusion with packed red blood cells and platelets and the use of erythropoiesis-stimulating agents were the only therapy available. More recently, chemotherapy agents directed at the underlying disorder have been developed and continue to be studied for patients with MDS (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ). However, due to the advanced age of most patients, the chronicity of the disease, and its attendant morbidities, supportive care remains a central component of the management of all patients with MDS. Patients should be treated as needed with antibiotics for infection and platelet transfusions for bleeding in the setting of thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus regarding a standard treatment approach for patients with symptomatic MDS, and patients should be encouraged to enroll on clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"mobipreview.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and revised IPSS (IPSS-R) MDS risk category, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions.",
"   </p>",
"   <p>",
"    This topic review will discuss the management of patients with MDS and an intermediate (&gt;3 to 4.5 points), low (&gt;1.5 to 3 points), or very low (&le;1.5 points) IPSS-R score. The treatment of patients with a high (&gt;4.5 to 6 points) or very high (&gt;6 points) IPSS-R score, the management of the complications of MDS, details on the use of hematopoietic cell transplantation in MDS, and the prognosis of MDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9049?source=see_link\">",
"     \"Treatment of high or very high risk myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/39/8826?source=see_link\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18197980\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with MDS require immediate treatment. Immediate treatment is indicated for patients with symptomatic cytopenia (anemia, thrombocytopenia, neutropenia with recurrent infections). Asymptomatic patients may be followed expectantly with serial examinations and laboratory studies. Immunizations should be updated and smoking ceased. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515110#H515110\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Indications for treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515117#H515117\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Management of asymptomatic MDS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18197993\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to affect treatment options. In addition to a history and physical examination, it is our practice to perform laboratory studies and a unilateral bone marrow biopsy in all patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H516641#H516641\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding a standard treatment approach for patients with symptomatic MDS, and patients should be encouraged to enroll on clinical trials whenever available. Our treatment approach is similar to that proposed by the MDS Panel for Practice Guidelines of the",
"    <a class=\"external\" href=\"file://www.nccn.org/index.asp\">",
"     National Comprehensive Cancer Network",
"    </a>",
"    (NCCN). This approach incorporates knowledge of the patient&rsquo;s performance status, the International Prognostic Scoring System (IPSS) (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"mobipreview.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and revised IPSS (IPSS-R) MDS risk categories, and other disease characteristics (ie, cytopenias present, serum erythropoietin level) to help guide management decisions. However, despite the increased availability of treatment guidelines, it is important to individualize care for the patient with MDS.",
"   </p>",
"   <p>",
"    Treatment options for patients with MDS typically fall into one of three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care includes the use of antibiotics for infection and red cell and platelet transfusions in the setting of symptomatic anemia and thrombocytopenia, respectively. Prophylactic antibiotics are generally not helpful and this strategy may select for antibiotic resistance. Supportive care is an important adjunct to the management of all patients with MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low intensity therapies include hematopoietic growth factors, DNA hypomethylating agents, immunosuppressive therapy, and low intensity chemotherapy. These can be administered in the outpatient setting and have a low risk of treatment-related morbidity and mortality. Low intensity treatments can improve symptoms and quality of life, but are not curative.",
"     </li>",
"     <li>",
"      High intensity therapies include combination chemotherapy and allogeneic hematopoietic cell transplantation (HCT). They require hospitalization and entail significant risk of treatment-related mortality. However, these treatments may improve blood counts more quickly than less intensive therapy, reduce the risk of death from MDS, and may alter the MDS disease course. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/39/8826?source=see_link\">",
"       \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High intensity therapies are generally reserved for patients with high or very high IPSS-R scores. This allows for the avoidance of treatment-related morbidity and mortality in most patients with a relatively good prognosis, and allows for the aggressive treatment of disease in those with a poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519324\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a very low (&le;1.5 points) or low (&gt;1.5 to 3 points) IPSS-R score are primarily treated with supportive care or DNA hypomethylating agents or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    . This treatment approach may also be considered for patients with a WHO Prognostic Scoring System (WPSS) score of very low, low, or intermediate risk or an original IPSS score of low or intermediate-1 risk. Patients with an intermediate risk IPSS-R score may be treated with this approach or with those used for higher risk MDS. (See",
"    <a class=\"local\" href=\"#H17341115\">",
"     'Intermediate risk IPSS-R'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with a very low or low IPSS-R score have a low rate of transformation to AML and a median overall survival of greater than five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/1\">",
"     1",
"    </a>",
"    ]. The main goals of therapy are to control symptoms due to cytopenias, improve quality of life, and minimize the toxicity of therapy. More intensive therapies (eg, hematopoietic cell transplantation, induction therapy such as that used for acute myeloid leukemia) are generally avoided because this group has a relatively good expected median survival and a relatively low rate of transformation to acute myeloid leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/2\">",
"     2",
"    </a>",
"    ]. Although there is a significant chance of cure after allogeneic hematopoietic cell transplantation in low and intermediate risk patients (approximately 60 and 40 percent, respectively), transplant-related mortality and the relapse rate at five years are as high as 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=see_link&amp;anchor=H861596#H861596\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\", section on 'WHO prognostic scoring system (WPSS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A choice among these therapies depends primarily upon the cytopenia present, the serum erythropoietin level, and the probability of responding to immunosuppressive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptomatic anemia and a serum erythropoietin level &le;500",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      we suggest initial treatment with erythropoietin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a serum erythropoietin level &gt;500",
"      <span class=\"nowrap\">",
"       mU/mL",
"      </span>",
"      are unlikely to respond to epoetin therapy. Instead, treatment options include immunosuppressive therapy, DNA hypomethylating agents, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients with symptomatic anemia, a serum erythropoietin level &gt;500",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      and a good probability of responding to immunosuppressive therapy, we suggest a trial of antithymocyte globulin (ATG) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . Patients with a good probability of responding to immunosuppressive therapy include younger (&lt;60 years old) patients, those with a hypoplastic bone marrow, those who are HLA-DR15 positive, or those with a detectable PNH clone. (See",
"      <a class=\"local\" href=\"#H2816086\">",
"       'Hypoplastic MDS'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H2816177\">",
"       'PNH-positive cells'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with an erythropoietin level &gt;500",
"      <span class=\"nowrap\">",
"       mU/mL",
"      </span>",
"      who are not thought to be good candidates for immunosuppressive therapy can be treated with DNA hypomethylating agents or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients with symptomatic thrombocytopenia or symptomatic neutropenia, we suggest treatment with a DNA hypomethylating agent or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      . Trials of thrombopoietin mimetics are ongoing. (See",
"      <a class=\"local\" href=\"#H2447218\">",
"       'DNA hypomethylating agents'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H2104265#H2104265\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Thrombopoietin mimetics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with del(5q) with or without other cytogenetic abnormalities, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2443602\">",
"       'Patients with 5q deletion'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive care is an important adjunct to the management of all patients with MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. Such patients include frail older adults with multiple comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, there are certain patient populations that require special attention and modification of this approach. As an example, patients with therapy-related MDS have a particularly poor prognosis and are treated in a similar fashion to those with therapy-related acute myeloid leukemia (AML). In addition, patients with 5q deletion and those with chronic myelomonocytic leukemia demonstrating a platelet-derived growth factor receptor beta (PDGFRB) fusion gene have superior outcomes when treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , respectively. (See",
"    <a class=\"local\" href=\"#H1102942\">",
"     'Special patient populations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2445207\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care remains a central component of the management of",
"    <strong>",
"     all",
"    </strong>",
"    patients with MDS. Patients should be treated as needed with antibiotics for infection and red cell and platelet transfusions for symptomatic anemia or thrombocytopenia, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2447218\">",
"    <span class=\"h2\">",
"     DNA hypomethylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA hypomethylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    ) target the aberrant DNA methylation seen in MDS and result in at least a hematologic response in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Both azacitidine and decitabine have been approved by the US Food and Drug Administration for use in patients with MDS. While they have each demonstrated superior response rates and a longer time to AML transformation when compared with supportive care alone, they have not been directly compared with each other or with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    in a randomized trial.",
"   </p>",
"   <p>",
"    A 2010 meta-analysis of hypomethylating agents for the treatment of MDS incorporated data from 952 patients enrolled on clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/9\">",
"     9",
"    </a>",
"    ]. Treatment with a hypomethylating agent significantly improved overall survival (hazard ratio 0.72, 95% CI 0.60 to 0.85) and the combined endpoint of time to transformation to AML or death (hazard ratio 0.69, 95% CI 0.58 to 0.82). In a subgroup analysis by drug type, these benefits were seen for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    but not for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    . However the data were not obtained in a randomized trial, and it is quite plausible that the patients chosen to receive azacitidine or decitabine had a better inherent prognosis despite a similar IPSS score, given the considerable heterogeneity in survival within a particular IPSS class, especially low and intermediate-1 IPSS.",
"   </p>",
"   <p>",
"    Given the prospective trials demonstrating a potential benefit with each of these agents and the lack of a randomized trial comparing these agents to one another, either agent may be used. Some clinicians prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    because it is given intravenously over fewer days. Other clinicians prefer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    because it can be administered subcutaneously as an outpatient and requires less time in an infusion center. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2446335\">",
"    <span class=\"h3\">",
"     Azacitidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     Azacitidine",
"    </a>",
"    (5-azacitidine, 5-aza, Vidaza&trade;) is a pyrimidine nucleoside analog of cytidine, which is believed to exert its",
"    <span class=\"nowrap\">",
"     beneficial/antineoplastic",
"    </span>",
"    effects by causing hypomethylation (demethylation) of DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. This agent also has direct cytotoxicity on abnormal bone marrow hematopoietic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/10,13,14\">",
"     10,13,14",
"    </a>",
"    ]. Available studies indicate overall response rates in patients with low or intermediate-1 risk MDS of approximately 50 percent, with survival benefits observed in responders versus nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/7,8,15\">",
"     7,8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase III clinical trial in 191 patients with MDS (54 percent with low or intermediate-1 IPSS) randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    (initial dose: 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day subcutaneously for 7 consecutive days every 28 days) or supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. Patients on the supportive care arm could cross over to the azacitidine treatment arm after four months if their disease was worsening. When compared with supportive care, azacitidine resulted in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A superior complete plus partial response rate (23 versus zero percent)",
"     </li>",
"     <li>",
"      A longer median time to leukemic transformation or death (21 versus 13 months)",
"     </li>",
"     <li>",
"      Significantly improved quality of life (eg, fatigue, dyspnea, physical functioning, positive affect, and psychological distress)",
"     </li>",
"     <li>",
"      Similar median overall survival (20 versus 14 months), although the crossover design was limiting in this regard. However, landmark analysis after six months demonstrated a superior median survival (an additional 18 versus 11 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    in the setting of intermediate-2 or high risk disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9049?source=see_link&amp;anchor=H48546561#H48546561\">",
"     \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'DNA hypomethylating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     Azacitidine",
"    </a>",
"    has been approved by the United States FDA for use in patients with the following forms of MDS: RA or RARS (if accompanied by neutropenia or thrombocytopenia, or requiring transfusions), RAEB, RAEB-T, and CMML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     Azacitidine",
"    </a>",
"    is administered in an outpatient setting at a dose of 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day subcutaneously for 7 consecutive days every 28 days. Best responses may not occur until six cycles have been given. However it is unclear whether patients who have had no response after three cycles should receive additional cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/19\">",
"     19",
"    </a>",
"    ]. Most patients will have at least one hospitalization for neutropenic fever during this time. We perform a response evaluation after two to four cycles to determine whether additional cycles are indicated. In the combined CALGB experience, the median number of cycles to first response was three, with 90 percent of responses seen by cycle six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More convenient dosing regimens, in which the agent is given for only five consecutive days, or with a \"drug holiday\" over the weekend, or as a 10-day cycle are being tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Dose adjustment and growth factor support may be necessary for some patients, such as those with renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2446356\">",
"    <span class=\"h3\">",
"     Decitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     Decitabine",
"    </a>",
"    (5-aza-2'-deoxycytidine, Dacogen&trade;) is another pyrimidine nucleoside analog of cytidine that strongly inhibits DNA methylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/10-12,24\">",
"     10-12,24",
"    </a>",
"    ]. This agent is capable of inducing cell differentiation, and has been shown to be clinically effective in patients with various forms of MDS, including relapsed disease, and patients previously treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/25-35\">",
"     25-35",
"    </a>",
"    ]. However, it is unclear if these patients had received enough azacitidine to be considered truly resistant to this drug.",
"   </p>",
"   <p>",
"    A phase II multicenter trial evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV over four hours every eight hours for three consecutive days) repeated every six weeks in 66 patients with MDS (median age 68 years, range: 38 to 84) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The overall response rate was 25, 48, and 64 percent for those in the intermediate-I, intermediate-II, and high IPSS risk groups, respectively (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"mobipreview.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ). Toxicity was appreciable, with fever, infection, sepsis, neutropenia, anemia, and thrombocytopenia occurring in 27, 20, 11, 12, 11, and 5 percent of patients, respectively. Three deaths were attributable to use of this agent.",
"   </p>",
"   <p>",
"    A phase III multicenter trial in 170 patients with MDS (30 percent intermediate-1 IPSS) randomly assigned treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV over four hours every eight hours for three consecutive days) repeated every six weeks, or best supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/28\">",
"     28",
"    </a>",
"    ]. When compared with best supportive care, decitabine resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly higher overall response rate (17 versus 0 percent)",
"     </li>",
"     <li>",
"      A trend toward a longer median time to AML transformation or death (12 versus 8 months)",
"     </li>",
"     <li>",
"      No benefit in survival",
"     </li>",
"     <li>",
"      Temporary dose reductions or delays in 35 percent of patients. The median number of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      courses administered was three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The US Food and Drug Administration has approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (Dacogen&reg;, MGI Pharma, Inc.) for the treatment of patients with previously treated, untreated, de novo, and secondary MDS of all FAB subtypes, including CMML, and intermediate-1, intermediate-2, and high-risk IPSS groups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     Decitabine",
"    </a>",
"    can be administered in an inpatient setting at a dose of 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV over four hours every eight hours for three consecutive days, repeated every six weeks. Treatment should be continued for as long as a benefit persists. Dose adjustment and growth factor support may be necessary for some patients, such as those with renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, more convenient dosing regimens are being tested. As an example, a multicenter phase II trial (the ADOPT trial) evaluated an outpatient schedule of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously over a one-hour period once daily for five consecutive days; cycles were repeated every four weeks) in 99 patients with MDS of any subtype and an IPSS &ge;0.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete and overall response rates were 17 and 32 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients who improved, 82 percent demonstrated responses by the end of the second cycle.",
"     </li>",
"     <li>",
"      Seventeen of the 33 patients assessable for cytogenetic response experienced a cytogenetic CR or partial response.",
"     </li>",
"     <li>",
"      Cytopenias were common, delaying 32 percent of the treatment cycles. Overall, 19 percent of the cycles were associated with hospitalization; 65 percent of the patients were hospitalized at some point in the study, most in cycles one and two.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of these responses as defined by the investigators is not clear since they do not have an obvious correlation with improved survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515600#H515600\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2447560\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive agents, such as antithymocyte globulin (ATG) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can produce hematologic responses in a subset of patients with MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/37-51\">",
"     37-51",
"    </a>",
"    ]. Although clinical responses may be seen with these agents, they do not appear to improve overall survival rates. Serum sickness has occurred in virtually all patients, and was generally controllable by concomitant use of steroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29930?source=see_link&amp;anchor=H14#H14\">",
"     \"Aplastic anemia: Prognosis and treatment\", section on 'Immunosuppressive regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Response to immunosuppressive agents may be predicted using a scoring system developed by the National Institutes of Health, which includes information on age, duration of transfusion dependence, and the presence of HLA-DR15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients likely to respond to immunosuppressive therapy include those with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HLA-DR15 positive disease",
"     </li>",
"     <li>",
"      PNH-positive cells present by flow cytometry (see",
"      <a class=\"local\" href=\"#H2816177\">",
"       'PNH-positive cells'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Hypoplastic MDS (see",
"      <a class=\"local\" href=\"#H2816086\">",
"       'Hypoplastic MDS'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Less than 5 percent bone marrow blasts",
"     </li>",
"     <li>",
"      Shorter duration of red cell transfusion dependence",
"     </li>",
"     <li>",
"      Younger age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a non-randomized study, 21 of 61 red cell transfusion-dependent patients with refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), or refractory anemia with excess blasts (RAEB) became transfusion independent at a median time of 10 weeks after receiving a four-day course of ATG plus steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/38\">",
"     38",
"    </a>",
"    ]. After treatment, 19 of the 21 responders had normal neutrophil and platelet counts. On multivariate analysis, predictors of response to ATG included younger age and lower initial platelet count.",
"   </p>",
"   <p>",
"    A randomized multicenter phase III trial of 88 patients compared the combination of ATG plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    with best supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/53\">",
"     53",
"    </a>",
"    ]. ATG plus cyclosporine resulted in significantly higher rates of hematologic response by six months (29 versus 9 percent, respectively), but no difference in the overall survival (49 versus 66 percent) or transformation-free survival (46 versus 55 percent) at two years. Responses were more likely to be seen with hypoplastic MDS and in those with low blast counts. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities were thrombocytopenia (53 percent), anemia (47 percent), leukopenia (33 percent), and neutropenia (38 percent). &nbsp;",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    as an alternative immunosuppressive regimen in younger patients with MDS, a shorter duration of red cell transfusion dependence, and the presence of HLA-DR15 is under active investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1102942\">",
"    <span class=\"h1\">",
"     SPECIAL PATIENT POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MDS with a very low or low IPSS-R score in most patients can be guided by the treatment strategy outlined above. However, there are certain patient populations that require special attention and modification of this approach. These patient populations are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17341115\">",
"    <span class=\"h2\">",
"     Intermediate risk IPSS-R",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no general consensus regarding the optimal treatment of patients with intermediate risk MDS as defined by the Revised International Prognostic Scoring System (IPSS-R). Options include those used for patients with low or very low risk IPSS-R scores, and the more intensive therapies typically used for patients with high or very high risk IPSS-R scores. A choice among these treatments must take into consideration the patient&rsquo;s values and preferences, and their interpretation of what constitutes a reasonable survival and reasonable risk.",
"   </p>",
"   <p>",
"    In the original cohort used to develop the IPSS-R, half of the patients with intermediate-risk disease were alive at three years and approximately one-quarter had progressed to acute myeloid leukemia when treated with supportive care alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment with DNA hypomethylating agents had increased survival in patients with MDS, but available reports are not stratified by IPSS-R so the expected increase is not known. More intensive therapies such as those used for higher risk disease have the potential for cure, but have higher mortality rates short-term and the potential for long term toxicities. &nbsp;",
"   </p>",
"   <p>",
"    Supportive care and hypomethylating agents may be favored by patients who want to focus on quality rather than quantity of remaining years. In contrast, more intensive chemotherapy with or without transplantation may be preferred by younger, fit patients who value a possible increase in survival over the higher risk of treatment-related mortality and morbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9049?source=see_link\">",
"     \"Treatment of high or very high risk myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2444300\">",
"    <span class=\"h2\">",
"     Therapy-related MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who are exposed to cytotoxic agents are at risk of developing acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS), and myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/myeloproliferative",
"    </span>",
"    neoplasms",
"    <span class=\"nowrap\">",
"     (t-MDS/MPN).",
"    </span>",
"    These conditions lie along a continuum of disease and are categorized by the 2008 WHO classification system as therapy-related myeloid neoplasms (t-MN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/55\">",
"     55",
"    </a>",
"    ]. This is a heterogeneous and poorly defined group of patients who have a shorter median survival than patients with de novo AML, MDS, or",
"    <span class=\"nowrap\">",
"     MDS/MPN.",
"    </span>",
"    The treatment of t-MDS is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2443602\">",
"    <span class=\"h2\">",
"     Patients with 5q deletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of patients with MDS present with &ldquo;5q minus syndrome&rdquo; characterized by severe anemia, preserved platelet counts, and del(5q) as the sole cytogenetic abnormality. Patients with 5q minus syndrome and those with del(5q) and other cytogenetic abnormalities have demonstrated high response rates to treatment with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    . For patients with low or intermediate-1 risk MDS who demonstrate del(5q) with or without other cytogenetic abnormalities, we recommend low-dose lenalidomide therapy.",
"   </p>",
"   <p>",
"    Initial studies of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    in patients with MDS indicated excellent responses in patients with the 5q minus syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/56\">",
"     56",
"    </a>",
"    ]. This issue was specifically explored in a multicenter phase II trial of low-dose lenalidomide (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    PO for 21 days every month or 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with dose reduction as needed) in 148 patients with the 5q minus syndrome and transfusion-dependent low or intermediate-1 risk MDS (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"mobipreview.htm?26/37/27228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion independence was achieved in 67 percent, with a median rise in hemoglobin of 5.4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      as compared with the baseline nadir value before transfusion (range: 1.1 to 11.4",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"      An additional 9 percent of patients had a &ge;50 percent reduction in the number of transfusions required. The median response duration had not been reached after 104 weeks of follow-up. Erythrocytosis, with hemoglobin values exceeding 17",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      developed in four patients responding to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Complete and partial cytogenetic responses were achieved in 45 and 28 percent of evaluable subjects, respectively. After 24 weeks of treatment there was complete resolution of cytologic dysplasia in all hematopoietic lineages in 36 percent. Progression to a more advanced French-American-British (FAB) type of MDS or acute myeloid leukemia was noted in eight patients each.",
"     </li>",
"     <li>",
"      Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (55 percent) or thrombocytopenia (44 percent) were the most common events causing dose reduction or interruption. Of interest, it has been suggested that such myelosuppression is associated with a better chance of response to this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. There were three deaths from neutropenic infection. Eighty-four percent of patients required dose reductions from the 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      starting dose due to adverse events. At week 24 of the study, 32 percent were taking 10",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      44 percent 5",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and 24 percent 5 mg every other day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These high response rates were confirmed in a randomized phase III trial of 205 patients with transfusion-dependent, lower-risk MDS with del(5q) in which treatment was randomly assigned in a 1:1:1 fashion to low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (10 mg daily on days 1 to 21), lower-dose lenalidomide (5 mg daily on days 1 to 28), or placebo (days 1 to 28), each delivered in a 28-day cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients without an erythroid response by week 16 were unblinded and eligible for open label treatment (crossover). Approximately half of the patients had received prior therapy with erythropoietin. When compared with placebo, lenalidomide resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of achieving red blood cell transfusion independence for 26 weeks or greater (56 versus 43 versus 6 percent for 10 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , 5 mg lenalidomide, and placebo, respectively). Median response duration was at least 83 and 41 weeks with 10 mg and 5 mg lenalidomide, respectively.",
"     </li>",
"     <li>",
"      Rates of complete cytogenetic response of 29 and 16 percent for 10 mg and 5 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After a median followup of 31 to 36 months, 101 patients (49 percent) had died. Interpretation of the overall survival data is limited by the allowance of crossover in the study design. Median overall survival rates did not differ according to initial therapy and the three-year overall survival rate for patients who received 5 mg or 10 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    was 57 percent. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    adverse events were myelosuppression and venous thromboembolism. Rates of adverse events were similar between the two lenalidomide doses.",
"   </p>",
"   <p>",
"    Available data suggest that about 50 percent of these patients have clinical (increased transfusion frequency) and cytogenetic relapse after two to three years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. It is therefore uncertain whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    can eradicate the malignant clone despite a high percentage of complete cytogenetic remissions. As an example, one small study showed that a minor but distinct population of stem cells was selectively resistant to this agent at the time of complete clinical and cytogenetic remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/61\">",
"     61",
"    </a>",
"    ]. Persistence, growth,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clonal evolution of this sub-population might explain",
"    <span class=\"nowrap\">",
"     relapse/disease",
"    </span>",
"    evolution.",
"   </p>",
"   <p>",
"    Results of ongoing trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , used alone or in combination with other agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) are awaited, especially since the lowest safe and effective dose of this agent was not firmly established in the above-noted trial. In small studies, alternative schedules of this agent (eg, 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 21 days every 4 weeks; 10 mg every other day for 21 days every 4 weeks) have shown activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration granted restricted distribution approval for low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (10 mg daily) for use in patients with transfusion-dependent anemia due to low or intermediate-1 risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/56\">",
"     56",
"    </a>",
"    ]. While FDA-approved labeling for lenalidomide does not contain renal dosing adjustment guidelines, dose reduction has been suggested for those with MDS and reduced creatinine clearance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H32#H32\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Lenalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This agent is available under a special restricted distribution program (RevAssist), similar to the STEPS program instituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/66\">",
"     66",
"    </a>",
"    ]. It carries \"black box\" warnings about pregnancy prevention, significant thrombocytopenia and neutropenia (and the potential need for dose reduction), and increased risk of deep vein thrombosis and pulmonary embolism in patients with multiple myeloma treated with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link&amp;anchor=H9#H9\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Thalidomide analogues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2816086\">",
"    <span class=\"h2\">",
"     Hypoplastic MDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with low or intermediate-1 risk MDS, primarily those with hypocellular bone marrows (ie, hypoplastic MDS), may be incorrectly diagnosed as having idiopathic aplastic anemia. They are believed to have immune-mediated hematopoietic suppression, perhaps secondary to an as yet defined alteration in T cell function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. For patients with low- or intermediate-1 prognosis disease by the IPSS, those with hypoplastic MDS have a better overall prognosis than those with",
"    <span class=\"nowrap\">",
"     normal/hypercellular",
"    </span>",
"    marrows and are less likely to transform into AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/37,74,75\">",
"     37,74,75",
"    </a>",
"    ]. These patients are also more likely to respond to immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H2447560\">",
"     'Immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A variable proportion of these patients, generally those who are younger, have normal cytogenetics, marrow hypoplasia, early stage disease, a shorter duration of red cell transfusion dependence, presence of PNH-positive cells, and the presence of HLA-DR15 have responded to immunosuppressive therapies such as antithymocyte globulin (ATG, 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously for four days) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (starting dose range: 5 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/5,37-40,52,68,69,76\">",
"     5,37-40,52,68,69,76",
"    </a>",
"    ]. Serum sickness has occurred in virtually all patients, and was generally controllable by concomitant use of steroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29930?source=see_link&amp;anchor=H14#H14\">",
"     \"Aplastic anemia: Prognosis and treatment\", section on 'Immunosuppressive regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Younger patients with relatively higher platelet counts, particularly with low or intermediate-1 IPSS scores and a hypo- or normocellular marrow, may have a 30 percent chance of becoming RBC transfusion independent with immunosuppressive therapies. The expected probability of response in HLA-DR15 positive patients would approach 50 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    induced substantial hematologic responses in patients with MDS of the refractory anemia subtype with hypercellular, normocellular, or hypocellular bone marrows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/41\">",
"     41",
"    </a>",
"    ]. Anemia improved in 14 of the 17 patients, and all transfusion-dependent patients achieved transfusion independence. Complete trilineage recovery was observed in four patients (23 percent) and two patients benefited from combination therapy with erythropoietin. The response to cyclosporine persisted in all successfully treated patients during follow-up times ranging from 5 to 30 months. The dose of cyclosporine was 5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day administered twice daily, modified as needed to achieve therapeutic blood levels between 100 to 300",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2816177\">",
"    <span class=\"h2\">",
"     PNH-positive cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The existence of a minor population of paroxysmal nocturnal hemoglobinuria-positive (PNH+) cells may serve as a marker for immune-mediated bone marrow failure in patients with MDS, and may also predict for hematologic improvement after treatment with ATG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyclosporin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. In one study, for example, response rates to ATG for patients with a normal (PNH-) or GPI-anchored protein-deficient (PNH+) granulocyte population were 27 and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypothesis that patients with bone marrow failure associated with aplastic anemia or refractory anemia who are PNH+ without evidence for neutrophil clonality should be treated with immunotherapy, while those with neutrophil clonality should receive other treatment (eg, hematopoietic cell transplantation), is currently being tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2444494\">",
"    <span class=\"h2\">",
"     Chronic myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myelomonocytic leukemia (CMML) is considered by the WHO to have elements of both a myelodysplastic as well as a myeloproliferative nature. Indications for treatment have not been clearly defined, but usually include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased systemic symptoms (eg, fever, weight loss)",
"     </li>",
"     <li>",
"      Organ involvement (eg, symptomatic splenomegaly, skin disease, renal dysfunction, pulmonary involvement)",
"     </li>",
"     <li>",
"      Alterations in blood counts (eg, hyperleukocytosis, leukostasis, worsening cytopenias, increasing blast percentage)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of preferred therapy in CMML is dependent upon whether there is a fusion gene involving platelet derived growth factor receptor beta (PDGFRB), most commonly due to t(5;12)(q33;p13):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with CMML and a fusion gene involving platelet-derived growth factor receptor beta (PDGFRB), most commonly due to t(5;12)(q33;p13), we recommend the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . Fusion genes involving PDGFRB have also been noted in low numbers in some patients with MDS, but their significance and response to treatment with imatinib are unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with CMML who do not demonstrate a fusion gene involving PDGFRB are candidates for treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      . The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      plus supportive measures (eg, transfusions of red cells and platelets, erythropoietin) is an acceptable alternative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/82-84\">",
"       82-84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Selected patients with CMML have also been treated with myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/39/8826?source=see_link&amp;anchor=H13#H13\">",
"       \"Hematopoietic cell transplantation in myelodysplastic syndromes\", section on 'Chronic myelomonocytic leukemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is commonly used for the treatment of chronic myeloid leukemia due to its activity as a tyrosine kinase inhibitor. Several small reports have described the activity of imatinib in the treatment of patients with CMML with a PDGFRB fusion gene and no BCR-ABL translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. As an example, a report of 12 patients with CMML that was PDGFRB positive and BCR-ABL negative reported prompt responses with normalization of blood counts in eleven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/87\">",
"     87",
"    </a>",
"    ]. Ten had complete resolution of cytogenetic abnormalities. The clinical use of imatinib is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CMML were included in many of the trials that investigated the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    in MDS. As an example, a trial of decitabine in 77 patients with higher risk MDS (ie, IPSS &gt;1.0) and 18 with CMML investigated various treatment programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/28,31,88\">",
"     28,31,88",
"    </a>",
"    ] by randomly assigning patients to receive one of three schedules (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously daily x 5 days; 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneously daily x 5 days; or 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously daily x 10 days) every four weeks for a median of &ge;7 courses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response rates were 39, 21, and 24 percent for the five-day intravenous, five-day subcutaneous, and 10-day intravenous schedules, respectively. Overall and complete response rates in the 18 patients with CMML were 67 and 50 percent, respectively, with an estimated 18-month survival rate of 57 percent.",
"     </li>",
"     <li>",
"      The five-day intravenous schedule was superior at inducing hypomethylation at day 5 and at activating P15 expression at days 12 or 28 after therapy.",
"     </li>",
"     <li>",
"      The 10-day intravenous schedule is unlikely to be superior to the two five-day schedules, is more cumbersome, and is likely to be associated with more toxicity. A larger study will be required to distinguish between the five-day subcutaneous and intravenous schedules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse prognostic factors for overall survival included abnormalities of chromosomes 5 or 7, older age, and prior therapy for MDS other than growth factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/90\">",
"       90",
"      </a>",
"      ]. Patients with none, one, or two to three of these adverse factors had estimated 18-month survival rates of 82, 50, and 33 percent, respectively.",
"     </li>",
"     <li>",
"      The incidence of hospitalization for febrile episodes was 14 percent per course of therapy. At a median of &ge;7 courses of treatment, two-thirds of the patients required a one-time hospitalization for this complication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were reported from a single institution study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    in 19 patients with CMML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/80\">",
"     80",
"    </a>",
"    ]. Overall and complete response rates were 68 and 58 percent, respectively; the two-year overall survival rate was 48 percent. Toxicity was minimal.",
"   </p>",
"   <p>",
"    Response rates are lower with more advanced disease. A phase 2 trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    in 39 patients with CMML and poor prognostic features (eg, IPSS intermediate-2 or high risk or WBC &ge;13",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    plus other high risk features) reported an overall response rate of 38 percent (10 percent complete) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/92\">",
"     92",
"    </a>",
"    ]. At a median follow-up of 23 months, the estimated two-year overall survival rate was 48 percent.",
"   </p>",
"   <p>",
"    Many questions remain regarding the ideal management of patients with CMML. While overall response rates with DNA hypomethylating agents are high, the clinical significance of a less than complete response is not well established. Importantly, no trial has directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    to less costly approaches, such as best supportive care or low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2444913\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are followed longitudinally to assess disease response to therapy and to monitor for disease progression. Standardized response criteria have been developed that use bone marrow and peripheral blood analysis to allow better comparisons between published studies and to help guide treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515592#H515592\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Patient follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2445027\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general lack of effective treatments for the management of recurrent or refractory MDS and patients should be encouraged to participate in clinical trials, whenever available.",
"   </p>",
"   <p>",
"    Outside of a clinical trial, the management of patients with recurrent or refractory low or intermediate-1 risk MDS is largely dependent upon the patient&rsquo;s prior therapy. Patients who have not yet been treated with DNA hypomethylating agents (ie, those initially treated with immunosuppressive therapy) may be offered a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    . There is a paucity of data regarding the use of a DNA hypomethylating agent after the failure of another DNA hypomethylating agent (eg, the use of decitabine after failure of azacitidine or vice versa).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is not approved by the US Food and Drug Administration for use in MDS without del(5q), however there is some evidence of activity in this setting, although much lower than that seen with del(5q):",
"   </p>",
"   <p>",
"    The safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    were initially tested in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial in patients with MDS (with or without 5q minus) and red cell transfusion-dependent disease or symptomatic anemia, the majority of whom had failed prior treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erythropoietin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/93\">",
"     93",
"    </a>",
"    ]. Initial results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-one of the 43 evaluable patients (49 percent) had either a &gt;2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      increase in hemoglobin level or became red cell transfusion independent. Increases in platelet count (10 percent of patients) and neutrophils (17 percent of patients) were less frequently noted.",
"     </li>",
"     <li>",
"      Restoration of a normal karyotype was noted in 10 of 20 informative patients and in 9 of 12 with the 5q minus (5q-) syndrome",
"     </li>",
"     <li>",
"      Erythroid response was highest in patients with",
"      <span class=\"nowrap\">",
"       Low/Int-1",
"      </span>",
"      IPSS scores (60 percent) and in those with the 5q- syndrome (83 percent). In the latter patients, hematologic improvement was associated with resolution of megakaryocytic dysplasia on bone marrow examination. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H359933#H359933\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS with isolated del(5q)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dose-dependent myelosuppression was the most common adverse event and required treatment interruption or dose reduction in 58 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A phase II study evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    treatment in 214 transfusion-dependent patients with low- or intermediate-1 IPSS MDS without the 5q- deletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/94\">",
"     94",
"    </a>",
"    ]. Eligible patients had a platelet count",
"    <span class=\"nowrap\">",
"     &ge;50,000/microL",
"    </span>",
"    and required &ge;2 units of red cells within the previous eight weeks. They received either 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of lenalidomide or 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    on days 1 through 21 of a 28-day cycle. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-six percent of patients (56 of 214) achieved transfusion independence (TI) after a median of 4.8 weeks of treatment. TI continued for a median duration of 41 weeks. The median rise in hemoglobin was 3.2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (range 1.0 to 9.8",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      for those achieving TI.",
"     </li>",
"     <li>",
"      A &ge;50 percent reduction in transfusion requirement was noted in an additional 37 patients (17 percent), yielding an overall rate of hematologic improvement of 43 percent.",
"     </li>",
"     <li>",
"      The most common grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      adverse events were neutropenia (30 percent) and thrombocytopenia (25 percent). Fifty-five percent of patients required a dose adjustment at a median treatment time of seven weeks. There were no differences in hematologic toxicity between the two treatment schedules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2448392\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ). For interested patients, relatives, and physicians, the Aplastic Anemia and MDS International Foundation maintains a website (",
"    <a class=\"external\" href=\"file://www.aamds.org/\">",
"     www.aamds.org",
"    </a>",
"    ), which contains additional information as well as a listing of clinical trials in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/30/31210/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515621#H515621\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no agreed upon standard treatment approach for patients with symptomatic myelodysplastic syndrome (MDS) and patients should be encouraged to enroll in clinical trials whenever available. Our treatment approach incorporates knowledge of the patient&rsquo;s performance status, the revised International Prognostic Scoring System (IPSS-R) (",
"      <a class=\"graphic graphic_table graphicRef85832 \" href=\"mobipreview.htm?20/16/20749\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?41/54/42849?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) MDS risk category to help guide management decisions. (See",
"      <a class=\"local\" href=\"#H519324\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate treatment is indicated for patients with symptomatic cytopenia (anemia, thrombocytopenia, neutropenia with recurrent infections). Asymptomatic patients may be followed expectantly with serial examinations and laboratory studies. Immunizations should be updated and smoking ceased. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515110#H515110\">",
"       \"Overview of the treatment of myelodysplastic syndromes\", section on 'Indications for treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515117#H515117\">",
"       \"Overview of the treatment of myelodysplastic syndromes\", section on 'Management of asymptomatic MDS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supportive care is an important adjunct to the management of all patients with symptomatic MDS and can be considered as the sole treatment modality for a subset of patients with lower risk MDS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"       \"Management of the complications of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a very low (&le;1.5 points) or low (&gt;1.5 to 3 points) IPSS-R score are primarily treated with supportive care or low intensity therapies such as DNA hypomethylating agents or immunosuppressive therapy (See",
"      <a class=\"local\" href=\"#H519324\">",
"       'Choice of therapy'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with symptomatic anemia and a serum erythropoietin level &le;500",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      we suggest initial treatment with erythropoietin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with symptomatic anemia, a serum erythropoietin level &gt;500",
"      <span class=\"nowrap\">",
"       mU/mL,",
"      </span>",
"      and a good probability of responding to immunosuppressive therapy, we suggest a trial of antithymocyte globulin (ATG) plus cyclosporin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with a good probability of responding to immunosuppressive therapy include younger (&lt;60 years old) patients, those with a hypocellular bone marrow, those who are HLA-DR15 positive, or those with a detectable PNH clone. (See",
"      <a class=\"local\" href=\"#H2447560\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2816086\">",
"       'Hypoplastic MDS'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2816177\">",
"       'PNH-positive cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic anemia and an erythropoietin level &gt;500",
"      <span class=\"nowrap\">",
"       mU/mL",
"      </span>",
"      who are not thought to be good candidates for immunosuppressive therapy, we suggest treatment with a DNA hypomethylating agent or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2447218\">",
"       'DNA hypomethylating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic thrombocytopenia or symptomatic neutropenia, we suggest treatment with a DNA hypomethylating agent or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      . Trials of thrombopoietin mimetics are ongoing. (See",
"      <a class=\"local\" href=\"#H2447218\">",
"       'DNA hypomethylating agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H2104265#H2104265\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Thrombopoietin mimetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of MDS in most patients can be guided by the treatment strategy outlined above. However, there are certain patient populations that require special attention and modification of this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intermediate risk MDS &mdash; Treatment options for patients with an intermediate risk (&gt;3 to 4.5 points) IPSS-R score include those used for patients with low or very low risk IPSS-R scores, and the more intensive therapies typically used for patients with high or very high risk IPSS-R scores. A choice among these treatments must take into consideration the patient&rsquo;s values and preferences, and their interpretation of what constitutes a reasonable survival and reasonable risk. (See",
"      <a class=\"local\" href=\"#H17341115\">",
"       'Intermediate risk IPSS-R'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy-related MDS &mdash; Patients with therapy-related MDS are treated in a similar fashion to those with therapy-related acute myeloid leukemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      5q minus syndrome &mdash; For patients with transfusion-dependent anemia due to low or intermediate-1 risk MDS with del(5q) with or without other cytogenetic abnormalities, we recommend initial treatment with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We administer lenalidomide 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      with dose reduction as needed. (See",
"      <a class=\"local\" href=\"#H2443602\">",
"       'Patients with 5q deletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMML &mdash; For patients with chronic myelomonocytic leukemia and a fusion gene involving platelet derived growth factor receptor beta (PDGFRB), most commonly due to t(5;12)(q33;p13), we recommend the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2444494\">",
"       'Chronic myelomonocytic leukemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are followed longitudinally to assess disease response to therapy and to monitor for disease progression. Standardized response criteria have been developed that use bone marrow and peripheral blood analysis to allow better comparisons between published studies and to help guide treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H515592#H515592\">",
"       \"Overview of the treatment of myelodysplastic syndromes\", section on 'Patient follow-up'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is a general lack of effective treatments for the management of recurrent or refractory MDS, and patients should be encouraged to participate in clinical trials. Outside of a clinical trial, the management of patients with recurrent or refractory MDS is largely dependent upon the patient&rsquo;s prior therapy. Patients who have not yet been treated with DNA hypomethylating agents may be offered a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2445027\">",
"       'Treatment of recurrent or refractory disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2448392\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/1\">",
"      Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/2\">",
"      Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/3\">",
"      Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/4\">",
"      Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/5\">",
"      Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113:6296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/6\">",
"      Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114:3448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/7\">",
"      Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/8\">",
"      Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010; 116:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/9\">",
"      Gurion R, Vidal L, Gafter-Gvili A, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. Haematologica 2010; 95:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/10\">",
"      Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J 2007; 13:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/11\">",
"      Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15:3938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/12\">",
"      Quint&aacute;s-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/13\">",
"      Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007; 138:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/14\">",
"      Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma 2007; 48:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/15\">",
"      van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011; 155:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/16\">",
"      Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/17\">",
"      Kaminskas E, Farrell AT, Wang YC, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005; 10:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/18\">",
"      Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11:3604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/19\">",
"      Scott BL, Ramakrishnan A, Storer B, et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2010; 148:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/20\">",
"      Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24:3895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/21\">",
"      Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009; 27:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/22\">",
"      Gr&ouml;vdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010; 150:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/23\">",
"      Batty GN, Kantarjian H, Issa JP, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 2010; 10:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/24\">",
"      Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/25\">",
"      Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/26\">",
"      Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/27\">",
"      Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/28\">",
"      Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/29\">",
"      Wijermans P, L&uuml;bbert M, Verhoef G, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/30\">",
"      L&uuml;bbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001; 114:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/31\">",
"      R&uuml;ter B, Wijermans PW, L&uuml;bbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/32\">",
"      Oki Y, Jelinek J, Shen L, et al. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 2008; 111:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/33\">",
"      Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008; 112:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/34\">",
"      Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008; 49:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/35\">",
"      Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009; 115:5746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/36\">",
"      Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27:3842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/37\">",
"      Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/38\">",
"      Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/39\">",
"      Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003; 120:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/40\">",
"      Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/41\">",
"      Jon&aacute;sova A, Neuwirtov&aacute; R, Cerm&aacute;k J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/42\">",
"      Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/43\">",
"      Tichelli A, Gratwohl A, Wuersch A, et al. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 1988; 68:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/44\">",
"      Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/45\">",
"      Aivado M, Rong A, Stadler M, et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/46\">",
"      Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/47\">",
"      Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/48\">",
"      Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/49\">",
"      Asano Y, Maeda M, Uchida N, et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001; 80:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/50\">",
"      Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006; 91:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/51\">",
"      Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011; 305:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/52\">",
"      Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/53\">",
"      Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol 2011; 29:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/54\">",
"      Sloand EM, Olnes MJ, Weinstein B, et al. Alemtuzumab treatment of Intermediate-1 (INT-1) myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions (abstract). Blood 2009; 114:53.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/56\">",
"      Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 2008; 140:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/57\">",
"      List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/58\">",
"      Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008; 26:5943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/59\">",
"      Sekeres MA, List AF. Active treatment strategies improving outcomes in patients with myelodysplastic syndromes with the deletion 5q abnormality. Clinical Leukemia 2008; 2:28. (Also see: Clinical Cancer Update, December 2008.)",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/60\">",
"      Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/61\">",
"      Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010; 363:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/62\">",
"      J&auml;dersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009; 94:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/63\">",
"      G&ouml;hring G, Giagounidis A, B&uuml;sche G, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010; 89:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/64\">",
"      Giagounidis A, Fenaux P, Mufti GJ, et al. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 2008; 87:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/65\">",
"      Defina M, Rondoni M, Gozzetti A, et al. Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion. Br J Haematol 2010; 148:483.",
"     </a>",
"    </li>",
"    <li>",
"     Information available at the US Food and Drug Administration website: www.fda.gov/cder/drug/infopage/lenalidomide/default.htm (Accessed on February 17, 2011).",
"    </li>",
"    <li>",
"     Revlimid to launch with risk management plan; Restrictions could be lifted. \"The Pink Sheet\" F-D-C Reports 2006; 68:5 (January 2, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/68\">",
"      Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol 2001; 114:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/69\">",
"      Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100:3639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/70\">",
"      Zeng W, Maciejewski JP, Chen G, et al. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br J Haematol 2002; 119:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/71\">",
"      Selleri C, Maciejewski JP, Catalano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 2002; 95:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/72\">",
"      Wlodarski MW, Gondek LP, Nearman ZP, et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006; 108:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/73\">",
"      de Vries AC, Langerak AW, Verhaaf B, et al. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia. Leukemia 2008; 22:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/74\">",
"      Marisavljevic D, Cemerikic V, Rolovic Z, et al. Hypocellular myelodysplastic syndromes: clinical and biological significance. Med Oncol 2005; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/75\">",
"      Huang TC, Ko BS, Tang JL, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia 2008; 22:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/76\">",
"      Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/77\">",
"      Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002; 100:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/78\">",
"      Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/79\">",
"      Ishiyama K, Chuhjo T, Wang H, et al. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 2003; 102:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/80\">",
"      Aribi A, Borthakur G, Ravandi F, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/81\">",
"      Galimberti S, Ferreri MI, Simi P, et al. Platelet-derived growth factor beta receptor (PDGFRB) gene is rearranged in a significant percentage of myelodysplastic syndromes with normal karyotype. Br J Haematol 2009; 147:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/82\">",
"      Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran&ccedil;ais des My&eacute;lodysplasies and European CMML Group. Blood 1996; 88:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/83\">",
"      Beran M, Kantarjian H, O'Brien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/84\">",
"      Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999; 17:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/85\">",
"      Magnusson MK, Meade KE, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 2002; 100:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/86\">",
"      Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/87\">",
"      David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/88\">",
"      Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/89\">",
"      Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/90\">",
"      Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007; 109:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/91\">",
"      Kantarjian H, Huang X, Issa JP. Response: Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule. Blood. 2007; 110:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/92\">",
"      Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011; 118:3824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/93\">",
"      List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/30/31210/abstract/94\">",
"      Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111:86.",
"     </a>",
"    </li>",
"    <li>",
"     www.aamds.org/aplastic (Accessed on July 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4542 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31210=[""].join("\n");
var outline_f30_30_31210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18197980\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18197993\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519324\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2445207\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2447218\">",
"      DNA hypomethylating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2446335\">",
"      - Azacitidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2446356\">",
"      - Decitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2447560\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1102942\">",
"      SPECIAL PATIENT POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17341115\">",
"      Intermediate risk IPSS-R",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2444300\">",
"      Therapy-related MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2443602\">",
"      Patients with 5q deletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2816086\">",
"      Hypoplastic MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2816177\">",
"      PNH-positive cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2444494\">",
"      Chronic myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2444913\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2445027\">",
"      TREATMENT OF RECURRENT OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2448392\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/37/27228\" title=\"table 1\">",
"      IPSS in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/16/20749\" title=\"table 2\">",
"      IPSS-R in MDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/14/9441?source=related_link\" title=\"calculator 1\">",
"      Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?41/54/42849?source=related_link\" title=\"calculator 2\">",
"      Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/39/8826?source=related_link\">",
"      Hematopoietic cell transplantation in myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42392?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9049?source=related_link\">",
"      Treatment of high or very high risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_30_31211="Compare elemental Ca";
var content_f30_30_31211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elemental calcium content of different calcium salts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Calcium salt",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Elemental calcium content",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        mg Ca++ per gram",
"       </td>",
"       <td class=\"subtitle2\">",
"        mEq Ca++ per gram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium acetate",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium carbonate",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium chloride",
"       </td>",
"       <td>",
"        270",
"       </td>",
"       <td>",
"        13.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium citrate",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        10.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium glubionate",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium gluconate",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium lactate",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium phosphate, tribasic",
"       </td>",
"       <td>",
"        390",
"       </td>",
"       <td>",
"        19.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lexicomp database, Accessed 1/4/2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31211=[""].join("\n");
var outline_f30_30_31211=null;
var title_f30_30_31212="IHC staining Paget breast";
var content_f30_30_31212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    IHC staining of ductal cells, Paget cells, and epidermal cells",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Monoclonal antibody",
"      </td>",
"      <td class=\"subtitle1\">",
"       Keratin specificity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Mammary ductal cells",
"      </td>",
"      <td class=\"subtitle1\">",
"       Paget cells",
"      </td>",
"      <td class=\"subtitle1\">",
"       Nipple epidermal basal cells",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LE41",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TROMA1",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CAM5.2",
"      </td>",
"      <td>",
"       8, 18",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LE61",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MO8",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LP2K",
"      </td>",
"      <td>",
"       18",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       BA16",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       BA17",
"      </td>",
"      <td>",
"       19",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LP34",
"      </td>",
"      <td>",
"       All epithelia",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       LPK",
"      </td>",
"      <td>",
"       Type II keratins",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PAb421",
"      </td>",
"      <td>",
"       Basal keratinocytes",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HMFG1",
"      </td>",
"      <td>",
"       Membrane proteins",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HMFG2",
"      </td>",
"      <td>",
"       Membrane proteins",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IHC: immunohistochemical.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chaudary MA, et al. Breast Cancer Res Treat 1986; 8:139.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31212=[""].join("\n");
var outline_f30_30_31212=null;
var title_f30_30_31213="Survival after relapse RT HL";
var content_f30_30_31213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Survival in relapsed Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 282px; background-image: url(data:image/gif;base64,R0lGODlh1AEaAdUAAP///4CAgP+AgICZzAAAAEBAQMDAwAAzmUBms/8AAMDN5jAwMPDw8BAQENDQ0P9AQHBwcCAgIKCgoFBQUP/AwLCwsGBgYJCQkODg4FBzuWCAv/Dz+RBAn3CNxqCz2SBNpv9QULDA3/+goODm8zBZrP9gYP/w8P8QENDZ7P8gIP9wcJCm0/+wsP+QkP8wMP/g4P/Q0EBZjIBAQICMpgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADUARoBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2fwYGt7u8qgEBvcHCob/DxseYxcjLzI7KzdDRhM/S1dZ61Nfa23DZ3N/gSQ66QxUBFxhDDr8OTN7h8OAYEg0EQxAECw0N6RUEEREIVFjyLp7BawEIKBTCgEADABcIQACwgIADB/kIAjvI8dtCAAYIFAApEsDHjyB/qfxVQIaAlzApdJzZ7GPIkTdN2tM5xMBK/5UtYb58IICm0WMfMS4A4G8CgHoMGj5Uku3l0au8MIQkYCBdwAoTCEgAYIHALwIWNBaxirUtrYQKzQJwULHBRAAMwhKYwEAtEQFEhQp+KdOtYWbZKAweTPSw42MFlQBeXPix5ViRkyhmXPSyZ1eZoUyO+bm0qdBPNg/tbLo1qBkxBsiWrSDL6MW4K7venQj27AEIBmRRjZsz7+OIqMlewxa5c0HKhatp/rx6n+jMWVvfnkd58N8Dao+hzr08HWoKwAOXLoa8+fdvQi8fH1iwCBPwd8fdP5KNfPZhECcUCAmAcF9+pRWg4IIF3LXGf26YIAKBD7CA4IVeyPfdb+KhIf9hCg+8gOFjDkywoINqhJYeeMGxYYIACQiA34huVRRXfw9uBMV8bLzwQAoW0oiVWPZYoGOKRzrBYxssnADCjELSxFUEBkCAI5JSLNmGCSCcUBxhUXITQQBl7dUGakasN1uHa7CgQnGNhanNRXnxdWaSTawoW4t4uCcnNAb01Q2eUWhJx21C6fbnMAWgNZAbaCqhJngdhACHgKstiowENkZwwZ1X6KkeBx7c4aemvTjQ6JVpRDoFChxoYMepqNrCqUINfOofoVtsQEIGGxyqXa28NGrBo6CKsUEGJAQrB6K5iUhsK4HG4aoVGnCAghyYDlbCAwkk8ICB054SwDwrjbX/qxkecLACm3y8oFgKKYhQKwUU4GcCBdImAcMD9hrxb8BOqPCAHVw1emOyZYTA7AEkaPDuHyLQS7Cc4YIAAAUxLsHxsEJ8DAW4dgQ6Ti4GtLOuGgqsoAEJEGsALx4VpyBAC/jCIGS4CeDbMQAtjBukCd8SWJQIDwi98c8hCwCDCDJRAMIDKuBH8gvfUo2fCAJQ8EAJ+hocJ9IPtODFBchCyisaCmggqx8iqDD1AyeEe0LSINysaHUJuHACkB2rkIDcCVjowuAldAzCmykkIC/TAMBYtwAsFCi4xiR7LUDiJQAAbgmXA5CClyqkAIDghJvNRaMRQJCOFeacqw477qzN/zYJh8CAbwubH+5CCTjzDbC4HZ/gAgAmFAhDAp2L/AJgjfusHYxBGi1A454nIIQI34qbvRCHA3DCCSUIIOLfL3nPhQMQ2JgWFWXpwxVT/3zlFxwHPEJBCyX4XsKBu/EeuDqmPnGJ7GMvMB73eiayIcCoMOASyvdQx7GDkex7MABB407wggTY7CUX0wIDJLCqKiiEAQkBRkUukhEh+OQnASiA7dBAgpk1Yn9+K4HOWuM9jimucDBqgQn+RgHBda1AXmMg5B4ohBYgkQWdIxm4WCACAfbMiZiDGrgyGCMKcK0L+FDIBMgxhbJEYAEL6MtJdpISGMpQDhrIgAK2NQkYlP/AeF/Ko2D2Vg31Ja4oXErACVSwvbpFEACJM54Sp9czBzauQBg0pBUb9wD8EMiD9iJa3bzUhQIsQAKCqkJE6tKONd7vDQroAAI+cIAPIKAD4aFjIySkx1rGSVMXZEPKsICRkURkJFCRyinngIL0qJKVrtSApUhBKxrlcg0KwgIGHFKBsqSlLGd5XxKu5YZiDsCVIxgFtHJTri9UYClYkEBAGmCBvuRFjKFEAjfhsIEBHGAAzvpEt4xTzk7yh2GAGMEql8mKZvZzClY6EUADEQJwFrQ+tYyoRCdK0YpalI+OmScd6nnPfJ5inxYNqUhHStJMzSKhCkJRq2bYB4F+gKD/B3XCOPWI0UwoTCGsQoNG7wDLmEIBpHAC2ScikLaVKsJQPuWCQTWxgJyeYad2QGpStQCtmkoioRVxysoQIdWpYkFAt8TETSOgshwdFUBeDcNMS8pWynjBAa/b6iHUFAIF2NWuskzrV9vK1zxaNQoFOJZCyoqlROgJAYhNLCsPwFjGkiCxiM2AbCqlV1MIpABn1GZhM3HXu3pgNhzoQGVJwRV2xnChoBgBCUgQztGCYgEBuYAFnGoGqEqiAxyAqWs3YYAGLAADuUKtKEIQ2t3Cw7aTUC1rjfsN5FICt+FpLXOr4VxKOAwBjEWAzKb7iGrJobqXGIEC+MRdRnAFAuqK/w9LTdHV8hJiLxGQ4S/Su9lXtNe9ggjjP+XqivviNxB0sQDKCGvUWAxAtP81BngxQVxgJTgR77SL2maxrNw++BCrqsh6wbBgTTTYoxcGhECEYCXhvqLCug1xHxoAjDqZGBYDeJuK/6DfEfN3FgrA3YwBcYECTKCoBb5F/naMmQ2vooZEhkWHOxFH9XAoyaRYMidEpZ44QhkO8cRC7F63jgAQ+AhSNsUGDgDiK6dBQfSlAgMqgkZd+AMgNt6mkW2RgVKZmQ1hZOeXn1AWXQlhhUrpCQxjOOdaeCADd27DCOuRDyA3oR6N+i1PJt3Gn7wRGmMuc6LJwL6A/KMkUlCIAf+sOWmUyLPQtZCspjcdBta5DgDzmEI9SAJMAkTFIcNcxnhjlVdWhwFtWcAmNsliloRoFsyotsUIOvCBD6xg1b7OAnqFcIFkM0Qvd3nnXrJshDCzwmEHyECKo20FBhhgAQI2gIlejOkVNLsD0iV3Fbayn2Pr1NrCQEG2gvMuu0Jb3kfAQADi+4sLcPup+B7GBj6rgcQ2lgOJhaWTJ07xilv84hjPOHhs2Ba4Wivh0hCvXTVO8pKb/OQsQmtbziWBdLHb1/7tSML2a1aAFyHmHDEZynZ5Y4BPCuVAnzjHj+Lt6VI56Ejfk8otux+cvtzmb8C5Jxik0J5DXQ4/T3rQO2D/51UU/eqh0rrYv/mBrs+hAOxjkErvDfZWeKDZZofDzBdm9bab4u1lNxfI7Y4JvAN96Gq20o8nzPdXeEDiJgf8FG4a5/oW/jByWTNty/D1xyOjAI86bd0tPxMFwVZBEdBqzTnflqY7ffOkn1bloS5yu8a7DChAQNyFEPvZK0GVeGBAtef79NQzwZ6NXToAsPsFBdzzCMYXPhKIfwe9nH70vqeCPWWmgBHUcwUAuL4CWBme9KDAA9Vv+CuDNQAPrEC7zjq/uIWwgYZn4PgeiKylkk8E74MfAArIwPiHn78RiL8DwfJZ46UBwbIBqsQn8YcA2NcFEpEwe1cFq2dz9vQd/+FkTx6gAQfwfRxwALJnTxsYHsGBgbLiWKwkKx1wAB3wfpYCMx2AgcKRAbDESuJ1fEPggfcUAuF2gohGfOMVYwcgK9ilAToIAB/AAQf2AQBwgil4AAu4BaUlcJNHBhHoc411AOKRARu4gMxnTwR1gdiFAADAgdknhhyAO2OWASjwg/h3fCMAHKxkVzQoBFwoBO8nG6zEf0LghWLIfDADABwQKwMQThzwAbIhhlzQABIwARHQAFE4BlMob/aEVh7AWK21hVYoBEpofGBoiGLIiQhAf8k3AmV4gVZIfzV4ifz3G3iYiXs4ZMSHAhnAShwwAq00G7ZnBRIgAQ6wD3tWW/8PSHoTSBsAACsIUIbBgl0hgAL2JB7IOImbCIZhCIYqaE/PNoipdE/GJ0fYBYcAsoxCsALhpgAhAIT504yt2DLhNnzgh12wiI2fBQmPSG7Ax1j4RAIcsAHGJyvExYTeOIwb+IXRKARiuCwHUFwA0C4ceHwYWIalGIcA0I8PuVg7mD+wkpBgiF2shADB8n6tVCrtt4FG2AV04RBrx3bRtwrMxwYB4UlygXonCQopuQY2tm4u+ZLgMG0AEACi53g2aRCmB2pVoBVl1WW9SATx2JOuQHUpVW4V0R9vZj9U8YtIeRRh1B+A1kJyNpU00WODN29mAWqm5EKDdmlaeRA15mj/TcAArZMTpcZGL2RpUlmWvBB5NCkF9OZ0wYRrUSmXB2FjJTYF5mYAo9QO2GRsucaX3BAWLOlnVMCW2mYne4mY8BBhJYlwkgkPufhxlxkOdUl4m8kN6jRgvfeZl0dzPEma0tByKpFmJoma2mBuRemLrqkNEhAXaTSasxkMDTAm+GBvlpmb1dAA5PCX0AeczRAAEJALFjBGsRkGR2mcncB4z9ea0MkMqulyp1md1fGc2skN3Nmd2vCd4GkN4jmek3BpELCTQWaevSBwBBcATYWb7EktpheXUVCe89kI5oZuudCcjmif+WkQ+BmgjEAPdFecBFoLkLaUNZmgrCBhg+Kg/7sAAb6ZnRL6CozXiGIwoBdqCCjVIPLZoaZgbiQaoiI6CrXJFQtQmZQHoCdaCWdEJZqHoC/KCglTJRrqnC5ao5IQARawAAEAoTTKo6ngD7gSV1IwQr8QV0RZO0QKC+uADlYAFw7RD/XTeMj2pKDhFBiAefOWDmGhQhYRaJGppauAiEIwW1hQFmMRlpW2EmRppqkwPzmZo0pApm76lnC6o3K6CGhUARUgpFNAD7f5FLYmTGXap6dgpFUqSiQZAGNRmGhxmIo6CgInpVWQoXihF5CZlZV6ChDAotT5qaOgphFKqqVwASzGew2Kqpegqa3qqpVwMv1porIaCQxgJSWClv8tequioBejpp6j6qucQAA95hN2+gUcSqxvcFkG4GO2yqyMYAH7EBCs+ZvSygmU6ZnZ2lx82q16UAE+RkbRCq6FgBFxgaRDaq7w2ACAymLqxa6XoHlxuq7y2ghUeqAWeq+MkK/TuZ78Gg3LGrCWMLAESwkGe7CSkLAKC4/f2rCiwLAQi68PO7GfILEWqwgYm7HJUbEcuwkb+7GFELIiOwgkW7KBcLIo+wcqu7JroKSg1AQt67Jp0JRYmag0GwpNAQBhkTZ6ChTyNWhCO7REW7RGe7RIm7RKu7RM27RO+7RQG7VSO7VUW7VTS67YIBcpRAQ/yxJBa7Vw+rVgG7ZjO5b/Ylu2ClK2Zqu2lna2Y5u2bAu0ceu1c0tofrC1W0upWxCBfFuxU9i3Uuixqze4HpsFETER+MCYp/afvRq4jtu4jBu5kqujj8sH00QlAaGuWbqhgtu5lTu5lAu6HOa3pPsH6vQP19ptDwu4nzu6stm6yuq5opshhWuvWcC6s9sFfyu7nAu5odu7Dpu7usu7vyu8XEC4vuu6xnsIuTAGzUsGz+u8WPsF0Su9ZVC9YIC92Tu9XqC93cu9ORu+4ju+5DstMHtwgIAB1WZwizAOmksISlq7Y6Ck7DsIPIcXLReziWCz6FQIN9W/h7CLLRnAkBYBEGazDYC+ebAOQMm/ibCz/z1rCBUQFQEBvoFgI/IbBgHhn7iQEY1iwXigME5pJhF8CHg7wIaQuclhFyhMCBgBZ8I6CGuWDz5qv6B2whmsrFrbwoNwuIiAEebAw4IQEgtwbmKBCAxArQFRqIDAljiMCD6cuIfQm4ngrzkskiWRt4YQEcAQpkMMalFsrIhwuQagwoUQFmMSACDcB1oxamjxvoHwFRWxxn1Qm0VcEam7wKMUKGRsxodwuhGQx37QdFesw4UsknUhyIAAAfUwJoLAeLoAyIpcvpRcyZZ8yZicyZq8yZzcyZ78yaAcyqJcCLnAZV0RBqoyyVeQyqMsBQkxEgywDwosTWrsvELcykqglv8CkRCfgkI+9igJZQHt4BMOIAG60GMNgqRgEVhdUcuQ2mPtJASJ2CBREUNdOQQtp77pQEIF8CkhAQzqpiC68syX5gCzNQFjgQGzJcyc/GYtpA/waREAwJu7mZMOYRZlAQHwSUa1OQE6qcZyoRCwNakJ4c9UAs8rRASNUg9VIhFhcQHfnJNG0ihtahcPPU1AupzABaT70MkK0w69RCZygaOzlhCPEhb+TK6jBKkkAQwl0RDAZMB4cRMifSSNIii7eRYFENG6NwEaZhKwLBIvDAEGFxETTaeazJY0/QsG0BTnZA8JQQ5JbCNpE0MKkZwB3R8lAZRLXctD0ChD8A+rGdGu+nABXAzUQlAS4loPQIoWKgHHlMyWT4GIgtlyZlEBAWHP5GABEC3F1Jac/RzRYDkSD61uvUXXF0BfYC0EYWoALSfYVIIPLl3EfTZqFXDYSnHZEMDB4SvXJaIQRDXDcKbXQhCkJEkEeA1Pgq3VsEyt/4ABn/0PabPYeOHaLBbRKdooLr0PEgFrNrIA7fDU+QDXuGwIQFncxZqsyL3czN3czv3c0B3d0j3d1F3dWhoEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cause-specific survival after first relapse following radiotherapy for clinical stages I and II Hodgkin lymphoma, comparing patients with isolated nodal relapse (n = 169) with and extranodal component to their recurrence (n = 137) (p &lt;0.005).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Mauch, PM, Armitage, JO, Diehl, V, et al. Management of recurrent Hodgkin's disease. In: Hodgkin's Disease, Lippincott Williams &amp; Wilkins, Philadelphia, 1999. p.,511.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31213=[""].join("\n");
var outline_f30_30_31213=null;
var title_f30_30_31214="Lung injury positive pressure";
var content_f30_30_31214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Lung injury with positive pressure and high volume ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 264px; background-image: url(data:image/gif;base64,R0lGODlhLQIIAcQAAP///yBzOQAzmYCAgP8AAAAAABA5HAAZTMDAwH8AAEBAQBAQENDQ0ODg4PDw8DAwMKCgoGBgYHBwcCAgIFBQULCwsJCQkD8AAAAMJggcDgAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAtAggBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk38NAwMQLQoSMwwIDiYMCggAEgp/CKmkMptKEAoMJ6KZOaKkr7FhDqkjuACtNbOUbBAFEw8FD6AqBaesBaskEQugCgV/BdkFC7QvzUoIAw0nCAUDJdYz06AD0GIS2RUi7aTfNZbRdumDDcagFgUiWJIXbpyFc/ZMDIwAqwIwa/kAOFgQQUQ6BwMsSGR4KeKbbAAaICOFicEAk6TC/+US8Q3COQAuAYSrwFAeAIcRLpFQCfMcxkwNGEaIVXCjgo7lJJg6h2CCOY8icOoUMbEiAHoADrLbhAmL04Dz3DUbcHQera4uHUpwwDAWvqsQLCiIsGyE3E0NwiGgQMEtw03LIFAAjFEBBZsKB1QwZTPoXKInIdwavBamAgUa4cql2/SpIICcJG4DsOABgAgFLDgoQAFAwhLlmm2b4DQTxBLFcqVTsCAWMgmoX8oBCZO16wXZ+rWmUGDciG/70rVbYK15hWQDnJJgUICTUwbXLTQoPWDBgqvufgePzbsABAjIFXQjcf1B9msicocN574U63bOVBEecuyItYAEzGlkD/90xjhFnTEymeNaMk5ZJQJqEgzwAH9HmSfTUahV1A4F2SHwwAIaFrDSTsakyMB49nk4nTkjlggPgqlN+ECF8DUznx/tCAcSahM9oMB1mbzG4jnplMOkOyQ8YJpF5vRXTkVO0kFcOackM4I1ypXAIJXokQIPAmD+gt8Ix3BnHzwNAJQTRPRcGeEAWV73ZApp7gOAlCMECZZrE7AUIBWoBdUfVt+s1qUzY2bZpISNvsYciSS5cyZMDH2zQKEScTlAcORIqKecZEHTjk2fUjXRBJd8U+kpfgZSTGsAuFkcPMUQ6dqhS6p5p5r59JOZmk4xJWGWcxDX66+9JFMAYoYKKyz/VvREt+aF3T0ggZSmtZPTJZZAk6WT50pYKzr47WNsoMYsCCmwUazWjFPhijUvtNBOumeW8pLAFjLTYgvNjVzyG+FRHZWqbKzjioOVwoRe0lXA6wKCjGLIyGNva9lM+Q13wg3rr5rjjgNPXWB+t9oECMBTMhzZIADfAuMkNNFoYp5yqQTIlVmmzBVoR182FsTGiZsVxGwSNC/H/NSy6k7LAMkkEG30yvBWkOCf0xZDLxSo3vd0PRuiphFywEVa9bABjxBB0vAclFoFHlpTgdgAJLgXAuZJZkEm1LEYgYkqMu30xH5TsNdTMWFs9SBsZbMAYl9/DS1Azokg6TWfa0MK/0UkTDqBAz1aM/NH2vRVrdzdmTCyUxQgIzQ9DlhD27YiIBeL71ER/EC5t8Q39cM3IWcB5wLrbjTp8H7iOwNOWTP2E8gscyOjyMUOk3nw0Ar62wDvGyhyB6Ln1ASxMGD8KWwhN0EDDDBnTAXczVeOg7RUIDzxVJmGMRoQv20gZF94y1EhzFMBaqmAAhaaQTGgQgLJPM6BfUBG52jQAMnAZ0o3sCBzMGgCCJaggzYrTXEoOAIENK0doWHExGpgAVC1UELDwEGPcMUCCmxQBhVYnQlQ0yJBcOd6MHBfNlyHAyLCqgU+LIESWROLILKgGNugiyNmSAPFwAaHOQyjGMdIxv8ymvGMaLyDJ+iTkR+m8Y1wjKMOOhg0EcDjRDiTox7XgIAVBVE8I/ijG/cohXYQZzXnAQ0h5/gJE6COXIvcwdMCdEfzqCwZloykFbb0jYTJxGIWY6EmqeI/KJHAkNsY5ChhUB1nIDIr3XmlIlcpBU6ewpPhAGVZaFmqmpkAAeNgjhB56QJcdrIZCUsmKBtGTCMQR1fX4WEJptJMdrEQNbTIJShFSUxj3hKZx7zlMndZzSDkpWbjcIrX+nMCapaTShTUlefGOcxqehKaVPRSNNtZz3fiAJUSYgAy0ocCd77zNib4YF1MYNB3MgAgGwKFOpmTiYmyc5r99OcSGkrMXSD/wwJEkRBADtQVfmr0S9pwh0C3EZqVEpShGT0pEjjKy9hk45tP0sb1aCrTLsa0p0XgKVBZINShvqCoRh0CUpMKU6baYKlO9QFUo3qVn1K1qVc9wlSjutWsVtWrRugqU8V6VbKCVQZmHWpanbrWs7qgrTKFq1Hl6lYV0NWfd+1pXuuKVb6e0qpn3atfAwVYrhbWq4Id7FcVO4/DZjWxg4UsLyWbA20u87KYzWwo7UDZunZ2lJ99agYMQNrSmva0qE0taTPgWDKEFqyvXWRsZzAAAwTgtrjNrW53y9vbGqC1Y5htWYGrVuIG1ba9Ta5yfWtcMAiXqs+VY3SPitzlWle3/7/lbHMZ21fFTvet1b2ueLNbh+8m1bxpRO8Kaive9gaAvHRQL1Dla0b6FjS87lUufOdg35P2d4z/nSZ+89vb/cohwO9EcA4VPI8BE3i3Bo4Dg5s54UlMmL0P1u92vVDhyW5Yoxd2cIZxG2E4dJiWE7asZlesWW6aIcQjTm6J33DiVV54tKrNsY5X++ErwDjGvJ2xG2oM2h7/AMNAxq6Rq/DjJOdWyG0gsiab7GTmSnjJPUByld+LZSxIOZJUrjKUzxBmJ495DV+WbZd3oGUxrzkKZU7ymdWQZkLGGchzdu2bc9BmM++ZCnXe451jnOfg/vkGfZbzoQu5aNg2uosiJv/0o5Uw6BEXmsyTLucjVWPXTMcg0Xj2tFZ/qmIWm3qb6420pUW9UVbT0gHIsAY1UlDpDF86DEsdAAYOwOte+/rXwA42rzGQUVBLegxBFEcg21hQV6+yHKZBqEmzYOxVX7kFAziAALbN7W57+9vg3vYBiq1qWzubBqg5kaYwmcfuchcFsKZQBFVMTh+X+8G3du5Psx3ufvub2+NO9ZZJfO4ZZAMj5pCl9zDKhVKf+tQudkP88FUXehfcrvcmcL6/kGtt//vj3w44xgdu5TCg5hjKSGYn6cmFAeB4xzA/LWv1AJBzCJPWF6d1xvO7cQ7v2+MgD7oARK5zknNZDBDdhif/wvlJXeZ85CTvuRmKsSFk/OivWqi2ua9NVKAL/eNEv6/Rpc6EI8ISFvo0jrvtPfanIwFoRcR51nfuXrJvoeNfD3rY20n39tpdCf24XIgAYNGrL3bubVdErfHt9iz/PO8g3ztD+z7exrcAAg7SoktjyPC7U/66fz+w5U/5eeuG3suPh/y/JS/gxJd39K2POuwZjXjZc329Xlc9uFlPetfHd/aBKv1yT29i4Gud8be3a+51723eB9/3/AV+g6FviMVrfPYmOckJggiBhXYe98zvt/Onb/vXt1z4Gla88dEvY9hfZ3cOTLeXmo3t5Ydf3OSmfvK9zP4CS/8J1sdzsIcM/1czfyKgK9hEf113f7uXf+X3e+enf4QQgHUHe8RBHJ7jJUEyT05XfwwYcg44cMR3d/93fNenfrUnghaIHxgoAviSLBxoMfVGa/Z3f+N3Ff0XZP+nAx1mggKIgtSWgxAGewTySiQQJxbAHBSEdx/YbTfogxWoXRH4gIdAgX4He8EhLsPyQga4du1Ug+H3hEKoZFLoeRI4CFZYeVjgAPZDAaDwORThfVi3gE0IcCG4ZSOYdSU4hk+2g02QhqDnh7SVenU4dHfoZmWYgngoiK2miIhYfB5YiIYocFQoelOogkDIf2eYBkxYiGK4iVG2h6AICEvlcA/HYtwEhVe4fwUFhv/M94mVyIpWoIpqmAi5tmvClou6OGyH6GeyyFCuqHuwiInmxwKmeIor5mK0GIiZqHySOIlQR4w0Roh1OIyLmIh2hYu7uI3ARmxExYcE14w0+IzW+IjTGIme2IuKho3jSI4xtYymx4iURo1NWI6+CIl0mI6UKI3Rh476uI/XaIv0+IH2uI74CH6SWJChxo6t+IzQGI0BiQidWI3quJAH6YwJWZHHVowImZHfOIp/MJH1qJHWdpHt+I9FF4sm2ZDu+JEqiYYDyYAKuZHnmI8UCZDm2I82eZM4eY8SGZM2SJJbt5Jf2JIQmZOWuJMj6ZL8WH1AGYZCiXxECYxGmZJN+Yv/0xSMwviO4FhyP+mPS3mUPjlkT/mKUXmCHImRHtmTBvmVSimTZ/mDU5mVVSl2L0mWYBmWYtmWVViWW8mWFlmTHcmTVhmROjmYhFmYSFkIIkmQcRmFc3lKWgl5M1mSEPiWcMmUhumUeZmZexmYeImZUAmYNHmYaomSijmWnCmaZkmalhmaiOmYrjmUlxmbsjmbUumWthmUuImWgnmaemmXVxmZgTKZlMmVIAkkfql6lUmbsAmct5mafJmUu8mbvSmXevBI/dSYnimdoBmKnWmd3lma1Amd0Tmer6lG8WFD01adrfmZ5MkG3CmewrmZX5BsziFICuie7wmf6WkH30FU/8t5nNcJmb95konJd8lZBfEmJWbCboM0n/RZn4tJB9yxO9JkceE5mv7pnODJmn/Zobn5BWozAgrHeYS1oRwqor55B9CGON2goSDKnI+5isQ5D8b5dc05ol5gPMOjcuLUgTNKo5pZoXNgdhu4n+Y5oZO3oIamoiGKnh7aBTUTIkDadDI4oARaoDaaB+o0EnI3pHm3oy36ofxJpCyKnV8QNFyCT9KUomI6psh5l3LgUoYHp2e6pVLKo/KppTpao7UIBsFBKoXXnkvKpE1Kp6Top0JHpmpqpofanxSqml3AhtnQUgOFongaqZI6qdPJmIyqd4DKjDd6FTnaqKMajwxZlP916anfCapQiqZ7WqZ9Gqt66qrxWar81qoKqqghGaqRl6rDJ48wIKGdmqjDeaAsuZZpaqB9aatyyqWB+pwIGpy9mqzUuqyoiav/OYHACnbCmn66eqqiKq2kWpucGqWz+qiwGqeoaq6qOq68GnvYCqnVaq3Xap/eCq1/Cq/DipWSOa+956t09q3gWqSUuq/uWq7N2qXZyqrbiqz6qqwQG7ESa6SCYKzqmq8YiwYaK6vcOqXyKrADW6+Lyq/v2rDTaq/aiq/0OrEPS5Uk+3wE2wcfe6scm7AFi7IMu67OWp73ep4hy6cKm6fRqrLnGrN0yaxDS6sjy7RNy65Fm644e7H/OsuJButvjvqz5ICMpxhxPHCzVWu1nzq1QYuoJQuzHpu14heu7UdUF5AAcju3dFu3dnu3CXABmSa2R4u08aqbVNu3Ucu1U5B9K8JGymaoZ7uig+uwBZUABBC5kju5lFu5lksACbC3bNu2CFu2MMmzweqv4moF76dOJdCgG6Kki3usL9ux8wC5lxu7sou5mgu6oSu6byuQtrt6but/WECA8gQ7x6K6LSu0ZPuqDAW7s7u8k5u5ScC3/Yq7vqu7C3u7Puu4U3CBvOOjziGjRhu917uy7aS8zMu8zjtTmxtuN4iDTroH0NuzjSu+tcSCvFOlg+K9gQu+8Zu0j1u+/nu+/6O2u7zbucj7udV7sH77r1dQhDwzAmyqJJu6uht7vLk6TeTrv7ILwGGVvg1IwBWcsRzcfL2rg1iQhWCRJYMKRt+Xvykbvvw7vhhsvrV7wAicwKP7rDSstSM8hGvYhm8oIZa6cF4osxabtq57FRccw5arwUEVwiLswd1qwN/bwvv7t0obsFBLwVF8SkmsxJTLxETwvvBbxQoMuBIMsjnruVgrwJxrw7lrV13sxZILxkrlxE44pyb7q2ysvjtMhk+boFosshYsx7FLx0Igxtbrwla8mlM8xoFMtDubw22syGVMa3FMyIYcBIhcw5R8w4zMwo7cule7tnvcwW48vXBMyP+Xm8lAsMkDLL0kTL2NnMhpXMBrLMl8DMs8vF6XLMesfGR2bIdQLMggXMogqMt+TLFEDMiirMaB0ste/MtSFcz4N8yQXMy4bMqd/MZXXJwzy76+OgDQrMTS7HjGfMzI3IfiWLzdScaeXKvZjM7bjMqWrMpLPMOzTMu1/MGB4MqT7M7czLIV67JGPMqva8+VW85hS80POc+xbMbsjLY0m8dl4M+5fMoPXc8I3bz4DMqh3My2bKHA1GnnfMfpHI5/TNATrbYHvdFz3NFnjMb7vMVHihzbSc1bi71ohtN9rM687NIv/bwMvb7wWMl4QDA3XdLCjNG7rMxLW8QrfcTiDNT/kavQKZAXK6GfihvREh3VBm1iB6LC+BvTgjvTxEzK8fzETJ3MGg3UVn0C8eYMldRuK0zWZW3W1xwH3BFEYs1yaW3Sa+3TTo3FUE1+eTzVVP3WJgAPlZJIQhzBXM24AE3PnJVSKlzXkT3BIM3PmKbU1RzYKJ3KiU1cTsJ0yiSk+czJk53RdpAXCBAiqnR4Hq3aj+y0kZzaOnzSXtnWLq3YJjoBEnClp52lnv3ZoL3beZCkxDvQxrvZNN3Zf73UDt3UvL3Rvp2BKYV2prFPQ/zUhW3YLK3H0W3cq03dAr3MKg3eUj3OMXzdoYIAEBULhdrdhP3d4EzRNsvTun10Kd3c/wXtzC3t1s11T5m63Oid3ur91cpZ3Dktv7c926883Wzdv6Mt1MXd0OU94e2K2/+M17Z9yxx+0RIu2NWN0O5dAxYt4iMe2jgc4tqc4SR+3t6N4EX9zslL1bRr4eNN3jDO4p9s11Ts4VL74ED+0V4N4EiM4yfuUxdO1F3J3xDN3O0s5IRL5Jkt08591gHe2zB95Vie5Xl9sjve4C+80wze0z4OwxWOvk2Ox+G94GOO5sgNzy4uzz0+5ze+5gG84xhO5TotxRCe28cN5d2Mo99c4wGt5gKu43Vu53dO6D/u5XcN5h+O1o0O2CuO54Os5xvc5tZc6WJ+6dL96HkIaPo96P9nhtiLzuZ87uTtqwcp7ui1PeQgHugdPutVzsVK3uVSPuV+7uDYLOo8jut/XutFrs+UTuvPvOuMbuu3TuzA3s+nnumQTufO/uK/Xuabvup7LuzDDu3aHuzXLuvJnuuWPu5qTe2pzt4YvOSD6On7XerWfuy0Xe7Ffu70HuGk/o7s/r+8fuD+/d8hHerojun7DrDenMX2Hu1bbt3/PuMIft9vnt9nHu/EelTTfvA/zelNDO+ofvHdXvCjnu2LPO+Srr8kb9SKzuXNnu/6rvFRDvBdLfFHXNEZn/I2vu0sz+re3ufgXvJme/JB/vMqb+ZxbvFE1e/l6+5oNdRuXvMUf/T/H4/whq7wAs/ZSc7xYez0n67sBO/yz371z/1iN0/0Oa/rWl/HHq/uIN/pUs/2VG+qh/7k687sPC/yI4/ziR70vS7ZZr/3UmC4CuESgGTgEO/rCx/uy572h8z1SC/LeO/zYq/lTVC608IuliOHjVXxU7/x3O72Pe/qNcsHsZ7uMF8FwNuFN+EA8baEZZ/4QK/zDt/yQj/0f0/ZGx75ZB77UKC9iVE4MXgJM1j7yD75YZ71n9/xrf70Ch713r77RR8Fvi9FvKEAyzDWxF/vxg/qyL/zIQ/2Yb/9Xi/ezy/n1S4FDHwe7XTZkN33rCv+5t7wJv7w9c3MsB/94g7+2H77/6wNAoA4ishwoqm6sihCwkBUnEUEIDQwScNSQGKikzA2OAiSyiWz6UweBsXRwBC4YrPaLfdqkE6HCQK5bD6j04QEOOx+G9vh47NuX0bf1S6/j/3CBQoOEhbCEekh3S025c1Z+UVuAepdJFxiZmpuciZcyMU4UBQUUDjg6IwWLICSILrRMcpCtcLsSeJ61dqOqfn+ru0aBr7OKc7KOj7m5lIOP0NHFxZPxSIvKhfdMkc6z/UCh5uxScMKux5f22ULbXP3eWuDi4uTlwtSa6er17G3Q76Dd+4ewYINLAywcKrawCH7+DUa6C4gl3jy6GG0V9BWQwDWIDrxZwsgxYoNB//Mw/hL40aGhx6CxHOSZEktFlvilKaAVIEHczp+jCkTFs2af4CmVKmGJc587WAKFemqqNEAN3kpDcc0pyugUKPOrDqpI9eybio4cDChwAttXoWGlEjV6FWsWVeSfebUyFeQUqnMrVmXStK74/KGgnCiwYgKCRm3ews3op7AJQebzQxnLWQcKhRInqzk7xDLFDGLMexr68a9tvpCJO3RdEDUKFUvRWyL5wLGEnou6B35pWgmsmeLtalbM3MAFgpIIGEiBWjixWkRTZ4FtcfCuFkXdI3uOvZl2nXp8a4aPBwEjEcNcLDKOfThiciXN3+ee/P+v2/8ZN11sk0kFne34Yb/Bnv3iEcFbPwQSNs7tqln2IKBzABBDgqgwuF0KFR3H37HFVgVf/1pNsoEJ7RlHywPqhPheeill6CCyxHSoEMjyjWjVSdVeNeFbzDQU4dHfnhCiC/iJwCJEnJzIopm8USKMDp6BOM1Ms54YJBZDRkNlkFNxuV+QNp4RphTQLDAA6cU6VMFpbhoTJNP+ijllHtyJGBxZmrnZZqHmTWmlsgAmhyFg5axphDPLdBDEGtVMEoQcfj5Z1hd4sjnnobymB2nh3yplKPDgEpeogaiyWgwz+zEE4cMPLBKdHVWcyiim57pqa/4hKapqL3W6OqphqQ6YI+jwlKqSsdKk6yyleXZ/+mvzUkr2qomIuXqq2VlW+ayxH7jLbRiBivssIFae61m4cK1LV3dGtvuIemKu66irTJ6LjTwxssru+4SjKs+oeo3cLH92qsHvgHry+rCg/qr18MQR8xtwRtTcXFM8gpGL8OFeuzXuAqXWy+KAINFLbMcF8yyyRnPS6q5DZuTab4J7ztxmhWjWvLMNIcM88Yyx3Zyzz7bCPS9OmNcDZTMLKpyf0gn7TK5Rl+LdYxKS8x0gk47DHXLPIed8shXC5010ZfhzHU5Xm8JtsZifxe3SyJOi/bdalOsNzFtQyjw0nL/Sveub58mcuAkm/2x3TU3e/PKhH+tNcqIe6r4LCDDbf+z1Vx5nszkRVc+OnOlm6754ZzzyTo2p4eO93qCG/wUwlJXa7uFuJfNd99+Uw577JgvTjzqqa9NOvKf096470ICn7Pw6ipfu/GfPt969tJPD2b1XUU+NO8vV+NsRuPvzeTu52+9Pdvluw3/5ulbDm73jIAOPuA/s88t9Kuf/V4nP2ztb3aMq43jAAi56+2sgGnDn+relUAFLnBCDUlSCzrowQG0SG6yu0P/GCi65uVkhOuIngmZ97j5QTCCEvxbNSzRiRvi8BKfgJ0K+8FCDZ7whc4bYOa+18L/NS2AuePLnQw3wYvkD3E9fEIJgRg+UylxinHJYJT4JcTVXZCETqT/IRQraDQtUsaIVnShA/VHxLpxkWpebCMC3wjHODZjjnQUYRh9iEdcCMqMrekjFX/YxSs+S4mYimHUZlg8CgqSY2g0jiHlGMQ9NoWQW1TjIdmYxMvZMXmctKQnP8m5SQ5llHm8pCmHyEjJ/VESVUOhBUMJPdc9sR3qWx8PNZlGRy4PiWPLoi8pGctu6HGYoHwlLI/ph1nS8ozFTCUwtSfMvD3QfcPTxtRWWUpswlCb2+Rm774JTilOczSV9KY5f5dNO6lqnYBM5jnBaEvvqXKeiExkL++JwWr675q3e2eu3vePcgrUneGEZzxxSUZdeutb6PSnGJ0pEFYq043MJOBB/9FXxi/WcqMc7Wj8IBpFPlJ0hRblQyCjOciU+jGfsqTnQBdaUIOS9H4mjeTR0pkfcnr0o5hsCSrVudIuQHOoBD0YTo3QTX22U6ETFWkRAXrEhFJvqbprqEyRuU96kC1HPv0pUEtqhF2CVZHRGmsVOxlV8WmViVy16hohCdLMFNWoRzXJV9PaT6reka5uxSpcNSpObclzpn3VilrJB9jACpaUhC3snhygGAgsRICPvWVXn9nAVqaQrYn16luxuMzDItahjxSqUplTq534pH0MxV5ZdbrTuwbCsgPAbIA2i8/aGvC2rXUlamUI3FyeNaJhNcScKACAUVRAtjcdp1MROv9ZfhritUaSLlOpOxLrsjaj5dAtbzVb3EYe96HJPenVdDAAHZTgM6D54AAUgIED4De/+t0vf/uLXwzMt4MKyIABCmzgAyM4wQoucAYC7EEF2DCHEs7EBRzcghCKoLnPLUB0zTvb1Hb2oqXFbjm0G9slvqaJqg1meMW7MvfC1zPUsTB9a2zjG+M4xzreMY+XRAUYt4GDCqAxC+zr3yMjOb8A/uCAF+zkJxu4wfSF8ISrrEMirwDDQtAwdD08Xe9+N6jr5alZnhOd31iAuwdc8+CMAOQRCBnLPJ4znets5zuvwMfaeLOMQSRn6tw3yYLu75KZTGAoIzrBUmZyhK0s4Qr/01fL5WhAASaAAM6omc2a5q6ZAYDmTG861I6dA5/jjOdTozrVqmby+CCwlglcysuinnXHYkBpS2Na1rSetY46/WkU7zrUWDJssGntFFdXOtbALvYBdXTrSxegM31idrCHTVw4t6UB7gGAAqLjAASAmwFFALcItM2Ybn+7ReaOAbnDwABwIyCzJHj3Kb4tbggogAHv7ky7pZPtbXcbAOlGgLiF0G8h7Bvb1s5du9cd8IEXnN3/PrcE0j2CdWPbDe8Gt7xHQG+BExwA+Nb3tkuA4YYD3NvwjjgMDh6DhJt8CB1BNqxBTe01LxwnLgcAKYbg3iDkgCdvikHPPfJzAPwA/zIzYLkIij6FWJFC2SLYyQs25JmD2KDcdIJB0d8rhd2iQugd53kBwvAcAFGaAjsfhFO6fvSgk2LoXC+70b8ehKSLYOkkcHoRoA6EGFAdSQPAOtq3PgK32z3scR8732Nwdq071yN6cwrKKQ7ycI974tyueL8x7m+Nw3vsAPi4vUWeb5jjQMuV3/zlQ25wSXu85KmXvNEQ7xGgF4BDo0jz3H2e+Bl4ewETEALfHSABBUSg4FQv0gIAzxbBN4DSBTjFe6VOdt/f/ki7JzrdRWB85Itb+tT/ezTWbnuwW337va979oEvcOGv3/vHT/7U2cJ851c991cXv9Glfn7c614B8P/e3nWfwM1f+JHC+F1KzvXW+nld9sFdTzAe3T0g2OGdDBQA011fGPid9QWe1ZkA4UEe92Ef+lWJ3BGg2WUdAKQd7cGMldSXDuif1T3g3CmJDM5KpYmcABJfAT4AK/zguT1f43GbDQzADHDIe72ApexA83HfDUrBDOpfDabgCPzgAAThhk2KE+YEDO5EFHrIFMbY4dFADILh6OkgBPBgFYrAFWZh4BHhTkTAEYrhEv7dBHAhGUIhz4VhEo5h0/kgEAoHE+Jhxt2D+VHg2+mf+lVhBQaB+zkA/JHgCHwf/RUhwc0HDHzgDA4e/1XfJDqi9q0hGxog+LFgAvbf7L1gleD/ICqsSNK9Fym8ACu2IgDUCgKMgug5XZFEx5ykmRyOwg3IShFWiR++wJzkW31wX5WcYQ68YrTF4hB2Hy8CgC9WY+5RI1fQYjNWmg9AI0/MIiueoS2yRS7GHzVaIzBm3TD6XR1eYzLeCgEyIx+6ojc2QDSGo8fVhzUiYzY2hxe2Ig3+Idntof4VyfCp4QCSohsKBxwWYP3NIRIanR1uYQ8WZB+yX/zZoiC+xx3mYe0lIjcugAKoHQuG3gY+oP7Rx05E3iSighTkgBTAFmicwspd4pEooQj8wE5oIEoG5CqQ5AtoG8dt4EsaJdLlXgaWhe1J4UiW5FDGm0+O43OwpEvG/6RRzmR8pF7IbaIx6mRSaiBThqFTCuVJOt1VXiVS8iSKbCM9OqM94iPZzaNK3qI5uiQ68qA6CiMpcEg7emU/KuPczWUYPuM9gmNR4mWaAWY8co1YHskUOKbA8USHPSERCB8uKmXg9d3zCWRb/MZ2geJPcghklqEUXOYoFNxnnlgXhqRbqmQRRKZ8kAJl6qFlWhpq3uRm5p9Xelrc9SD2SeFowmZpIt1tKmVvguY/tmZTBqVJEmVkUqXhxR9a6kBW1iTmdeVEfuVahqZINidUnsJZ6kBa7uRxyo1jWh1pAqdwzsDwDSdPjF6t1FxuCkF25uQpkl93uqZw9iB80kqyXc9c1FHJcmKkerLfa7Znf/bcf86nZtYnZ7ojflqfVO5nGLBifAKo1uWncq7nYw5nh0rmbA4nChQnZoqbg+IfTj4fcq5mI4qmhRLnaR6nat5cjdrojeLoIKDna/7mgbKnDr7ngsrnpaCoJkIob0rfhFJocMKofw5pgG5ojkrplFJplVrplWJplmrplnJpl3rpl4JpmIrpmJJpmZrpmaJpmqrpmrJpm7rpm8JpnMrpnNJpndrpneJpnurpnvJpn/rpnwJqoArqoBJqoRrqoWppCAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effects of various modalities of positive pressure ventilation in rats. Extravascular lung water (Qwl), dry lung weight, and albumin space are indicative of the development of lung injury. These abnormalities were induced in rats ventilated with high pressure and high tidal volume (HiP-HiV), low pressure and high volume (LoP-HiV), but not in those ventilated with high pressure and low volume (HiP-LoV). The HiP-HiV and LoP-HiV were always different from controls (p &lt;0.0001). Thus, ventilator-induced lung injury in this rat model appears to be more a function of high tidal volume than of high airway pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Dreyfuss, D, Soler, P, Bassett, G, Saumon, G, Am Rev Respir Dis 1988; 137:1159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31214=[""].join("\n");
var outline_f30_30_31214=null;
var title_f30_30_31215="Papilledema";
var content_f30_30_31215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papilledema, characterized by blurring of the optic disc margins, loss of physiologic cupping, hyperemia, and fullness of the veins, in a 5-year-old girl with intracranial hypertension due to vitamin A intoxication.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerald Striph, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_30_31215=[""].join("\n");
var outline_f30_30_31215=null;
